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AIM & OUTLINE OF THE THESIS
The cardiac conduction system (CCS) ensures initiation and coordination of 
the electrical activation of the heart, resulting in controlled contraction of the 
myocardium. This process is crucial to maintain constant perfusion to the organs 
in the body. Failure of the CCS, clinically manifested as cardiac arrhythmias, 
causes serious morbidity and mortality and poses an important disease burden 
on the pediatric and adult population. 
Understanding the developmental processes ultimately giving rise to the mature 
CCS can help to understand the pathophysiology of cardiac arrhythmias. This 
in turn can lead to new therapeutic strategies to prevent or treat this group 
of debilitating diseases. The main aim of the current thesis is to study the 
embryological origin and characteristics of key components of the developing 
CCS. 
In chapter 2 of this thesis, a general introduction on cardiac and CCS development 
is given. The development of the CCS is linked to clinical arrhythmias and 
arrhythmias occurring in the setting of congenital heart disease. Based on the 
results from the literature, a working model for the developmental background 
of clinical arrhythmias is provided.
The avian embryo has long been a popular and vital model system in 
developmental biology. A large number of the experiments described in the 
current thesis were performed using chick embryos. In chapter 3 an overview 
of advantages and limitations of this model system is given. Furthermore, the 
techniques used in the avian embryo to study the developing CCS are described. 
The results obtained from these experiments are discussed briefly to underscribe 
the importance of the avian model system in understanding the development of 
the CCS.
 
The atrioventricular node (AVN) is an essential component of the CCS, responsible 
for delaying the electrical activation wave from the atria. This allows time for the 
right and left ventricular lumen to fill with blood during diastole, necessary for 
efficient output of the heart. The AVN itself is a complex structure that consists of 
multiple cell types.1 The developmental origin of the different components of the 
AVN remains controversial.1 A contribution from the myocardium of the sinus 
venosus to the developing AVN was suggested2 and is investigated in chapter 4.
In a recent study by Sun et al. it was suggested that the dorsal mesenchymal 
protrusion (DMP) acts as a temporary pacemaker during early development.3 
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In chapter 5 the anatomical description of the DMP that is provided by Sun et 
al., and therefore the conclusion that this structure acts a temporary pacemaker 
during development, is probed.
Disturbance of the RHOA-ROCK signaling pathway results in bradycardia, atrial 
fibrillation and AV block in adult mice.4,5 The developmental processes leading 
to these arrhythmias remain to be elucidated. In chapter 6, the development of 
the sinus venosus myocardium and sinoatrial node after inhibition of the RHOA-
ROCK pathway is studied in chicken embryos. The effect of inhibition of this 
pathway on AV canal and AVN development is studied in chapter 7. 
The cardiac autonomic nervous system (cANS) modulates heart rate, contraction 
force and conduction velocity.6 In the adult heart, both the SAN and AVN have 
a rich autonomic innervation. Prior to establishment of the cANS, the early 
embryonic chicken heart already responds to epinephrine.7 In chapter 8 this 
early autonomic innervation is examined and a potential role for the epicardium 
in early modulation of the autonomic response is investigated.
 
In chapter 9 the different fate mapping and cell tracing techniques aimed at 
elucidating the developmental origin of the CCS are discussed. Special focus 
will be on the specific limitations and advantages of these techniques. The data 
obtained from these experiments will be evaluated critically and a possible 
working model for the development of the CCS is generated.
Chapter 10 provides a summary of the work described in this thesis.
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ABSTRACT
The cardiac conduction system is a specialized network that initiates and closely 
coordinates the heartbeat. Cardiac conduction system development is intricately 
related to the development and maturation of the embryonic heart towards its 
four-chambered form, as is indicated by the fact that disturbed development of 
cardiac structures is often accompanied by a disturbed formation of the CCS. 
Electrophysiological studies have shown that selected conduction disturbances 
and cardiac arrhythmias do not take place randomly in the heart but rather 
at anatomical predilection sites. Knowledge on development of the CCS may 
facilitate understanding of the etiology of arrhythmogenic events. In this chapter 
we will focus on embryonic development of the CCS in relation to clinical 
arrhythmias, as well as on specific cardiac conduction abnormalities that are 




The cardiac conduction system (CCS, Fig. 1) is a specialized network that initiates 
and closely coordinates the heartbeat. The development of the CCS is intricately 
related to the development and maturation of the embryonic heart towards its 
four-chambered form, as is indicated by the fact that disturbed development of 
cardiac structures is often accompanied by a disturbed formation of the CCS. 
 Both in the young and in the adult population conduction disturbances and 
cardiac arrhythmias can occur. Electrophysiological studies have shown that 
these events do not take place randomly in the heart but rather at anatomical 
predilection sites. Specifically, ectopic foci have been reported in sinus venosus-
related structures at the venous pole of the heart such as the crista terminalis1 and 
the ostia of the caval veins2, coronary sinus3 and pulmonary veins.4 Interestingly, 
during embryonic development, the area covered by the developing CCS includes 
structures that will not contribute to the mature CCS5,6 like the left cardinal 
vein which during development goes in regression to become the ligament of 
Marshall, a known arrhythmogenic substrate.7 Knowledge on development of 
the CCS may facilitate understanding of the etiology of arrhythmogenic events. 
In this chapter we will focus on embryonic development of the CCS in relation 
to clinical arrhythmias, as well as on specific cardiac conduction abnormalities 
that are observed in patients with congenital heart disease. We will first address 
the ‘building blocks’ necessary for proper cardiac development, after which 
development of the CCS will more specifically be discussed.  The main focus of 
this chapter will be on the proximal part of the developing CCS, that includes the 
sinoatrial node (SAN), AV node (AVN) and AV junction.
2. EARLY CARDIAC DEVELOPMENT
In human, the development of the heart starts around day 19 (+/- mouse 
embryonic day (E)7.5, and chick Hamburger Hamilton (HH) stage 5-6) in the 
splanchnic part of the lateral plate mesoderm. Specific regions of the cardiac 
crescent will give rise to specific cardiac segments (Fig. 2a). The splanchnic 
mesoderm located at both sides of the primitive streak will fuse to form a single 
horseshoe-shaped heart primordium8,9 or primary heart tube with a venous and 
an arterial pole, through which the blood is propulsed in a peristaltic fashion 
(Fig. 2b). This tube contains a myocardial layer on the outside, an endocardial 
covering on the inside, with endocardial jelly located in between (Fig. 2b). 
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3. THE “BUILDING BLOCKS” OF THE HEART
3.1. FIRST AND SECOND HEART FIELD
A widely used but controversial concept in cardiac development is the 
subdivision of the cardiac progenitors in a first and second heart field (FHF and 
SHF respectively). This concept will be introduced in this introductory chapter 
and the FHF and SHF nomenclature will be used. In chapters 4, 9 and 10 the 
concept of dividing the cardiac progenitors into distinct and separate heart fields 
and the specificity of FHF and SHF markers will be discussed. 
Figure 1. The adult cardiac conduction system
Schematic representation of the adult CCS. The electrical impulse is generated in the sinoatrial 
node (SAN), located at the entrance of the superior caval vein (SCV) into the right atrium (RA). It 
is conducted through the internodal atrial myocardium to the atrioventricular node (AVN) located 
at the right side of the base of the atrial septum in the triangle of Koch, where it is delayed. The 
impulse is then propagated through the common bundle or His bundle (CB), situated on the top of the 
ventricular septum (VS), and the left and right bundle branches (LBB and RBB, respectively) located 
at each side of the ventricular septum, to the Purkinje fiber network (PF) resulting in the contraction 
of the ventricular myocardium. CS: coronary sinus, ICV: inferior caval vein, LA: left atrium, LV: left 
ventricle, MB: moderator band, PV: pulmonary vein, RV: right ventricle.
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 Initially, the primary heart tube will mainly consist of a left ventricle, 
an atrioventricular canal and part of the atria.10 The myocardial progenitor 
population that will contribute to this primary heart tube has been designated 
the FHF. Additionally, contribution from a second progenitor pool of myocardial 
precursors, the so-called SHF, located in the mesoderm dorsal to the primary 
heart tube, is necessary (Fig. 2b,c). As from E8.5 in mouse11 and stage HH14 in 
chick12,13 additional cardiomyocytes are incorporated at the arterial and venous 
pole of the primary heart tube. Both heart field populations (FHF and SHF) can 
already be distinguished in the early stages of the cardiac crescent (FHF), the SHF 
lying medial to the first heart field (Fig. 2a).10,14,15 
 The cellular addition from the SHF at the arterial pole will contribute to the 
formation of the outflow tract and the right ventricle, also referred to as derived 
from the anterior or secondary heart field.11,13,16,17 In this chapter we refer to 
Figure 2. Development of the heart from the first (FHF) and second (SHF) heart fields
a. Early in development, bilateral fields of cardiac mesoderm are present in the primitive plate. Cells 
depicted in yellow will contribute to the second heart field (SHF) parts of the heart, whereas cells 
depicted in grey depict the first heart field (FHF) that will contribute to the primary myocardial 
heart tube (PHT). b. Schematic representation of the primitive heart tube (grey) after fusion of the 
bilateral plates of mesoderm. The tube is lined on the inside by cardiac jelly (blue). The mesoderm 
of the SHF is depicted by the yellow area behind the PHT. This region will contribute myocardium 
to both the arterial and venous poles of the heart (depicted by the yellow myocardium in b) during 
development. c. At further developmental stages, segments of the heart will develop by contribution 
of myocardium to the venous pole from the posterior heart field (PHF, yellow) and to the arterial pole 
from the anterior heart field (AHF, yellow). The yellow lobulated structure that protrudes into the 
pericardial cavity at the venous pole of the heart is the proepicardial organ (vPEO). At the arterial 
pole, also a small PEO (aPEO) can be recognized. Cardiac neural crest cells (depicted by blue dots) 
migrate from the neural crest along the arterial and venous pole into the heart. BV: brain ventricles, 
C: coelomic cavity, DAo: dorsal aorta, G: gut, PAA: pharyngeal arch arteries.
20  Chapter 2 
2
this population as the anterior heart field (AHF). Complementary to the arterial 
contribution, the SHF contribution to the venous pole of the primary heart tube 
has been referred to by our lab as the posterior heart field (PHF, Fig. 2). The PHF 
can be subdivided into a myocardial component and a mesenchymal component. 
The myocardial component will contribute to the myocardium that surrounds 
the cardinal (embryonic) or caval (adult) veins and the pulmonary veins. This 
region also includes the definitive right-sided, as well as a transient left-sided 
sinoatrial node.18,19 Whether there is also a contribution to the atrioventricular 
node, is still controversial.20,21 The mesenchymal component will contribute to 
the development of the dorsal mesenchymal protrusion (DMP), important for 
atrial septation, as well as to the proepicardial organ (PEO) with its derivatives, 
the epicardium and epicardium-derived cells (EPDCs) (described later on). 
Several genes are expressed throughout the SHF and have an important role in 
the development of both the arterial and venous pole, like the LIM homeodomain 
transcription factor Islet1(Isl1). Mice lacking this transcription factor do not 
develop an outflow tract, right ventricle and part of the atria.10 Just like its 
counterpart at the arterial pole (AHF), a subset of genes and transcription 
factors have been found necessary for proper PHF-derived cardiac development. 
In contrast to the AHF derived myocardium at the arterial pole of the heart, the 
PHF derived myocardium is characterised by lack of expression of Nkx2.5, as well 
as by positive expression patterns of several markers including podoplanin18, its 
downstream receptor RHOA19,22, Tbx1823, Tbx524,25, Shox226, HCN427,28 and pdgf-
receptor alpha.29 The developmental aspects of the sinus venosus myocardium, 
SAN and AVN will be discussed later on.
3.2. EPICARDIUM AND EPICARDIUM-DERIVED CELLS (EPDCS)
The primary heart tube is initially not covered by epicardial cells. Epicardial cells 
derive during development from a villous structure at the venous pole of the 
heart, the proepicardial organ (PEO, Fig. 2c), with a possible exception of the 
epicardium covering the arterial pole of the heart30, that is most likely derived 
from the AHF. As the PEO and its derivatives are derived from the PHF, one could 
argue that this structure, that is in close relation to the developing heart, should 
not be regarded as an extracardiac structure.31–33 In mouse embryos of E9.5-10.5, 
epicardial cells start to migrate from the PEO over the complete outer layer of 
the developing heart32,34, and subsequently migrate to the subepicardial layer 
where EPDCs are generated by a process of epithelial-to-mesenchymal transition 
(EMT). EPDCs invade the myocardium, the subendocardial space and AV cushion 
tissue, where they contribute in formation of smooth muscle cells, the adventitial 




 Of interest for the CCS is the role of EPDCs in development of the annulus 
fibrosus, as mechanical inhibition of proper outgrowth of the epicardium results 
in broad accessory AV connections and pre-excitation (described in more detail 
below).35,36 Previous studies also indicate a role of the EPDCs in development 
of the peripheral conduction system (Purkinje fibers), as epicardial inhibition 
results in a significant reduction in numbers of Purkinje fiber cells as compared 
to normal embryos.34,37
3.3. NEURAL CREST CELLS (NCCS) 
Neural crest cells (NCCs, Fig. 2c) contribute to many organs and tissues during 
embryonic development. At the arterial pole NCCs are involved in formation of 
the pharyngeal arch arteries and remodeling of the outflow tract i.e. formation 
and myocardialisation of the aorticopulmonary septum38–40 and formation of 
the semilunar valves.41 Furthermore, NCCs contribute in the formation of the 
neurons and ganglia of the cardiac autonomous nerve system, which is important 
for the regulation of cardiac function.42,43 At the venous pole of the heart NCCs are 
involved in development of the base of the atrial septum and an important role of 
NCCs has been postulated in induction of the anlage of the CCS.44–46 Although the 
exact role of NCCs in CCS development remains uncertain, the fact that almost all 
NCCs located near the developing CCS become apoptotic at a certain time point 
suggests an inductive role.45,46 It was demonstrated that neural crest ablation in 
chick results in lack of differentiation of the compact lamellar organization of the 
His bundle, that separates it from the working myocardium.47
4. THE ORIGIN AND DEVELOPMENT OF THE CCS
It is now generally accepted that the myocardium is the main source from 
which the CCS develops.48 Initial histological studies on CCS development 
demonstrated that cardiomyocytes of the CCS are characterized by reduced 
numbers of myofibrils and a high accumulation of glycogen as compared to the 
working myocardium in both human and animal species.49,50 In the past years 
increasing numbers of molecular CCS markers have become available, which 
enabled detailed morphological analysis of the developing CCS at subsequent 
stages of development (reviewed in51). It should be noted however, that none 
of the markers solely stains the CCS, and in many cases also neuronal tissues 
are labeled.52 Based on the histological characteristics and expression patterns 
during embryonic development of the different markers known to date, the 
embryonic CCS covers a broader area as compared to the mature CCS.51
 In general two different approaches have been used to explain the origin of 
the cardiomyocytes that contribute to CCS formation: (1) “the recruitment model” 
puts forward that the CCS derives from a pool of multipotent undifferentiated 
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cardiomyogenic cells53–55, whereas (2) “the specification and ballooning model” 
suggests that a population of differentiated pre-specified conduction cells located 
in the embryonic primary heart tube will develop into the CCS.56 In the latter 
model the expression of specific genes/transcription factors in the primary heart 
tube myocardium prevents the differentiation of pre-specified cardiomyocytes to 
a working myocardium phenotype. The individual heart chambers subsequently 
balloon-out of the primary heart tube57,58, after which the myocardium of the 
primary heart tube is restricted to specific areas (i.e. the SAN region, the AV 
region, the primary fold and the outflow tract area) in between the working 
myocardium of the cardiac chambers. These areas will, under the control of 
several transcription factors, including the T box transcription factors Tbx2 
and Tbx3 that repress formation of the working myocardium, contribute to the 
developing CCS.59,60 
 The above mentioned specific areas that persist after ballooning, are highly 
comparable to the myocardium mentioned in the so-called "ring theory of CCS 
development" (that suggests that precursors of the CCS can be identified by 
several “rings” of tissue that, after looping of the heart has been initiated, can 
be distinguished from the surrounding working myocardium by specific cellular 
characteristics).61 Although the "ring theory" is nowadays highly controversial, it 
is interesting to note that after looping of the heart has occurred, several zones 
of tissue (so-called transitional zones) that overlap with the areas mentioned 
under “the specification and ballooning model” can be distinguished based on 
expression patterns of several markers involved in CCS development.6,62–64 These 
transitional zones largely correspond to the areas described in the “ring theory” 
including the sinoatrial transition, the AV transition, the primary fold area and 
the ventriculo-arterial transitional zone.51
5. NORMAL AND ABNORMAL DEVELOPMENT OF THE SINUS VENOSUS 
MYOCARDIUM AND SAN
5.1. NORMAL DEVELOPMENT
The SAN is located at the entrance of the superior caval vein into the right atrium 
(Fig. 1). In human and mouse the SAN is comma-shaped with a “head” at the 
border of the superior caval vein and the right atrium and a “tail” along the 
terminal crest.49,65,66 The terminal crest is the adult derivative of the embryonic 
right venous valve that is an anatomical boundary between the right atrial 
appendage and the smooth walled sinus venosus part of the right atrium. The 
anatomical “mature shape” of the SAN differs between several species.65,67,68
 The SAN can be recognized in human from the fifth week of development.69 In 
mouse the first signs of the SAN primordium can be observed around E10.5-11.5, 
which was suggested to derive from an area of loose mesenchymal cells near 
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the right atrium.50 Interestingly, also a left SAN has been described at the medial 
border of the entrance of the left cardinal vein in the right atrium in mouse and 
chick.19,22,50,70 Development of the head and tail region of the SAN is established 
independently in a functional order.71 
 Of interest for a possible relation to clinical arrhythmias is the fact that 
embryological development of the SAN is narrowly related to development of 
the myocardium surrounding the cardinal veins (sinus venosus myocardium) 
and pulmonary veins. The sinus venosus myocardium differentiates from the 
mesodermal precursor population of the posterior SHF and forms a “U-shaped” 
myocardial structure that comprises the area of the definitive right-sided SAN 
area as well as the transient left-sided SAN area (Fig. 3).18,19,22,70 During early 
developmental stages the sinus venosus myocardium expresses Tbx18 and 
is negative for Nkx2.5.18,23 Other genes expressed in this myocardium include 
podoplanin18, Shox226, HCN427,28, Isl110, pdgf-receptor alpha29, RHOA19, and 
Tbx3.72,73 The expression patterns are distinct from the non-PHF derived 
myocardium of the primary heart tube and working myocardium of the chambers. 
During further development, upregulation of Nkx2.5 and downregulation of 
other genes occurs in the sinus venosus myocardium including the transient left-
sided SAN, so that this myocardium gains a phenotype resembling the working 
myocardium. An exception is the definitive right-sided SAN, which can be 
distinguished also in late developmental stages from the working myocardium by 
distinct expression patterns. Data based on expression of the hyperpolarization-
Figure 3. Molecular characteristics of the sinus venosus myocardium
1. 3D reconstruction, dorso-inferior view of E12.5 mouse heart. Sinus venosus myocardium: lime 
green, encompasses area of definitive right-sided SAN and transient left-sided SAN. Reconstruction 
of sinus venosus myocardium based on lack of Nkx2.5 expression. Nkx2.5 is markedly expressed in 
working myocardium (grey). Pulmonary vein (PV): pink. a-d, e-h. Expression patterns of MLC-2a, 
Nkx2.5, HCN4  and pdgf-r alpha in left/right sided SAN. Right/left-sided SAN share same expression 
pattern, with staining of MLC-2a (a,e), HCN4 (c,g) and pdgf-r alpha (d,h), Nkx2.5 staining is absent 
(b,f). LA/RA: left/right atrium, LCV/RCV: left/right cardinal vein, LV/RV: left/right ventricle. Scale 
bars 100µm.
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Figure 4. The posterior heart field phenotype  (legend on page 25)
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activated cyclic nucleotide-gated channel HCN4 suggest that the SAN keeps a 
“primitive” phenotype, whereas the remainder of the sinus venosus myocardium 
will differentiate into a working myocardium phenotype.28 This corresponds to 
other studies suggesting a primitive phenotype of the CCS as compared to the 
working myocardium.74 
5.2. ABNORMAL DEVELOPMENT: MOUSE MODELS
In recent years several mutant mouse models have been described that are 
associated with what we refer to as a “posterior heart field phenotype”18, that 
Figure 4. The posterior heart field phenotype  (figure on page 24)
Figure demonstrates features of phenotypes observed in animal models with deficient PHF 
contribution. a1-8. Shox+/+ and -/- mouse embryos, E11.5. a1-2. Dorsal views 3D reconstructions 
Shox+/+ (a1) and Shox -/- (a2) mouse embryos. Color coding: lime green: Nkx2.5- sinus venosus 
myocardium, dark green: sinus venosus myocardium with aberrant upregulation Nkx2.5, grey: 
atrial/ventricular working myocardium, pink: primitive pulmonary vein. a3-a4. Overview sections 
Shox+/+ (a3) and Shox -/- (a4) embryonic hearts, MLC-2a staining. a5. Normal SAN. a6. Venous 
valves (arrows, VV), control. In knockout embryos, a hypoplastic SAN (a7) was observed, expressing 
MLC-2a (a4), with pathological upregulation of Nkx2.5 (a7) and hypoplastic VVs (arrows, a8). b1-
b8. Podoplanin +/+ and -/- mouse embryos, E15.5. b1-b2. 3D reconstructions, atrial level. Color 
coding: yellow: fibrous heart skeleton, including mitral valve (MV) and tricuspid valve (TV), grey: 
atrial myocardium, pink: primitive pulmonary vein, red: smooth muscle cells (SMCs) of the vascular 
wall. b3-b4. Myocardium of atrial septum (AS), left cardinal vein (LCV) and pulmonary vein (PV) 
is hypoplastic in knockout (b4) as compared to wildtype (b3). b5-b6, b7-b8. Enlargements boxed 
areas in b3 and b4, respectively. +/+ animals: SMCs (arrowheads, b6) cover inner wall left atrium, -/- 
animals: SMCs almost absent (arrowheads, b8). c1-c8. Id2 +/+ and -/- mouse embryos,  E9.5. c1-2. 
3D reconstructions, dorsal view, Id2 +/+ (c1), -/- (c2). Color coding: grey: myocardium, blue: lumen 
cardinal veins, lime green: MLC-2a+/Nkx2.5- sinus venosus myocardium, pink: pulmonary pit, PEO: 
purple. c3-c4. Overview WT-1 expression in wildtype (c3) and knockout (c4). c5, c8. Enlargements 
boxed areas in c3 and c4, respectively. c6-c7. 3D reconstructions PEO in +/+ (c6) and -/- (c7) 
embryos. Note smaller volume PEO in -/- embryo. Also reduced amount sinus venosus myocardium 
in -/- (lime green, c1 ), as compared to +/+ (lime green, c2). d1-d8. Pdgf receptor alpha +/+ and -/- 
embryos. d1-d2. E11.5 overview of +/+ (d1) and -/- (d2)  hearts, MLC-2a staining. Atrioventricular 
septal defect in -/- heart. Mesenchymal cap is lacking (compare arrow mesenchymal cap in d1 
with arrow in d2 where mesenchymal cap is lacking). d3-d4. E13.5, overview of +/+ (d3) and -/- 
(d4) heart, MLC-2a staining. Boxed area in d3 and d4 enlarged in d5-d6 and d7-d8, respectively. 
Indicate formation left ventricular (LV) compact myocardium and epicardial layer. Note pronounced 
myocardial blebbing in -/- (d7-d8) as compared to +/+ (d5-d6). Thin compact myocardial layer in 
-/- embryos (compare bars in d7 with d8). A: common atrium, LA/RA: left/right atrium, LCV/RCV: 
left/right cardinal vein, LV/RV: left/right ventricle, PEO: proepicardial organ, V: ventricle. Scale bars: 
a3-a4: 300µm, a5-a8: 60µm, b3-b8: 30µm, all others: 100µm.
Figures in panel A (Shox2) modified after: Blaschke et al. Circulation. 2007;115(14):1830-1838
Figures in panel B (Podoplanin) modified after: Douglas et al. Pediatr. Res. 2009 Jan;65(1):27-32
Figures in panel C (Id2) modified after: Jongbloed et al.  Dev. Dyn. 2011 Nov;240(11):2561-77
Figures in panel D (Pdgfr-alpha) modified after: Bax et al. Dev. Dyn. 2010;239;2307-17
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can be attributed to either a deficiency of the myocardial or of the mesenchymal 
contributions from the PHF. These mutant mouse models present with distinct 
and largely overlapping phenotypes that indicate a disturbed development of 
the heart during recruitment of myocardial and mesenchymal structures to the 
venous pole of the heart from the PHF (examples are shown in Fig. 4). During 
development, the homeodomain transcription factor Shox2 is expressed in the 
sinus venosus myocardium, including the SAN and venous valves. Shox2 mutant 
mouse embryos demonstrate hypoplasia of the entire sinus venosus myocardium, 
including the SAN.26 In addition, expression of Nkx2.5, which is normally lacking 
in the sinus venosus myocardium at early stages, is upregulated in the Shox2 
mutant (Fig. 4a). A similar phenotype is observed in the podoplanin knockout 
mouse, which shows hypoplasia of the myocardium surrounding the cardinal 
veins, including the SAN, and of the myocardium of the pulmonary veins and 
deficiency of the pulmonary venous vascular smooth muscle layer (Fig. 4b). In 
addition, atrial and atrioventricular septal defects were observed. Furthermore, 
the PEO is small and development of the ventricular myocardial compact layer is 
Figure 5. Schematic overview of the posterior heart field phenotype
Schematic summary of the phenotype observed in animal models with a deficiency of the 
contributions to the myocardial part (left) and mesenchymal part (right) of the posterior heart field. 
For description of the phenotypes and references: see text. Abbreviations: CCS: cardiac conduction 
system, DMP: dorsal mesenchymal protrusion, SAN: sinoatrial node, SV: sinus venosus, TAPVC: total 
anomalous pulmonary venous connections.
General introduction 27
2
deficient in the podoplanin mutant embryos.18,33,75 The phenotype of Id2 knockout 
embryos also includes a small PEO (Fig. 4c), thin sinus venosus myocardium and 
SAN hypoplasia, as well as large interatrial and interventricular communications 
and abnormal venous drainage patterns. The latter finding was also observed 
in Tbx3 knockout embryos52, in which also the SAN volume is diminished.73 
Pdgfr-alpha mutant mouse embryos show a phenotype with thin sinus venosus 
myocardium, upregulation of Nkx2.5 in the SAN, atrial and atrioventricular septal 
defects, and a small PEO with pronounced epicardial blebbing and deficient 
numbers of EPDCs at later stages (Fig. 4d).29 Furthermore, the pdgfr-alpha 
knockout is associated with anomalous drainage patterns of the systemic and 
pulmonary veins.76 A schematic overview of abnormalities observed in animal 
models with a deficient myocardial and mesenchymal contribution from the 
posterior heart field, is provided in Fig. 5.
5.3. CLINICAL IMPLICATIONS: RHYTHM AND CONDUCTION 
DISTURBANCES
The functional importance of some of the genes expressed in the sinus venosus 
myocardium is further substantiated by the fact that mutations in these genes 
result in cardiac conduction abnormalities or rhythm disturbances, some of which 
have been related to rhythm and/or conduction abnormalities in human. For 
instance mutations in the human HCN4 (responsible for If or funny-current) gene 
result in SAN bradycardia.77 Of interest, the funny current inhibitor Ivabradine is 
increasingly being applied in clinical practice for heart rate reduction, targeting 
the spontaneous diastolic depolarization of the SAN. Adult mice with an over- or 
underexpression of the small GTPase RhoA that is downstream of podoplanin19,22 
present phenotypes with atrial fibrillation and AV-block, indicating a possible 
role for RhoA in the function of specific ion channels in the CCS.78,79 Shox2 mutants 
show pronounced sinus bradycardia.26 Ectopic expression of Tbx3 has been 
shown to result in ectopic atrial pacemaker activity73,80 and SAN dysfunction.80
 With regard to the occurrence of clinical arrhythmias, the sinus venosus wide 
expression pattern of genes is interesting in the light of the electrophysiological 
development of this area. In human, clinical arrhythmias are often related to sinus 
venosus related structures in the atria, such as the crista terminalis (embryonic 
right venous valve), the myocardium of the caval veins and coronary sinus 
(embryonic left and right cardinal veins), the ligament of Marshall (embryonic 
left cardinal vein) and the myocardium surrounding the pulmonary veins, that 
have all been described as sources from which arrhythmias can originate.1–4,7 As 
described above, during development the entire sinus venosus myocardium, that 
includes the myocardium surrounding the cardinal veins (putative caval veins) 
demonstrates an expression pattern that is similar to that of the SAN, i.e. a nodal 
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phenotype. Results of electrophysiological recordings and optical mapping in 
chick embryonic hearts show that initially both atria have the potential to generate 
the first electrical activity, whereas later in development the activity becomes 
restricted to the right side, where the definitive SAN is located.19 Previous studies 
have demonstrated electrical activation originating at the left inflow portion.81 
Interestingly the capacity of both sides of the sinus venosus myocardium to 
generate the first electrical activity was observed until approximately HH28 
in chick, which correlated with the disappearance of markers like RHOA and 
Isl1 positive cells.19 Using electrophysiology and optical mapping techniques 
in mouse and chick the potential of the left SAN to generate the first electrical 
activity of the heart was demonstrated in early developmental stages (Fig. 
6).19,82,83 The left-sided SAN appears earlier in development and is initially larger 
Figure 6. Electrophysiological changes during development
During development, initially the entire sinus venosus myocardium is capable of generating the first 
electrical activation. During development the right-sided SAN will become the definitive pacemaker.
a. Representative example of an ex ovo electrophysiological recording of an embryonic chick heart 
(HH21), demonstrating left atrial activation (LAc) preceding right atrial activation (RAc) with 4,6ms.
b-c. Electrical activation pattern as obtained with optical mapping, dorsal view, showing initiation 
of the electrical signal (red) in the LA. d. Representative example of an ex ovo electrophysiological 
recording of an embryonic chick heart (HH29), demonstrating RA activation preceding LA activation 
with 3,1ms. e-f. Electrical activation pattern as obtained with optical mapping, dorsal view, showing 
initiation of the electrical signal (red) in the RA. OFT: outflow tract, SV: sinus venosus, V: ventricle. 
Modified after: Vicente-Steijn et al. J. Cardiovasc. Elect. 2010;21(11):1284-1292.
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in size than the right-sided SAN.18 The myocardium of the pulmonary veins, that 
is well known for its arrhythmogenic capacities4 may play a distinct role in this 
area, as expression patterns are not entirely similar to that of the cardinal veins. 
For instance, Tbx18, that is markedly present in the cardinal vein myocardium, 
is lacking in the pulmonary vein myocardium. However, several other markers 
expressed in the sinus venosus myocardium during development including 
the SAN, have similar expression patterns in the myocardium surrounding the 
pulmonary veins, such as HNK-162, CCS-lacZ6, podoplanin18, and HCN4.28 Of 
particular interest in this light is the expression pattern of the latter, which is as 
described above responsible for the funny current in the SAN of human. HCN4 
is expressed in the myocardium surrounding both the cardinal (putative caval) 
veins, as well as in the pulmonary vein myocardium during human84, mouse22 
and chick28 development. Interestingly, we have been able to follow cells from 
the left SAN region section-by-section towards the pulmonary vein myocardium 
in both chick and mouse (Fig. 7; Vicente Steijn et al., unpublished observations). 
The presence of a functional pacemaker gene in the pulmonary vein myocardium 
during development provides an interesting link to the observed arrhythmogenic 
potential of this myocardium.4 Elevated levels of HCN4 have been reported during 
heart failure, suggesting that the embryonic program can be reactivated during 
pathophysiological remodeling.85
 Shox2 may play an important role in regulation of HCN4 expression, as Shox2 
Figure 7. Left SAN and pulmonary veins
Cells from the region of the left-sided SAN can be traced section-to-section towards the myocardium 
surrounding the pulmonary veins (PV). a. Overview section, showing HCN4 expression at the level of 
the sinus venosus. b-d. Enlargements of the boxed area in a. Note marked expression of HCN4 in  the 
inner layer of the right venous valve (see inset a’), that appears as a bilayered structure with an inner 
HCN4 positive, and an outer HCN4 negative layer. Expression of HCN4 (b) is observed in the cluster of 
cells (open arrows in b-d) that could be followed section-to-section from the left SAN region toward 
the PV myocardium. These cells were also characterised by expression of MLC-2a (d) and mostly 
lacking expression of Nkx2.5 (c). LCV: left cardinal vein, RA: right atrium. Scale bars 100µm.
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knockout embryos showed absence of HCN4 expression (in situ hybridization).86 
In our own studies, we have not been able to demonstrate a reduced amount of 
HCN4 in the Shox2 mutant, which can possibly be attributed to different methods 
used (results based on protein expression data, Hahurij et al., unpublished data).
 Pitx2c, essential in the embryonic control of left/right asymmetry, has recently 
been shown to be associated with atrial fibrillation and regulation of the SAN 
genetic program by suppressing Shox2.87 During development Pitx2 defines the 
left sinus venosus myocardium and is expressed in the left pulmonary ridge. It is 
needed to repress left-sided pacemaker activity88, and Pitx2 mouse mutants show 
right atrial isomerism with bilateral SANs.72,88 Both in mouse models as well as in 
human, Pitx mutations have been associated with atrial arrhythmias.87,89–91 These 
results provide a plausible explanation for selected arrhythmias originating 
from ectopic pacemaker foci originating from e.g. the myocardium surrounding 
the caval and pulmonary veins and from the ligament of Marshall (remnant of 
the left cardinal vein).4,6,7 Failure to differentiate into a chamber phenotype in 
these areas, or re-expression of the embryonic program may potentially lead to 
arrhythmogenic substrates in the adult. 
5.4. CLINICAL IMPLICATIONS: ASSOCIATION CONGENITAL 
HEART DISEASE AND CONDUCTION SYSTEM DISEASE
The association of CCS disease with structural cardiac abnormalities, related 
to deficient contributions from the PHF, such as atrioventricular septal defects 
and abnormal venous drainage patterns, as observed in the mouse models 
described above (Fig. 4 and 5), would suggest a relation in the human situation. 
An interesting association between congenital heart disease and conduction 
disorders is observed in the human Holt Oram syndrome, based on a mutation 
in the Tbx5 gene. The majority of patients with conduction disease have AV 
conduction disorders, although sinus bradycardia and sick sinus syndrome 
have been reported.92,93 Although sick sinus syndrome can be observed in non-
syndromal patients with an atrial septal defect, this is usually attributed to 
previous surgery, such as the SAN disease observed after closure of atrial septal 
defects.94 Some suggestions in literature are present though, indicating pre-
existent sinus node disease in patients with atrial and atrioventricular septal 
defects95–99 including prolonged sinus node recovery times on electrophysiology 
study. Also results in patients with anomalous pulmonary vein connections have 
shown a propensity to sick sinus syndrome.100–102 Although the SAN disease is 
apparently asymptomatic in the majority of these patients, clinically this might 
imply that the SAN disease observed after surgery may be more pronounced 
due to pre-existent propensity to sick sinus syndrome that is developmentally 
associated with the occurrence of the septal/pulmonary drainage defects.
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6. DEVELOPMENT OF THE VENOUS VALVES AND SEPTUM SPURIUM: 
INTERNODAL PATHWAYS WITH DEBATED FUNCTION
During early embryonic stages a left and right venous valve will develop in the 
right atrium, encompassing the entrance of the cardinal veins. The first sign 
of these valves is visible around E10.5 in mouse, and they are fully developed 
around E11.5. The right and left venous valves are dorsal structures that 
run in between the SAN and AVN, and will connect to the dorsal AVN during 
development.62 Anteriorly, both valves fuse to form the septum spurium, that 
will initially connect to a transient anterior AVN.62 In the developing embryo the 
3 internodal tracts thus correspond to the right and left venous valves and the 
septum spurium, connecting to Bachmann’s bundle (situated retro-aortically in 
between the right and left atrium). 
 Whether or not the internodal tracts are functional is still a matter of debate. 
The initial assumed role of the internodal tracts in fast conduction mainly derives 
from histological observations like the arrangements of the cardiomyocytes103,104 
and the suggested presence of Purkinje fibers.105 The pathways were 
histologically described already several decades ago.104–106 More recent marker 
gene expression studies in embryonic and fetal hearts have also shown distinct 
expression patterns in these tracts in both human62 and animal models.5,6,107,108 
These sinus venosus related structures may represent the predilection sites of 
adult atrial arrhythmogenic areas. For instance, the adult counterpart of the right 
venous valve is the crista terminalis, a common site for atrial tachycardia and key 
player in the reentry path of common atrial flutter.1 The right venous valve is a 
bilaminar structure with distinct expression patterns of the layers bordering the 
sinus venosus part of the atrium, that express a.o. HCN4, versus the appendage 
site of the atrium, that expresses atrial working myocardial markers (see Fig. 
7a, inset). The left venous valve will become part of the atrial septum in human, 
whereas in mouse, and chick it will remain visible as a separate structure 
throughout development.
 Most agree that preferential conduction occurs over the crista terminalis, 
however this has been attributed to cardiac tissue alignment109 and not to 
specialized tracts. On the other hand, in the late seventies several studies showed 
preferential conduction of the cardiac impulse via pathways resembling to the 
internodal tracts as described by James.104–106 In these studies, the administration 
of high doses of potassium in dog led to deprived electrical conduction in the 
atria except in sites corresponding with the internodal pathways and Bachman´s 
bundle.110,111 Another recent study based on experiments with sodium channel 
blockers also indicates the presence of a preferential internodal conduction 
pathway in the right atrium.83 These observations are further substantiated by 
studies in atrial preparations of canine hearts in which exposure to elevated 
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potassium levels also resulted in preferential conduction via the internodal 
pathway112, as well as by results of optical mapping of atrial conduction patterns.113 
The implications of these findings for conduction pattern in the human situation 
however, remains to be determined.
7. NORMAL AND ABNORMAL DEVELOPMENT OF THE AVN 
7.1. NORMAL DEVELOPMENT
The AVN is located in the posterior wall of the right atrium (Fig. 1),  against the 
central fibrous body in the triangle of Koch, that is bordered by the ostium of the 
coronary sinus, the tendon of Todaro and the attachment of the septal leaflet 
of the tricuspid valve.114 In human and lower mammals the AVN consists of a 
compact nodal part, that is covered by transitional cells, believed to be an atrial 
contribution to the AVN.115 Nodal extensions originating from the AVN run towards 
the vestibules of the tricuspid and mitral valves.116–121 During development the 
AVN can be identified from approximately the fifth week in human (+/- E11.5 
in mouse).122 During early developmental stages, the AVN myocardium cannot 
be distinguished from the AV canal myocardium, a circumferential band of 
myocardium between the atria and ventricles. A dual anlage of the AVN has 
been described, with both an anterior and posterior node present during early 
development, which will fuse to form the AVN primordium.62,123,124 The posterior 
node connects to the His bundle and will eventually form the major part of the 
definitive AVN. The cellular origin of the AVN is still controversial. Among several 
hypotheses proposed over the past decades are (1) an origin from the AV canal 
myocardium122,125–127; (2) a confluence of the sinoatrial ring, AV ring and possibly 
the primary fold38,61, or from the primary fold alone128; (3) an origin from the 
atrial dorsal wall129, or (4) from the lower part of the interatrial septum130 and 
(5) an embryonic left-sided counterpart of the SAN, that by remodeling of the 
left cardinal vein will be positioned at its mature location near the ostium of 
the coronary sinus in the right atrium.49 The presence of morphologically and 
electrophysiologically distinct cells in the AVN may indicate that cells from 
multiple sources contribute to its formation.49,131,132
 Whereas an origin of the SAN from the PHF is nowadays well established, 
whether or not there is a SHF contribution to the AVN, is still unresolved. Lineage 
tracing studies indicate that at least the compact part is derived from the AV ring 
myocardium (itself first heart field-derived).20 However, other studies have also 
indicated a contribution from the second heart field.21 The lower part of the AVN 
was found to be derived from ventricular myocardium, whereas the origin and 
function of an eventual atrial septal component of the conduction axis remains 
unclear.20 During development, the murine AVN is molecularly characterized by 
expression of HCN4, Tbx3, Tbx5 and Cx45 and lacks Cx40 and Cx43.20,24 Whether 
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Figure 8. AVN development in chicken
a,d. Schematic representation of HCN4 expression in the heart at an early (a) and later (d) 
developmental stage, after looping has progressed. Next to HCN4 expression in the sinus venosus 
myocardium, HCN4 is expressed in the entire AV canal (AVC), including the putative AVN. b,e. 
Histological sections, level: base interatrial septum (AVN region) in HH24 (b) and HH35 (e) heart. 
cTNI staining. AVN region is characterized by the presence of loose cells with large intercellular 
spaces as compared to the working myocardium. c,f. Histological sections demonstrating expression 
of HCN4 mRNA at the same regions in HH24 (c) and HH35 (f) heart. AVR: AV ring, BB: bundle 
branches, CB: common bundle/His bundle, IAS: interatrial septum, LA: left atrium, LCV: left cardinal 
vein, LV: left ventricle, MB: moderator band, PF: primary fold, PV: pulmonary vein, RA: right atrium, 
RCV: right cardinal vein, RV: right ventricle, SAN: sinoatrial node. Scale bars: 150µm.
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the avian system has a circumscript AVN is still a matter of debate. In contrast 
to mouse, we were not able to distinguish a compact and transitional nodal 
part in chicken. However, a distinct expression pattern of HCN4 throughout the 
AV canal and lower part of the atrial septum, as well as Cx43 and PAS staining 
patterns could be observed (Fig. 8; Vicente Steijn et al., unpublished data). 
The maturation of the AVN seems not to be completed at the time of birth, as a 
number of structural changes with regard to rearrangement of myocardium as 
well as fibrous tissue occurs in the first year of life.133,134
 With regard to electrophysiology, an AV delay can be recorded already at 
early developmental stages in the AV canal, that possesses a slow-conducting 
phenotype.135 Later in development, the AVN becomes responsible for the AV 
delay.130 Eventually the AV myocardial continuity will disappear as a result of 
annulus fibrosus formation136, with the common bundle remaining as the only 
myocardial continuity that will propagate the electrical impulse to the ventricles. 
The common bundle and bundle branches will conduct the impulse rapidly to 
the ventricular working myocardium, and the immature base-to-apex activation 
pattern of the heart will shift to the mature apex-to-base activation pattern.136
7.2. ABNORMAL DEVELOPMENT: MOUSE MODELS
As described above, several genes are currently recognized in the AVN during 
development, and mouse models that display a disturbed AVN phenotype are 
available. Tbx3 disruption results in AV block, pre-excitation, and an increased 
risk for sudden cardiac death.80 Mutations in Tbx5, the pivotal gene disrupted in 
the human Holt-Oram syndrome137, result in deficient maturation of the AVN.24 
HCN4, which as described above is responsible for the sinoatrial “funny current” 
is also expressed in the AV canal and AVN during development27,28, and next to 
profound bradycardia, disruption results in AV block.138 Nkx2.5 knockout animals 
show conduction defects that include AV block.139 Mutations in the Nkx2.5 gene 
have been described in human patients with congenital AV block.140,141 
7.3. CLINICAL IMPLICATIONS: RHYTHM AND CONDUCTION 
DISORDERS FROM THE AVN AND AV JUNCTION
The presence of histologically, and perhaps electrophysiologically distinct cells 
within the AVN is of relevance for arrhythmias originating in the AVN, the so 
called AV nodal reentry tachycardia (AVNRT), as a prerequisite for the occurrence 
of reentry is the presence of 2 pathways with distinct electrophysiological 
characteristics.142 Extensions from the AVN, mostly referred to as inferior 
nodal extensions120,143 are considered the substrate for the “slow pathway” 
that underlies the occurrence of AVNRT and are the target for radiofrequency 
catheter ablation.144 The origin and cellular composition of the inferior nodal 
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extension has been described as a continuation of the compact AVN.20 However, 
as mentioned above, it may also consist of transitional cells extending into the 
AVN from the atrial or sinus venosus myocardium143 or be a combination of 
both. Interestingly, the gene expression profile of the inferior nodal extension 
was found to be similar to that of the SAN145, indicating a possible contribution 
of the sinus venosus myocardium. In this respect it is interesting to note that 
pacemaker activity of the AV junction has been attributed to the inferior nodal 
extension.146 Other arrhythmias originating from the AV junction include clinical 
arrhythmias originating from the tricuspid and mitral junction.147,148
  Persistence of a fetal phenotype of the AVN, so-called fetal dispersion134, has 
been related to the appearance of sudden cardiac death in the young.149,150
7.4. CLINICAL IMPLICATIONS: ASSOCIATION CONGENITAL 
HEART DISEASE AND CONDUCTION SYSTEM DISEASE
The dual developmental origin of the AVN62 is interesting in the light of congenitally 
corrected transposition of the great arteries (ccTGA), which is characterized by 
both a atrioventricular as well as a ventriculo-arterial discordance. Due to a 
malalignment of the atrial and ventricular septum, leaving a “gap” preventing 
the dorsal AVN to reach the ventricular CCS, an antero-superior position of the 
AVN can be found.151,152 In case of normal alignment a more normally situated 
postero-inferiorly position (between the annulus of the right-sided mitral valve 
and the ostium of the right atrial appendage) of the AVN is encountered, although 
a “sling of tissue” to an additional anterior AVN can also be observed.151,152 There 
seems to be a correlation between the diameter of the pulmonary trunk and 
septal malalignment.153 These findings indicate that normal development of 
the AVN depends on normal alignment of the atrial and ventricular septa152, 
whereas an anterior AVN will be dominant in cases with septal malalignment. In 
case of ccTGA the bundle of His penetrates the AV junction at the area of fibrous 
continuity between the pulmonary and mitral valves, and there is an inversion of 
the bundle branches. 
 As mentioned previously, human mutations in the Tbx5 gene are observed 
in the Holt-Oram syndrome, characterized by hand-limb disorders, atrial septal 
defects and  (predominantly) AV conduction disorders.92
 In patients with atrioventricular septal defects (AVSD), AV conduction 
disorders are also common.154–156 This is usually attributed to an abnormally 
positioned AVN, with a postero-inferior displacement of the AVN, and a long 
nonbranching bundle of His.157 Recent studies suggest an abnormal development 
of the CCS in AVSD158, rather than a downward displacement of the AVN, and 
lack of apposition of the two primordia of the AVN, resulting in a dorso-inferior 
persisting position of the inferior part of the AVN seems to be underlying the 
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abnormal location of the AVN in AVSD.158 The relatively long route of the His bundle 
probably predisposes to the damage and/or degeneration, resulting in AV block. 
Alternatively, a deficient contribution of the second heart field to the CCS might 
underlie the occurrence of conduction abnormalities in AVSD, as is suggested by 
results indicating a deficiency of the dorsal mesenchymal protrusion (vestibular 
spine) as the underlying cause of AVSD.158,159 The dorsal mesenchymal protrusion 
is derived form the PHF.160 However, a contribution of this mesenchymal structure 
to the AVN has thus far not been established20 although a SHF contribution to the 
AVN has been suggested.21 Additional lineage tracing studies are needed in order 
to determine the exact origin of cells contributing to the AVN. 
8. NORMAL AND ABNORMAL DEVELOPMENT OF THE ANNULUS 
FIBROSUS
8.1. NORMAL DEVELOPMENT
In a mature heart the AV conduction axis comprises the only myocardial continuity 
between the atria and ventricles, the remainder being separated by a layer of 
fibrous tissue at the AV junction i.e. the annulus fibrosus (Fig. 1). Development 
of the AV junction involves the fusion of the AV sulcus tissue from the epicardial 
side with the endocardially located cushion tissue of the developing heart.161–164 
Formation of the annulus fibrosus in mouse as well as in human already starts at 
pre-septation stages of development (around 7 weeks of human development) 
by formation of fibrous tissue near the primitive AV canal.165 Around the twelfth 
week of human development the complete atrial and ventricular myocardium 
are largely separated by the annulus fibrosus.164,165 Full formation of the annulus 
fibrosus is a gradual event and studies in chicken, mouse and human show 
persistence of accessory pathways (APs) until late developmental stages.136,165,166 
Electrophysiological recordings in embryonic and fetal quail hearts showed 
presence of antegrade conducting APs in otherwise normal developing 
hearts.35,136 These APs decreased in number and size at subsequent stages of 
development. Between species, differences exist in the preferential location of 
APs at the annulus fibrosus. At late stages of human heart development most 
APs were observed subendocardially at the lateral aspect of the tricuspid valve 
orifice.165 
 Epicardium-derived cells (EPDCs) are important for proper development 
of the annulus fibrosus. During development, EPDCs will migrate into the AV 
annulus and play a role in fibrosation of the annulus and fusion of the epicardial 
sulcus tissue with the endocardial cushion tissue.35,36 Another factor involved 
in formation of the annulus fibrosus is bone-morphogenetic protein (BMP) 
signaling.167,168 The extracellular matrix molecule periostin was postulated to have 
an important role in annulus fibrosus formation because of its ability to directly 
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regulate collagen-I fibrillogenesis.169 A study by the group of Zhou confirmed 
that EPDCs differentiate into fibroblasts contributing to the annulus fibrosus, 
and showed colocalization of EPDCs with periostin in the annulus fibrosus in 
mouse. The EPDCs in the annulus fibrosus were highly enriched for markers 
for fibroblasts as well as for markers for EMT and cellular migration.170 Recent 
studies indicate that distinct subpopulations of EPDCs can be found, suggesting 
that this might also be the case in the region of the annulus fibrosus.171 Periostin 
expression data in mouse showed that in the developing AV junction periostin 
is never co-expressed in cardiomyocytes.166 Whether periostin is the key factor 
in AV isolation remains doubtful, since recent studies in periostin mutant mice 
showed that periostin null mutants are largely normal and do not show an 
abnormal cardiac phenotype.172 
8.2. ABNORMAL DEVELOPMENT: ACCESSORY PATHWAYS IN 
ANIMAL MODELS AND HUMAN
APs are defined as accessory bundles of cardiomyocytes, which interconnect the 
atrial and ventricular myocardium next to the AV conduction axis. These APs 
may either conduct the action potential in an antegrade (atrium-to-ventricle) 
or a retrograde (ventricle-to-atrium) manner. Furthermore, APs may form the 
substrate for supraventricular arrhythmias such as WPW syndrome and Mahaim 
tachycardia. Studies in both human and animals have shown that APs can be 
located anywhere at the AV junction and can be positioned endocardially or 
epicardially. Although it has been well established that abnormal development 
of the AV junction, as observed in patients with Ebstein’s anomaly, coincides 
with high numbers of APs,173,174 there is still debate on the exact origin of APs. 
Electrophysiological studies in human175,176 and animal models177 demonstrated 
that not all APs share the same electrophysiological conducting properties, 
some APs even have decremental properties resembling to those of specialized 
CCS tissue175, whereas others demonstrate a working myocardium phenotype. 
Moreover, morphological analysis of APs indicated that not all APs show the same 
cellular morphology.178–180 In clinical practice not all APs in patients suffering 
from AV reentry tachycardia (AVRT) react similarly to anti-arrhythmic drugs.181 
All these arguments may indicate that not all APs share a common developmental 
origin.    
 Incomplete (pathological) maturation of the annulus fibrosus has 
developmentally been related to deficient contributions of EPDCs. Epicardial 
inhibition in chick and quail results in broad accessory AV connections, pre-
excitation on the electrogram, and, in contrast to the accessory AV connections 
observed during normal heart development, negative staining patterns for 
periostin.35,36 Furthermore, lack of expression of periostin in the AV endocardial 
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cushions was observed, as well as lack of delamination of mural valve leaflets, 
resulting in Ebstein-like valvular anomalies. The relation between EPDCs and 
periostin was further studied in vitro and in vivo, and indicated that during 
development, EPDCs are local producers of periostin.36 Alk3 is also required for 
periostin expression in the developing AV valves. Targeted deletion of Alk3 results 
in abnormalities of the cardiac inflow tract/AV valves, as well as in disruption 
of the annulus fibrosus resulting in ventricular pre-excitation.167 These data are 
interesting in the light of the co-occurence of accessory pathways and tricuspid 
valve anomalies in Ebstein’s anomaly and ccTGA.182 
 A special group of accessory pathways is formed by the so-called atrio-
fascicular tracts underlying Mahaim tachycardia. These tracts might be narrowly 
related to right ventricular inflow tract development as functional APs were 
observed at the right AV junction, connecting to the right bundle branch via 
the moderator band.183 In Mahaim tachycardia the APs have decremental 
properties resembling that of the AVN175,184, which might indicate that some APs 
are composed of specialized conducting tissue. Furthermore, it is well known 
that APs involved in Mahaim tachycardia have a morphological relation with 
the specialized CCS and interconnect the AVN or His bundle to the fascicles or 
ventricular muscle.132 Nevertheless, the question remains whether the presence 
of APs with decremental properties can also be related to the normal process of 
cardiac development. 
 Several genetic mutations have been identified that coincide with high 
percentages of APs. Mutations in the gene encoding the gamma2 regulatory 
subunit of AMP-activated kinase (PRKAG-2) have been found in families with 
WPW syndrome. Patients carrying this mutation suffer from ventricular pre-
excitation, atrial fibrillation, conduction defects and cardiac hypertrophy.185,186 
Mouse models with this specific mutation demonstrated postnatal development 
of APs responsible for ventricular pre-excitation.187 Another mutation 
recently related to AP etiology is in the BMP receptor Alk3 described above.167 
Furthermore, the conditional knockout of Tbx2 results in disturbed development 
of the AV myocardium and pre-excitation.188
8.3. CLINICAL IMPLICATIONS: PRE-EXCITATION SYNDROMES
AVRTs represent the largest group of tachy-arrhythmias pre- and postnatally 
and can be potentially life-threatening.189,190 APs underlying AVRT can present 
at the tricuspid as well as the mitral valve orifice. The incidence of APs tends to 
be higher at the left/mitral valve orifice.191–193 The etiology of the APs underlying 
this specific type of arrhythmia is largely unknown. In a minority of cases genetic 
mutations are involved, like PRKAG-2 (in familiar WPW syndrome)185,186 and 
Alk3 and Tbx2 (in mice).167,188 Furthermore, high numbers of APs are found 
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in combination with other forms of congenital heart disease i.e. Ebstein’s 
anomaly173,174 and ccTGA.182 
 In human, two-thirds of newborns diagnosed with AVRT based on the presence 
of APs remain free of symptoms before the age of one year without additional 
anti-arrhythmic therapy or invasive treatment strategies.190,194,195 This might 
suggest that annulus fibrosus formation and maturation is not finished by the 
time of birth and extends into the first year of life. Prolonged cardiac maturation 
during the first year of life might cause APs to spontaneously disappear, so that 
AVRT automatically resolves. This is supported by the observation that especially 
the development of the fibrous structures of the heart that includes the annulus 
fibrosus, extends into postnatal life.196,197 The ongoing maturation of the annulus 
fibrosus offers a good explanation for spontaneous AVRT disappearance. 
However, it remains uncertain why approximately one-third of patients have a 
recurrent episode of AVRT later in life.198 
8.4. CLINICAL IMPLICATIONS: CONGENITAL HEART DISEASE 
AND ACCESSORY PATHWAYS
The co-occurrence of right-sided AV valve anomalies and APs in Ebstein’s 
anomaly and ccTGA might indicate a common developmental pathway. We 
propose a disturbed function or contribution of EPDCs during development that 
could account for both the valve anomalies as well as the APs that were observed 
in animal models, as indicated above.36,167 In this respect it is also interesting to 
note the common occurrence of Mahaim tachycardia in patients with Ebstein’s 
anomaly of the tricuspid valve199, which has also been related to the deficient 
development of the right ventricular inflow tract.183 
 ccTGA is associated with accessory AV connections, indicating a deficient 
formation of the annulus fibrosus. Furthermore, Ebstein-like malformations 
of the tricuspid valve are frequently observed200, as well as ventricular non-
compaction.201 Interestingly, a deficient formation of the annulus fibrosus, 
abnormalities of the AV valves as well as ventricular non-compaction have all been 
observed in animals models with deficient contributions of the epicardium32,167, 
indicating a possible deficient contribution of the mesenchymal part of the 
posterior heart field, from the PEO and its derived cells. Also looping defects have 
been described in this phenotype.32 
40  Chapter 2 
2
Figure 9. Working model for the developmental background of clinical arrhythmias in the child/
adult (figure on page 41)
Selected clinical arrhythmias in human patients are frequently observed in anatomical predilection sites 
which may be related to the embryonic development of the CCS. Here a working model is presented 
relating embryonic structures to the adult counterparts, and the arrhythmias that have been observed 
to originate in these areas. For further explanation, see text.
A: common atrium, Ao: aorta, AoS: aortic sac, AV: atrioventricular, AVC: atrioventricular canal, AVN: 
atrioventricular node, AVRT: AV reentry tachycardia, AV-TZ: atrioventricular transitional zone, CS: 
coronary sinus, GCV: great cardiac vein, ICV: inferior caval vein, LA: left atrium, LBB: left bundle branch, 
LCV: left cardinal vein, LV: (putative) left ventricle, LVOT: left ventricular outflow tract, LVV: left venous 
valve, MB: moderator band, OFT: outflow tract, OFT-TZ: outflow tract transitional zone, PF: primary fold, 
PT: pulmonary trunk, PV: pulmonary vein(s),  RA: right atrium, RBB: right bundle branch,  RCV: right 
cardinal vein, RV: (putative) right ventricle, RVOT: right ventricular outflow tract, RVV: right venous 
valve, SAN: sinoatrial node, SA-TZ: sinoatrial transitional zone, SCV: superior caval vein, SP: septum 
primum, V: common ventricle, VM: vein of Marshall/Marshall ligament, VS: ventricular septum, VT: 
ventricular tachycardia, WPW: Wolff-Parkinson-White syndrome.
9. WORKING MODEL FOR DEVELOPMENTALLY BASED CLINICAL 
ARRHYTHMIAS (FIG. 9)
In children and adult patients with structurally normal hearts various 
arrhythmias can be observed. Electrophysiological studies have indicated 
predilection sites in the heart from which these arrhythmias may originate, 
that include the myocardium surrounding the caval veins, coronary sinus 
and pulmonary veins, the ligament of Marshall, accessory pathways at the AV 
junction, and the right ventricular outflow tract. In Fig. 9 a working model for a 
developmental background of selected arrhythmias in patients with structurally 
normal hearts is proposed. As described in this review, the embryonic CCS is 
much broader than the definitive adult CCS. This means that larger areas of tissue 
that show CCS characteristics during development will later on differentiate to a 
working myocardium phenotype. In the working model it is proposed that these 
embryonic sites still relate to predilection sites for arrhythmias as observed in 
the adult. In general, remnants of tissues with an embryonic phenotype may 
underlie the occurrence of arrhythmias in the young, whereas the occurrence 
of arrhythmias in the adult might relate to the re-expression of an embryonic 
phenotype. The spontaneous disappearance of arrhythmias in the young is 
according to this model related to postnatal cardiac maturation, whereas in the 
adult a pathophysiological state might contribute to the re-expression of the 
embryonic program, as is supported by the observation of increased expression 
of HCN4 in patients with heart failure and atrial fibrillation.85 
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Figure 9. Working model for the developmental background of clinical arrhythmias in the child/
adult (legend on page 40)
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ABSTRACT
The avian embryo has long been a popular model system in developmental 
biology. The easy accessibility of the embryo makes it particularly suitable 
for in ovo microsurgery and manipulation. Reincubation of the embryo allows 
long-term follow-up of these procedures. The current review focuses on the 
variety of techniques available to study development of the cardiac conduction 
system in avian embryos. Based on the large amount of relevant data arising 
from experiments in avian embryos, we conclude that the avian embryo 
has and will continue to be a powerful model system to study development 
in general and the developing cardiac conduction system in particular. 
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1. INTRODUCTION
The avian embryo has long been a popular model system in developmental biology. 
More than 300 years B.C., even Aristotle appreciated the value of the chick to study 
embryonic development.1 Since then, numerous elegant experimental techniques 
have been developed, utilizing the specific advantages of avian embryos. This 
chapter provides an overview of the different methods used in avian embryos, 
specifically to elucidate the development of the cardiac conduction system (CCS). 
We first provide an overview of cardiac and CCS development in general and then 
discuss the particular advantages and disadvantages of the avian embryo to study 
CCS development. Finally, the techniques most effective for exposing the embryo 
in the egg and studying the electrophysiology and molecular differentiation of 
the developing CCS are described, with a short discussion of results obtained 
from these experiments.
2. GENERAL CARDIAC AND CCS DEVELOPMENT AND FUNCTIONING 
During gastrulation, mesodermal cells arise from the primitive streak and 
subsequently migrate cranially and laterally to form the cardiogenic plates. The 
first sign of cardiomyocyte differentiation is evident in this region at approximately 
Hamburger and Hamilton (HH)2 stage 8-9 in chick, when cardiac troponin-I (CTNI) 
and sarcomeric myosin (MF20) are first detectable. Fusion of bilateral plates of 
splanchnic mesoderm establishes the primary heart tube (PHT).3,4 Subsequently, 
cells are added to the PHT from undifferentiated mesoderm, which is situated at 
the arterial and venous pole of the heart. Complex migration, proliferation and 
differentiation of different cardiac cell types (cardiomyocytes, endothelial cells, 
epicardial cells, (myo)fibroblasts and smooth muscle cells) finally establishes 
the mature 4-chambered heart, with its own (coronary) vasculature, specialized 
conduction system and valvular apparatus.5 In addition, neural crest cells migrate 
into the heart from the dorsal region of the rhombencephalon and take part in 
processes that include induction of aortopulmonary septum formation.6
 The CCS initiates and coordinates electrical activation of the myocardium, 
which is essential for normal functioning of the heart. Rhythmic contraction of 
the PHT starts around HH10 and differences in conduction velocity are already 
evident by HH13.7 The cells contributing to the CCS are derived from precursors 
within the myocardial cell lineage.8 The adult CCS has several components 
(Fig. 1): the sinoatrial node (SAN) consists of pacemaker cells responsible for 
initiating atrial electrical activation. Myocardial cells contributing to the SAN 
originate from the sinus venosus myocardium, an initially U-shaped region of 
myocardium with pacemaking capacity9 encompassing the bilateral cardinal 
veins (putative caval veins, that will remodel in favour of the right side during 
54  Chapter 3 
3
Figure 1. The components of the cardiac conduction system
Schematic drawing of the components of the adult CCS. AVN: atrioventricular node, CB: common 
bundle, CS: coronary sinus, ICV: inferior caval vein, LA: left atrium, LBB: left bundle branch, LV: left 
ventricle, MB: moderator band, PF: Purkinje fiber network, PV: pulmonary vein, RA: right atrium, 
RBB: right bundle branch, RV: right ventricle, SAN: sinoatrial node, SCV: superior caval vein, VS: 
ventricular septum.
subsequent development). The SAN will eventually become the primary 
pacemaker of the heart. After depolarization of the atria, the electrical current 
is delayed in the atrioventricular node (AVN), thereby ensuring adequate filling 
of the ventricles. A significant part of the AVN most likely originates from the AV 
canal, a component of the primary heart tube, although recent data indicate an 
additional sinus venosus contribution to the superior part of the node.10,11 After 
a short delay, the AV bundle, the bundle branches and Purkinje fibres propagate 
the electrical current at high velocity to the ventricular myocardium.  
 An important structure for proper CCS function is the annulus fibrosus, a layer 
of dense fibrous cells, which electrically isolates the atria and ventricles, with the 
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exception of the region where the AV bundle (also referred to as His or common 
bundle) penetrates this layer. This electrical isolation is essential for correct 
timing of atrial and ventricular activation. The fibrous cells contributing to the 
annulus fibrosus originate from the monolayer of epithelial cells lining the heart, 
the epicardium. The epicardial layer in turn is derived from the proepicardial 
organ (PEO), a cauliflower-like structure, which protrudes from the sinus 
venosus surface at the venous pole of the heart into the pericardial cavity. Cells 
derived from the PEO attach to the myocardium of the heart and then migrate 
over its entire surface. Through epithelial-to-mesenchymal transformation 
(EMT), epicardium-derived cells (EPDCs) are formed, which migrate into the 
myocardium and undergo further differentiation to several cell types including 
fibroblasts of the annulus fibrosus. Furthermore, the EPDCs play a role during 
development of the Purkinje fiber network, as discussed below.12
3.1. ADVANTAGES OF THE AVIAN EMBRYO AS A DEVELOPMENTAL 
MODEL 
The wide use of the avian embryo as a model system in developmental biology is 
because it has a number of specific advantages, which are described below. 
 The avian embryo is easily accessible. The avian embryo develops ex utero in 
an extracorporal egg. It is fairly easy to create a window in the eggshell without 
damaging the embryo (see Section 4). The embryo can thus be exposed and it 
is then possible to manipulate it directly in situ, essentially intact in its native 
environment. After micromanipulation of the embryo at room temperature, 
the egg can be re-sealed and incubated once more to allow development to 
proceed, thereby creating the opportunity to study long-term effects of the 
micromanipulation. 
 Timing of developmental stages is very precise. In 1951, Hamburger and 
Hamilton proposed staging criteria for avian embryos.2 Their HH-staging is still 
widely used among researchers working with avian embryos. This has greatly 
enhanced the reproducibility and precision of experiments between different 
laboratories, since through careful staging, comparable groups of embryos can 
be created simultaneously.
 The avian embryo is more widely ethically accepted than mammals and is cost-
effective. Advances in science still require the use of laboratory animals for many 
important research questions to be investigated. In contrast to developmental 
studies in placental mammals like rodents, sacrifice of the pregnant mother is 
not required. Furthermore, fertilized eggs are inexpensive and the only specialist 
equipment required is a humidified incubator. In addition, large numbers of 
biological repeats are easily carried out on avian embryos whilst this is more 
limited with rodents, where litter sizes are between 8 and 10 embryos. 
56  Chapter 3 
3
 In addition, the administrative burden of using fertilized chicken eggs is 
minimal, since they do not fall under laboratory animal regulations in most 
countries, at least during the first part of embryonic development. 
 Finally, the chicken genome has now been sequenced providing the possibility 
for comparing molecular data with other major laboratory species and human. 
This solved one major drawback of the chicken model. 
3.2. DISADVANTAGES OF THE AVIAN EMBRYO AS A DEVELOPMENTAL 
MODEL
The major disadvantage of the chick as a model is the paucity of genetic tools. 
Transgenic mice have become one of the most important tools for studying 
gene function and cell fate. Many transgenic mouse lines are now available 
and this has been invaluable for understanding development and disease in 
higher vertebrates.  Transgenic chicken embryos have not been available until 
very recently although recent advances in biotechnological methods have now 
enabled the creation of transgenic chickens13, which opens up a wide variety of 
possibilities for the chicken as a model system in developmental biology. 
 Another disadvantage is that many antibodies required for 
immunohistochemistry, Western blotting etc. are targeted against human or 
mammalian (predominantly rat and mouse) epitopes. Even though a large 
number of antibodies show specific cross-reactivity with avian tissue, the 
number of commercially available antibodies is less than for mammalian tissue. 
A possible method to (partially) overcome this problem is non-radioactive in situ 
hybridization. This method is used to visualize mRNA expression and was for 
example used to detect the expression of the hyperpolarization-activated cyclic 
nucleotide-gated channel 4 (HCN4), which is the ion channel responsible for the 
funny current.14 
4. OPENING THE EGG 
The first step to study the developing chick embryo is to open the eggshell 
without damaging the embryo. Our technique has proven particularly useful 
for accessing the embryo with minimal risk of damage and/or dehydration. 
Eggs of the White Leghorn chicken are incubated at 37°C and 80% humidity. 
Although earlier stages have been studied extensively15–17, we will use HH stage 
15 (embryonic day 2.5) as an example. 
 1. “Candling” the egg as a first and shown in Fig. 2a, ensures that the embryo 
is properly located before cutting a window in the shell. 2. The egg is then 
disinfected with 70% ethanol. 3. Three indentations are then sawn with a small 
handsaw in the eggshell (a “U” shape) until the eggshell membrane is reached 
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Figure 2. Procedure to safely open the egg
a. Start with "candling" the egg to locate the embryo (dotted line represents the embryo, arrowheads 
depict the embryonic vasculature) b. Saw a “U” shape in the eggshell (arrowhead) c. Place a drop of 
saline solution over the “U” shape and make a small opening (arrowhead) in the eggshell membrane 
to allow the saline solution to enter the egg. This creates room between the eggshell and the embryo, 
thereby preventing damage when opening the egg. d. Remove the egg shell to expose the embryo 
(arrowhead).
(Fig. 2b). 4. A drop of physiological saline is used to wash away eggshell debris 
and another drop is placed on the “U” shape. 5. Using blunt tweezers, a small 
hole is made in the eggshell membrane (Fig. 2c) to allow the saline solution to 
enter the egg, thereby creating space between the embryo and the eggshell; this 
facilitates opening the egg without damaging the embryo. 6. Blunt tweezers are 
then used to remove the “U” shaped window in the egg and remove the eggshell 
membrane and expose the embryo (Fig. 2d). 7. To gain access to the embryo 
it might be necessary to open the vitelline membrane.  8. After manipulation, 
imaging, microinjection etc. of the embryo as required, the window in the egg is 
covered with surgical or transparent tape. This prevents dehydration. 9. Finally, 
the egg is placed in the incubator to allow further development to the stage 
required.
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5. TECHNIQUES FOR STUDYING DEVELOPMENT OF THE CARDIAC 
CONDUCTION SYSTEM
The following section provides an overview of the different techniques that have 
been used to investigate the development of the CCS.  For every technique, a 
short description is given, followed by discussion of relevant results obtained for 
CCS development. 
5.1. INHIBITING OUTGROWTH OF THE EPICARDIAL LAYER 
In 1993, Manner described a method for inhibiting outgrowth of the epicardial 
lining of the heart.18 This was used to study the role of the epicardium during 
cardiac development. A recent review by Manner focuses on the different 
experimental techniques available to inhibit outgrowth of the epicardium from 
the PEO.19 Since these techniques have been described in detail, only a summary 
will be given here. The focus of the current report is the use of this model for 
studying CCS development. 
 The epicardial inhibition technique is carried out at HH stage 15-17 (day 
3 of development). After opening the egg (see section 4), the vitelline and 
chorionic membranes are opened to reach the pericardial cavity. A small piece 
of eggshell membrane is placed between the PEO and the heart tube (Fig. 3). 
The attachment and outgrowth of the epicardium over the heart tube is thus 
delayed or even inhibited entirely which retards development of the epicardium. 
Subsequently, the egg is closed with transparent tape and reincubated at 37 OC. 
The extent of epicardial inhibition is variable, and depends on the exact location 
of the eggshell membrane. In some hearts, only a small decrease in the number 
of subepicardial EPDCs is observed, while other hearts are (almost) entirely 
devoid of an epicardial layer, with severe reduction in myocardial wall thickness, 
abnormal shape of the heart and defects in coronary vasculogenesis and valvular 
development.20–22 
5.1.1. INHIBITING OUTGROWTH OF THE EPICARDIAL LAYER TO STUDY 
DEVELOPMENT OF THE ANNULUS FIBROSUS
In the normal adult heart, the atria do not share myocardial continuity with the 
ventricles, apart from the AV bundle. The annulus fibrosus forms the insulation 
between the atria and ventricles, which is essential for proper function of the CCS 
and the coordinated mechanical activity of the heart. Development of the annulus 
fibrosus starts with formation of fibrous tissue in the AV sulcus at the epicardial 
side of the developing AV canal. Subsequent fusion with the mesenchymal 
tissue of the endocardial cushions in the AV canal insulates the atrial from the 
ventricular myocardium. During normal development and in early postnatal 
stages, accessory pathways connecting atrial and ventricular myocardium are still 
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Figure 3. Inhibiting outgrowth of the epicardial layer
A chick embryo of HH15 is shown after epicardial inhibition. The red dotted line depicts the primary 
heart tube. A small piece of eggshell membrane (EM, blue dotted line) is placed between the 
proepicardial organ (PEO) and the ventricle (V), thereby inhibiting attachment and outgrowth of the 
epicardial layer. OFT: outflow tract, RCV: right cardinal vein, SV: sinus venosus.
present. Further differentiation and maturation of the fibrous tissue ultimately 
ensures electrical separation of the atrial and ventricular myocardium, apart 
from the penetrating AV bundle.23,24 
  Failure to form a complete mature annulus fibrosus underlies one of the 
most common cardiac arrhythmias, atrioventricular reentrant tachycardia 
(AVRT). Here, the myocardium of the atria and ventricles are connected through 
accessory pathways, which form the substrate for the reentrant circuit found in 
AVRT, bypassing the normal conduction axis. The treatment of choice for this 
debilitating arrhythmia in patients is catheter ablation of the accessory pathway. 
 It has been shown that inhibition of epicardial outgrowth in quail embryos 
resulted in the presence of large accessory pathways with prevalence within 
specific regions of the annulus fibrosus. Accessory pathways were observed 
at late stages of development, after they had disappeared in normal hearts, 
suggesting that they are retained and demonstrating the importance of EPDCs in 
proper development of the annulus fibrosus. Electrophysiological examination 
after epicardial inhibition showed that the ventricular base was activated prior 
to activation of the ventricular apex. This is characteristic of accessory pathways 
and underlies AVRT.  
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5.1.2. INHIBITING OUTGROWTH OF THE EPICARDIAL LAYER TO STUDY 
DEVELOPMENT OF THE PURKINJE FIBER NETWORK 
The Purkinje fiber network forms the distal part of the CCS, which conducts the 
electrical impulse at high velocity to the ventricular cardiomyocytes, followed by 
contraction of the ventricles. The Purkinje fibers are specialized cardiomyocytes 
that are clonally related to the ventricular myocardium.25 
 Eralp et al. performed mechanical and genetic inhibition of the epicardium 
to study the development of the Purkinje fiber network.26 Mechanical inhibition 
was achieved by the method described above, while antisense retroviral vectors 
disturbing Ets transcription were used for genetic inhibition. Ets transcription 
factors play numerous roles in normal physiology and their disruption resulted 
in impaired EMT, which retards EPDC formation.27 The developing Purkinje 
fiber network was studied using immunohistochemical techniques. In both 
models of epicardial inhibition, the Purkinje fiber network was affected as 
shown by a reduction in periarterially located Purkinje fibers. Furthermore, 
the subendocardially located Purkinje fibers displayed abnormal cellular 
morphology and did not form a continuous network.26
5.1.3. INHIBITING OUTGROWTH OF THE EPICARDIAL LAYER TO STUDY 
THE ROLE OF THE EPICARDIUM IN AUTONOMIC MODULATION OF THE 
DEVELOPING CHICK HEART
The cardiac autonomic nervous system (cANS) is essential in regulating heart 
rhythm, contractility and conduction velocity. The heart responds to adrenergic 
stimulation prior to development of the neuronal components of the cANS.28 
Recent work has shown evidence for a role of the epicardium in the autonomic 
response during early chicken heart development.29 The effect of epinephrine 
administration was investigated in microelectrode experiments ex vivo in 
control hearts and after inhibition of epicardial outgrowth. In control hearts, a 
rapid and marked increase in heart rate was seen directly after administration 
of epinephrine. Interestingly, the response was significantly decreased after 
epicardial inhibition. Furthermore, in control HH15 hearts, prior to development 
of the epicardial layer of the heart, no response was seen after administration of 
epinephrine.29 The elegant technique specifically limiting epicardial outgrowth 
was essential for establishing this previously unknown function of the epicardial 
layer.
5.2. MICROINJECTION EXPERIMENTS TO STUDY CCS 
DEVELOPMENT 
The accessibility of the avian embryo makes targeted microinjection experiments 
with signaling factors, teratogens, vital dyes, viruses, small hairpin RNA and cells 
fairly straightforward. Microinjection can be performed at very early stages of 
The avian embryo to study CCS development 61
3
Figure 4. Performing vital dye labeling experiments
a. A chick embryo of HH15 is shown after vital dye labeling with DiI (pink dotted line/arrow). 
Here, the myocardium of the sinus venosus (SV) is labeled. b. The result of labeling is shown on a 
microscopic section. In pink, the DiI label is shown, located in the TNNI2+ myocardium (white) of 
the SV. Blue: DAPI (nuclear stain). A: atrium, OFT: outflow tract, RCV: right cardinal vein, V: ventricle.
development with long-term follow-up. 
 Physical cell labeling experiments start with loading dyes, viral vectors etc. in 
a pulled glass needle. Injection is achieved with a programmable microinjector 
(IM-300 Narishige, Japan) and micromanipulator. After opening the egg (see 
Section 4), the vitelline and chorionic membranes are opened to gain access to the 
embryonic heart. Using a dissection microscope, the needle is positioned directly 
on the structure of interest and the solution is applied with the microinjector 
(Fig. 4), after which the egg is closed and reincubated at 37OC.  The embryos 
can be extracted from the egg at the required time points to analyze the fate of 
labeled cells, investigate the effect of reagents introduced into the embryo etc. 
It is also possible to perform in and ex ovo live imaging of labeled cells, thereby 
creating a live fate map of the cluster of labeled cells.30
5.2.1. IN OVO VIRAL MICROINJECTION EXPERIMENTS TO STUDY THE 
ORIGIN OF THE CCS
Labeling and subsequent follow-up of the fate of these cells can also be achieved 
by microinjection with viral vectors driving expression of a reporter construct. 
By choosing a lineage-specific promoter, it is possible to trace the subset of 
cells in the infected region expressing the gene of interest specifically. This has 
advantages over genetic tracing in conditional Cre mice since infection is of a small 
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subset of cells only. Apart from expression of reporter constructs, this technique 
also allows expression of specific genes thereby creating opportunities for site-
specific overexpression or knockdown of genes. A disadvantage of this technique 
is the difficulty in achieving stable transfection of quantitatively reproducible 
numbers of cells in different embryos. Furthermore, it is difficult to target one 
region only, since dissolved virus may also infect cells at a larger distance, unless 
injection takes place in a confined space such as the lumen of the neural tube. 
Finally, to reach a detectable threshold takes approximately 24 hours. Therefore, 
this technique is less suitable to trace cells directly after labeling. 
 Viral labeling in chicken embryos has been essential to understand the 
cellular origin of the CCS. Gourdie et al. induced β-gal expression in functioning 
cardiomyocytes by retroviral infection at embryonic day 3. Subsequent lineage 
analysis showed that the specialized, fast-conducting ventricular Purkinje fiber 
network was of myocardial origin. Later retro- and adenoviral lineage tracing 
studies showed that also central components of the CCS, such as the AV ring tissue, 
His bundle and bundle branches have a myocardial origin. In these experiments, 
no evidence was found that the components of the CCS derive from a neurogenic 
progenitor, as was previously assumed.8,31
5.2.2.  IN OVO VITAL DYE MICROINJECTION EXPERIMENTS TO STUDY THE 
ORIGIN OF THE CCS
Physical labeling of clusters of cells can be achieved by vital dye labeling. These 
dyes are incorporated in the cell membrane or cytoplasm and can be followed 
during development.30 A large number of dyes are available for this purpose, 
ranging from Indian ink to long-chain carbocyanines, such as DiI. The latter 
category is fluorescent and available in different colours (DiI, DiO, DiD, and DiR 
are, respectively, orange, green, red and infrared in fluorescence). This allows 
tracing of several cell populations simultaneously. Different fluorescent markers 
can mark different subcellular compartments. For instance, DiI will stain the 
cell membrane, whereas CFSE will stain the cytoplasm of the cell.30 Combining 
dyes will allow visualization of different cell compartments within the same cell 
simultaneously.11 Disadvantages of this technique are the dilution of dye over a 
longer period of time, since dye is diluted with each new cell division and its rate 
of disappearance thus depends on the cell division rate in the area labeled and 
the amount of label used. Another disadvantage is the potential cellular toxicity 
of dyes (or the solvents used to dissolve the dyes, such as DMSO. The latter can be 
used in ovo if 1% solvent is not exceeded). 
 Bressan et al. performed vital dye labeling experiments to investigate the 
origin of the cardiac pacemaker cells during early development at HH5, HH8 
and HH10.32 They found that pacemaker precursors were situated in the ISL1-/
NKX2-5- right lateral plate mesoderm. ISL1 is a transcription factor, which 
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plays an important role in cell proliferation, differentiation, and migration and 
is expressed in precardiac mesoderm. NKX2-5 is expressed in cardiomyocytes. 
Interestingly, cells from this ISL1-/NKX2-5- region also contributed to the atrial 
and atrioventricular myocardium and the PEO. These microinjection experiments 
identified a new region of cardiac progenitors. Furthermore, the results showed 
that during early development, an important portion of precardiac mesoderm 
does not (yet) express ISL1 and NKX2-5, at least at high enough levels to be 
detected with in situ hybridization.
 Another series of labeling experiments indicated a possible role for the 
myocardium of the sinus venosus in development of the posterior AV canal.11 
Vital dyes were injected in the ISL1+/TNNI2+ myocardium of the sinus 
venosus at HH15. At this stage, ISL1-/TNNI2+ myocardium is present between 
the ISL1+/TNNI2+ sinus venosus myocardium and ISL1-/TNNI2+ AV canal 
myocardium. Embryos were reincubated at 37OC for 24 or 48 hours after which 
the dye distribution was analyzed. Interestingly, incorporation of ISL1+/TNNI2+ 
sinus venosus myocardium in the posterior region of the AV canal was found. 
Electrophysiological characterization and analysis of gene expression of this 
region indicated a role in CCS functioning (these experiments are described in 
further detail in section 6 and 7). It was hypothesized that the myocardium of 
the sinus venosus plays a role during normal development of the AVN.11
5.3. HETEROSPECIFIC TRANSPLANTATION AND NEURAL 
CREST ABLATION STUDIES TO INVESTIGATE THE 
DEVELOPING CARDIAC AUTONOMOUS NERVE SYSTEM AND 
CCS 
The chick cardiac autonomic nerve system (cANS) is partially neural crest 
derived. Neural crest cells (NCCs) have their origin in the closing region of 
the neural tube after which they migrate throughout the body.  Development 
of cardiac autonomic innervation has been extensively studied in chick. Next 
to studies based on protein expression patterns29,33, several microsurgical 
techniques have been used to study the developing cANS. Inhibition of epicardial 
outgrowth is described above.29 Other techniques used are neural crest ablation 
and heterospecific transplantation studies (in which quail-derived tissue is 
transplanted to chick embryos), which will be described here. 
5.3.1. HETEROSPECIFIC TRANSPLANTATION OF NEURAL CREST CELLS 
(QUAIL-CHICK CHIMERAS)
Heterospecific transplantation of NCCs (quail-chick heterospecific chimeras)34 is 
a cell lineage tracing technique used to study cardiac neural crest development 
in which the chick neural crest is replaced by quail neural crest. More specifically, 
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Figure 5. Heterospecific transplantation of the neural crest
Schematic representation of the technique used to perform heterospecific transplantation of the 
neural crest. The dorsal part of the neural tube of the quail, containing the neural crest, is excised. In 
the chick, of comparable embryonic stage, the same region is removed and the quail neural crest is 
placed in the position of the removed neural crest. 1: somite 1, 2: somite 2, OV: otic vesicle.
the dorsal part of the neural tube containing the cardiac neural crest is removed, 
and replaced by quail cardiac neural crest from a comparable embryonic stage 
(Fig. 5).35 Quail cells can be distinguished from chick cells by differences in 
nuclear morphology and quail-specific antibodies. This allows the transplanted 
quail NCCs that contribute to cardiac neurons, to be traced in the chick. However, 
as the typical nuclear heterochromatin pattern used to distinguish the quail cells 
from chick cells is lost when the quail NCCs enter the heart, anti-quail nuclear 
antibody (anti-QCPN) can be used to visualize quail cells in the neural crest 
derived neuronal cells, that also express the markers HNK-1 or RMO-270.33,35,36 
 Heterospecific transplantation studies have shown that cardiac autonomic 
ganglia at the arterial pole are neural crest derived.34 In addition, studies by 
Verberne et al., using heterotopic transplantation in combination with retroviral 
lacZ transfer have shown a contribution of NCCs to parasympathetic neurons in 
the entire cardiac plexus, including at the venous pole of the heart.35
 Although the technique has been used to clarify the origin of cells contributing 
to the cardiac sympathetic and parasympathetic innervation successfully, 
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heterospecific transplantation reduces survival rates of treated embryos and 
causes surgical damage in the chimeras, confounding interpretation of results. 
5.3.2.  NEURAL CREST ABLATION TO INVESTIGATE THE DEVELOPING CANS
Neural crest ablation37,38 involves the surgical removal of regions of the neural 
crest in the developing chick embryo using for instance a microcautery needle 
or laser ablation. This technique has been used to study cardiac innervation and 
revealed disruption of parasympathetic innervation after bilateral ablation of 
the neural crest over occipital somites at early developmental stages.39 However, 
the technique is limited by the potential recruitment of neural derivatives 
from adjacent non-ablated regions compensating for the ablated cells.40 In 
addition ,partial regeneration of the neural crest following surgical removal, 
or an alteration in the contribution of incoming sympathetic or preganglionic 
parasympathetic elements may account for a limited extent or impact of the 
applied lesions.39
 More recently, cardiac neural crest ablation was used in chick to study 
ventricular activation patterns. Laser ablation of cardiac neural crest in chick 
embryos, followed by optical mapping techniques, resulted in immature 
(base-to-apex) activation patterns. Histological analysis of the laser-ablated 
embryos revealed a lack of differentiation and separation from the surrounding 
myocardium of the His bundle. This indicates a significant function of the cardiac 
neural crest in electrical isolation of components of the CCS from the surrounding 
myocardium.41 
5.4. EFFECTS OF DRUGS AND EXPERIMENTAL COMPOUNDS
 The easy accessibility of the chicken embryo makes it possible to directly 
administer test compounds of interest directly onto the embryo.42,43 Furthermore, 
long-term follow-up (even into adulthood) of the effects of the compound is 
achievable, since the embryos can continue normal development to hatching.  
 Our technique is as follows. After opening the egg and the extraembryonic 
membranes, the compound can be delivered directly on the embryo. Another 
option is to inject compounds in the pericardial cavity, or into the vitelline veins/
arteries. To perform functional inhibition, loaded heparin beads can be placed 
in the developing area of interest, after which the bead-bound compound is 
slowly released over time. We have carried this out using the ROCK inhibitor 
Y-27632 (Kelder and Vicente-Steijn, unpublished data) as have others.44 The 
measured outcome depends on the aim of the study (e.g. assessing the effects on 
electrophysiological function, cell migration, proliferation, or apoptosis). Timing 
of administration is important and again depends on the aim of the study. We 
were successful in administering the ROCK inhibitor Y-27632 in ovo at HH10-
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12 to study the effect on components of the developing CCS. Previous studies 
showed that the RHOA-ROCK signaling pathway is important in the developing 
CCS,45–47 which we recently confirmed (Kelder and Vicente-Steijn, unpublished 
data).
 A standardized approach to investigate the potential toxicity of compounds 
is called the Chick Embryotoxicity Screening Test (CHEST) as developed by 
Jelínek and colleagues.48 This method has two phases. In the first phase (CHEST 
I) the compound is administered at HH10-11 at increasing doses and shortening 
of the embryonic trunk is used as outcome parameter (indicating interference 
with function of the caudal morphogenetic system). In the second phase (CHEST 
II) the last ineffective (no significant shortening of trunk length) and first two 
effective (significant shortening of trunk length) are used. These doses are 
administered at E2-4 and the embryos are analyzed at E8. The method includes 
analysis of mortality, gross morphological abnormalities and analysis of cardiac 
defects such as ventricular septal defects or outflow tract abnormalities.48 This 
method was used to investigate the toxicity of bilirubin49, mirtazapine50, urban 
air particulate matter51, ibuprofen52, a selection of psychotropic drugs such as 
haloperidol48, and mycotoxins.53 The CHEST method can be used to study all 
known and newly developed compounds as a screen to identify potentially toxic 
substances. When a compound is identified as potentially harmful, additional 
experiments are carried out to assess human relevance.  
5.5. GENETIC CHARACTERIZATION OF THE CCS IN THE CHICK 
Quantitative gene expression can be determined using qPCR. Determining the 
type of input material is crucial to answer the question of interest. Expression 
can be studied in the entire heart or in specific regions, for example Pitx2c54 in 
the left side of the heart (providing left-sided identity) or only in the atria and 
not in the ventricles, like Nppa55 (exclusively found in the adult atrial tissue). 
Methods of tissue collection are described in the next sections.
5.5.1. QPCR OF MACROSCOPICALLY COLLECTED TISSUE  IN THE CHICK
Microdissection of the region of interest within the heart can be performed 
under a microscope and validated with a known panel of genes expressed in 
that region.56 Standard commercially available isolation kits (Qiagen RNEasy 
MicroKit) work well in chick and allow isolation of minute quantities of RNA from 
individual regions of the heart. qPCR analysis showed little sample-to-sample 
variation, a distinct advantage when comparing  individual hearts of control and 
treated or manipulated hearts since the variability within and between the groups 
can be assessed fairly precisely. Furthermore, this high reproducibility allows 
dose dependency to be studied. We have been able to study gene expression at 
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the inflow tract including the developing SAN of ED3 chicken hearts (HH17-19) 
quite reproducibly and robustly. At later stages, the right and left portion of the 
sinus venosus can be studied separately. This is relevant since several structures 
of the developing CCS are bilateral or dual in origin such as the SAN9,14 and 
possibly also the AVN.57 Using this technique, it is possible to study the effects on 
RNA expression of a specific treatment or chemical compound on the right-left 
asymmetry axis of the heart58, including the effects on lateralization of the CCS.
5.5.2. QPCR ANALYSIS AFTER LASER CAPTURE MICRODISSECTION OF 
SPECIFIC ELEMENTS OF THE CCS
In carrying out gene or protein characterization in conduction system tissues, an 
important drawback is the difficulty in dissecting subsets of cells within an organ. 
An elegant method to overcome this problem is laser capture microdissection 
(LCM).59,60 This technique enables the user to extract a specific region of tissue 
from a section at very high resolution. Combining high-resolution microscopy 
with, for example, fluorescent staining or fluorescent reporter gene expression, 
allows specific isolation of clusters of cells and their further characterization. 
The following section describes the LCM procedure we have used.
 The procedure starts with (cryo)sectioning tissue and mounting the tissue 
on membrane-coated slides (Carl Zeiss Microscopy). After drying (and when 
working with paraffin-embedded tissue, treatment with xylene to remove the 
paraffin) the slides are placed in the LCM microscope (PALM microbeam, Carl 
Zeiss Microscopy). The region of interest is excised with the laser beam (Fig. 
6), after which it is catapulted into an adhesive cap (Carl Zeiss Microscopy). The 
tissue is stored at -80oC until further characterization.
 We have used this approach to study the CCS in the region of the AV junction, 
exploring the myocardial continuity between the myocardium of the sinus venosus 
and AV canal.11 LCM was performed at HH21 to dissect tissue specifically from 
this continuity and compare gene expression with tissue obtained from the more 
caudal portion of the posterior AV canal. Expression of the myocardial markers 
TNNT2 and NKX2-5 was examined as well as HCN4, responsible for the “funny 
current", which enables cardiomyocytes to depolarize spontaneously, which is 
used as CCS marker. Finally, ISL1 expression was measured. ISL1 is expressed 
in precardiac mesoderm and relatively undifferentiated cardiomyocytes and 
was recently shown to act as an important transcriptional regulator of HCN4.61 
Results showed that ISL1 and HCN4 expression was high in the myocardial 
continuity. This shows that the myocardial continuity expresses genes known 
to be essential for normal functioning of the CCS. Furthermore, it indicates that 
even during early development, different cell populations can be distinguished 
within the region of the putative AVN. LCM was essential to isolate the different 
regions of tissue and make this point. 
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Figure 6. Laser capture microdissection of the SAN in chick
a-b. Microscopic section of the region of the SAN (arrow in a-b) prior to microdissection, shown 
at a higher magnification in b. The thin red line demarcates the dissection line, which in this case 
demarcates the SAN c-d. Section of the SAN (arrow in c-d) after LCM, shown at a higher magnification 
in d. The tissue containing the SAN is dissected and catapulted in the adhesive cap. LA/RA: left/right 
atrium, LCV: left cardinal vein, OFT: outflow tract, RVV: right venous valve.
5.6. ELECTROPHYSIOLOGICAL CHARACTERIZATION OF THE 
CCS IN THE CHICK
The main function of the CCS is coordinated electrical activation of 
the myocardium, resulting in synchronized contraction of the heart. 
Electrophysiological characteristics of the developing CCS indicate whether 
its function is normal or abnormal. In Fig. 7, an example is given of different 
electrophysiological techniques used to investigate the development of the early 
CCS. These are described in more detail below.
5.6.1. ELECTROCARDIOGRAPHY IN CHICK EMBRYOS
One of the most commonly used diagnostic tools in cardiology, the 
electrocardiogram (ECG), is also frequently used in the research setting. The ECG 
depicts the electrical activation of the myocardium. Most cardiac diseases (such 
as arrhythmias, channelopathies, cardiac hypertrophy and myocardial ischemia) 
cause abnormalities on the ECG. An important advantage of the chicken embryo 
is the ability to perform in ovo electrocardiography, enabling study of the 
developmental ECG changes without interfering with normal development. 
Furthermore the effect of different interventions like drug administration and 
microsurgery can be evaluated.  
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Figure 7. Examples of electrophysiological measurements to study the pacemaking potential 
of the sinus venosus myocardium
During early development, the left and right side of the sinus venosus myocardium have the potential 
to start electrical activation of the heart. a-b. Microelectrode recordings showing activation starting 
from the right (a) or left (b) side of the sinus venosus at HH20. The red line corresponds to the first 
electrical signal. c-d. Optical mapping recordings of the dorsal portion of the heart at HH24, showing 
first activation (arrow, color code white) from the right (c) or left (d) side of the sinus venosus (and 
atria). Each color respresents 1ms of propagation. e-f. Single-cell patch clamp trace of cells dissociated 
from the right (e) or left (f) part of the sinus venosus, both showing a pacemaker-like phenotype. LA: 
left atrium, LSV: left side sinus venosus, RA: right atrium, RSV: right side sinus venosus, V: ventricle.
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 Performing in ovo ECG recordings has been described in detail by Kolditz et 
al.62 Briefly, the egg is candled (Fig. 2) to locate the embryo and to determine 
exactly the location on which to place the three silver chloride electrodes 
through the eggshell. The bipolar ECG can be recorded using a digital recording 
device62 e.g. to investigate the effect of inhibition of epicardial outgrowth on 
the electrophysiological properties of the heart. Interestingly, after epicardial 
inhibition shortened PR intervals were found, which is one of the characteristics 
of AVRT. This arrhythmia is caused by strands of myocardium bypassing the 
insulating annulus fibrosus of the heart, resulting in pre-excitation of the 
ventricular myocardium. In ovo ECG recording provided important evidence that 
the epicardium plays a key role during normal annulus fibrosus development. 
Defects in epicardial development may result in AVRT.62
 In addition to in ovo ECG recordings it is also possible to record an ECG in vitro 
after extraction of the heart interrupting all connections between the central 
nervous system and the heart, specifically to investigate the CCS independent of 
autonomic innervation. Furthermore, dissection of different cardiac structures 
makes it possible to analyze electrophysiological functioning of the right 
atrium separately from the left atrium, for example. In general, the technique 
is comparable with in ovo ECG recording, with the exception that the in vitro 
electrode is placed in the direct vicinity of the heart, in the tissue dish. In vitro 
ECG recordings were for example used to study the effects of in ovo pacing on 
postanoxic recovery.63 ECG recordings showed a lower incidence of arrhythmias 
in hearts that were paced in ovo.63 
5.6.2. FETAL ULTRASOUND FOR DETECTION OF HEART RATE
In humans, detection of fetal arrhythmias and conduction disorders is usually by 
fetal ultrasound. In severe cases, the rhythm disorders may cause fetal hydrops, 
which is also detected by ultrasound.64–66 High frequency ultrasound has also been 
used to assess avian cardiovascular development.67 In chick, fetal ultrasound was 
used to study haemodynamics before and after administration of epinephrine. 
Dorsal aortic flow velocity baseline waveform recordings were used to calculate 
heart rate, by measuring the cycle length between pulse waves and converting 
these into beats per minute.28 The application of this technique in avian models 
for study of the fetal conduction system is to date limited.
5.6.3. EX OVO MICROELECTRODE MEASUREMENTS
Many electrophysiological measurements in embryonic chicken hearts have 
been conducted.7,9,29,63,68–71 Ex vivo electrophysiology of whole embryonic chicken 
hearts provides useful information on heart function in the absence of external 
whole body influences like sympathetic or parasympathetic stimuli, which 
alter cardiac parameters such as heart rate, conduction velocity, and force of 
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contraction. For this purpose, whole heart electrophysiology of embryonic stage 
hearts is a useful tool to study cardiac function throughout development. 
 Whole heart ex ovo electrophysiology can be used to analyze intracardiac 
conduction i.e. in the presence of myocardial accessory pathways62,72,73 or to 
characterize the cardiac pacemaking signal.9,29 Briefly, hearts from chicken 
embryos are isolated under a dissection microscope and placed in a temperature-
controlled tissue bath at 37oC, in a Petri dish containing 3% agarose gel. The heart 
is immobilized by placing a holding pin through non-cardiac tissue around the 
outflow tract of the heart. Tungsten electrodes are placed on the cardiac surface 
where the electrophysiological measurements are to be taken. The measuring 
resolution between electrodes is in milliseconds. For smaller conduction 
differences, optical mapping is used (see section 5.6.4.). 
 With ex ovo microelectrode measurements several cardiac parameters can be 
calculated, such as heart rate in beats per minute (bpm) or atrioventricular (AV) 
conduction time in milliseconds (ms), measuring the total time the signal takes to 
travel from the atrium to the ventricle.9,29,62,72,73 These parameters are interesting 
in light of abnormal models resulting in pacemaker defects like bradycardia, 
tachycardia or atrial fibrillation or in models with abnormal AV conduction such 
as different degrees of AV block  or shortened AV time as in cases with  pre-
excitation.62,72,73 
 Furthermore, electrical activity between two points determined by the 
observer can be measured, allowing for instance location of the site of first atrial 
activity (i.e. the pacemaking site) and ectopic activation patterns.9 Likewise, 
AV conduction patterns can be recorded to study the pattern of ventricular 
activation. This has been used to determine the maturity of ventricular activation 
i.e. distinction of an immature base-to-apex from mature apex-to-base activation 
patterns, and the presence and location of accessory myocardial pathways 
causing pre-excitation.62,73 These recordings are very stable and spontaneous 
arrhythmias hardly occur making this an excellent method to measure electrical 
signals in toto without the necessity of adding chemical compounds to visualize 
the signal as required when performing optical mapping.  The disadvantage is 
limitation to fixed number of electrodes. If any abnormalities occur outside of 
the studied region e.g. when measuring pre-excitation, the initial pacemaker site 
cannot be traced because only one electrode can be placed at the atrial level. 
Optical mapping measurements provide useful complementary data as a detailed 
conduction map of the area studied can be obtained. 
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5.6.4. OPTICAL MAPPING STUDIES
Optical mapping is an electrophysiological technique that allows the 
depolarization wave of the cardiac electrical impulse to be followed using voltage 
sensitive dyes. This technique has been broadly used in both adult and fetal 
stages.  This has been reviewed elsewhere for various stages of development.74 
 Optical mapping is accomplished by loading the cardiac tissue with a voltage 
sensitive dye (such as di-4-ANEPPS).  Current developments allow monitoring 
of a wide range of parameters74, such as ion propagation signals of calcium 
and sodium75, which provide new insights into the mechanisms of specific 
arrhythmias. Other parameters commonly measured are conduction time and 
conduction velocity. Parameters like heart rate or AV delay can also be measured. 
The combination of voltage and calcium mapping reveals arrhythmogenic 
sites within the developing heart and information on the changes of ionic 
concentrations within regions of the developing heart. This has recently provided 
new insights into the pacemaking potential of the outflow tract of the heart.74 
 It is necessary to induce electromechanical dissociation for example with 
blebbistatin to avoid motion artifacts. These compounds have no obvious effect 
on cardiac parameters such as heart rate and AV delay.76 However, inclusion 
of proper controls is advisable to allow conclusions from optical mapping 
experiments. 
 The main use for optical mapping is to study activation conduction patterns 
throughout development9,32,71,77–79 and compare them with disease models.41,80–82 
For example, experiments have been performed showing that mechanical 
loading during early development is imperative for proper development of the 
CCS.81 Furthermore, it was shown that exposure to prolonged hypoxia during 
development affects maturation of the CCS.82
5.6.5. MICROELECTRODE ARRAY STUDIES
Microelectrode arrays (MEA) are commonly used as a straightforward 
measure of electrical activity in monolayers of spontaneously beating cultured 
cardiomyocytes. Chicken cardiomyocytes are well-suited for this purpose and 
reliable measurements have already been conducted83,84 providing a model to 
study toxicity for example.85 A major advantage of MEAs is that the measurements 
can be conducted on a selected cardiomyocyte population, like sinoatrial, atrial 
or ventricular cardiomyocytes, avoiding interference from other regions of the 
heart, but still within a tissue monolayer, as opposed to single-cell patch clamp 
electrophysiology (see next section). This allows cell-cell interactions influencing 
the electrophysiological parameters as expected in the whole heart, but without 
the main pacemaker present. 
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 Another advantage is the study of effects of a specific drug.85 Long-term effects 
after in ovo drug or chemical compound administration can result in permanent 
modifications or alterations to normal heart development including altered gene 
expression.58 Short-term effects of drugs on the action potential of a specific 
cardiomyocyte cell population can also be studied using MEA. Compounds can be 
administered directly onto the cell culture and the effects on electrophysiology 
can be studied during chosen time intervals.86 From the recorded field potential 
it is possible to derive information on the action potential86 allowing study 
of the effects of, for example, in ovo micromanipulation or drugs on specific 
populations of cardiomyocytes. This provides an excellent experimental model 
to study drug toxicity or responses in cardiomyocytes.85 After proper comparison 
and validation to human cardiomyocytes, chick cardiomyocytes could provide a 
good model for high throughput drug testing. 
5.6.6. SINGLE-CELL PATCH CLAMP RECORDINGS IN CHICK EMBRYONIC 
CARDIOMYOCYTES.
Single-cell patch clamping is used to study ion channel function and currents 
in cardiomyocytes combined with electrophysiological characteristics of the 
different types of cardiomyocytes in the developing heart. 
 To perform single-cell patch clamp the cells have to be dissociated first. Briefly 
(see11 for more details) the region of cardiac conduction tissue is collected and 
trypsinized. After dissociation cells are plated on glass coverslips to attach. Patch 
clamp options include perforated patch clamp, whole-cell patch, and inside-out 
patch. Description of the different methods87 is beyond the scope of the technical 
comment here. The acquired data can be further analyzed to quantify various 
electrophysiological parameters including maximal upstroke velocity, action 
potential duration, and action potential amplitude. 
 Patch clamp experiments in chick embryonic cardiomyocytes have 
been of great importance in understanding normal and abnormal cardiac 
electrophysiological functioning. First, the presence and function of ion 
channels and currents was investigated in a large number of studies.88–108 
Detailed description is beyond the scope here but one example is the description 
of the pacemaker current in chick embryonic ventricular and atrial cells, which 
demonstrated that not only pacemaker cells display this current.96 Second, 
recent work characterized the electrical phenotype of cells derived from specific 
regions.11 In section 5.2.2. and 5.5.2., the continuity between the sinus venosus 
myocardium and the AV canal is described. Genetic characterization of this 
region showed that the myocardial continuity has a pacemaker-like phenotype 
(expression of HCN4/ISL1). Electrophysiological characterization with single-
cell patch clamp confirmed the pacemaker-like phenotype of the myocardial 
continuity.11 The functional electrophysiological characterization using patch 
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clamp was paramount to attributing a role in CCS function to this specific cardiac 
region. Third, the single-cell patch clamp technique is also useful in studying 
the effects of different compounds on electrophysiological characteristics.109–116 
For instance, several studies have analyzed the effects of Bay K8644, a calcium 
channel antagonist, on electrophysiological properties.110,111 This also opens 
the possibility of testing the therapeutic potential of drugs. Alternatively, the 
patch clamp technique is also useful in studying potential arrhythmogenic 
properties of new pharmaceutical compounds. Fourth, the effects of hormones, 
growth factors and neurotransmitters normally present in the body, on cardiac 
electrical functioning and maturation can be studied.117–125 Several studies 
were aimed at elucidating the role of taurine in cardiac electrophysiology.122–125 
It was for example shown that taurine, an organic acid with a wide variety of 
functions in normal physiology, plays a role during spontaneous electrical 
activity of cardiomyocytes.124 Fifth, patch clamp recordings can be used to 
study electrophysiological characteristics of cardiomyocytes in experimental 
disease models126,127, such as after ablation of the neural crest during chick 
development.127 Patch clamp experiments showed evidence that neural crest 
cells are necessary for normal development of myocardial calcium channels.127  
 In summary, cardiac patch clamp experiments performed in chicken embryos 
have increased our knowledge of normal cardiac electrophysiology at the single 
cellular level. The technique can be used to characterize cells on the basis of 
their electrophysiological profile and to test the effects of (pharmaceutical) 
compounds.  
6. CONCLUSIONS 
We have provided here an overview of different techniques used in the avian 
model system to understand normal and abnormal development and functioning 
of the CCS. The avian embryo has and will continue to be a powerful model 
system to study development in general and the developing CCS in particular. 
Since the avian embryo is considered an animal friendly alternative, is easy to 
use and is inexpensive, we hope to have encouraged readers to incorporate this 
model system in their own laboratory.       
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The presence of distinct electrophysiological pathways within the atrioventricular 
node is a prerequisite for atrioventricular nodal reentrant tachycardia to occur. 
In this study, the different cell contributions that may account for the anatomical 
and functional heterogeneity of the atrioventricular node were investigated.
RESULTS: 
To study the temporal development of the atrioventricular node, the expression 
pattern of ISL1, expressed in cardiac progenitor cells, was studied in sequential 
stages performing co-staining with myocardial markers (TNNI2 and NKX2-5) and 
HCN4 (cardiac conduction system marker). An ISL1+/TNNI2+/HCN4+ continuity 
between the myocardium of the sinus venosus and atrioventricular canal was 
identified in the region of the putative atrioventricular node, which showed 
a pacemaker-like phenotype based on single-cell patch clamp experiments. 
Furthermore, qPCR analysis showed that even during early development, different 
cell populations can be identified in the region of the putative atrioventricular 
node. Fate mapping was performed by in ovo vital dye microinjection. Embryos 
were harvested and analyzed 24 and 48 hours post-injection. These experiments 
showed incorporation of sinus venosus myocardium in the posterior region of 
the atrioventricular canal.
CONCLUSION: 
The myocardium of the sinus venosus contributes to the atrioventricular canal. 
It is postulated that the myocardium of the sinus venosus contributes to nodal 
extensions or transitional cells of the atrioventricular node, since these cells are 
located in the posterior region of the atrioventricular node. This finding may help 
to understand the origin of atrioventricular nodal reentrant tachycardia.
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1. INTRODUCTION
The cardiac conduction system (CCS) initiates electrical activation of the heart 
and ensures proper electrical propagation resulting in coordinated mechanical 
activation of the myocardium. Disturbances in the normal electrical activation 
pattern of the heart resulting in cardiac arrhythmias are an important cause of 
mortality and morbidity in the general population.1 
 During early cardiac development fusion of the bilateral cardiogenic plates 
establishes the primary heart tube (PHT). During further development a 
subpopulation of cells from the splanchnic mesoderm continues to differentiate 
towards a cardiac fate and is recruited to the PHT at the venous and arterial 
poles. The splanchnic mesoderm at the venous pole gives rise to the myocardium 
of the sinus venosus. This myocardium surrounds the cardinal and pulmonary 
veins and shows distinct expression patterns as compared with the atrial 
working myocardium.2 In contrast to the atrial myocardium, the sinus venosus 
myocardium expresses Tbx183, ISL12,4, Shox25, Pdgf-receptor alpha6, Tbx37,8 and 
RHOA2, while it is negative for NKX2-5 during early stages of development.3,9 The 
sinus venosus myocardium includes the definitive right-sided sinoatrial node 
(SAN) as well as a transient left-sided SAN, and will differentiate into a working 
myocardial phenotype during further development, with exception of the future 
right-sided SAN. The SAN will retain a primitive phenotype as characterized 
by relatively high automaticity, slow conduction and poor coupling of cells and 
becomes the dominant pacemaker of the heart.10 The right and left venous valves 
are also components of the sinus venosus myocardium and are known substrates 
for atrial fibrillation and tachycardia in the fully developed heart.1 They extend 
along the posterior wall of the right atrium towards another important structure 
of the CCS, the atrioventricular node (AVN). 
 The AVN delays conduction of the electrical impulse generated by the SAN, 
thereby ensuring adequate filling of the ventricles. The AVN is part of the 
myocardium of the atrioventricular (AV) canal and consists of a compact node, 
situated in the posterior part of the AV canal, covered by transitional cells as well 
as nodal extensions running towards the vestibules of the mitral and tricuspid 
valves.11 The exact origin of the individual components of the AVN is still unclear. 
Studies indicate that at least the compact node derives from the myocardium 
of the AV canal12,13, suggesting that the majority of cells of the AVN is formed 
from one source of cells. However, the presence of electrophysiologically and 
morphologically distinct cells (i.e. compact nodal cells, transitional cells and 
nodal extensions) in the region of the AVN indicates contributions from different 
sources, and/or with different transcriptional programs. A dual contribution 
would be a possible explanation for the occurrence of these different cell types 
and may help to understand the occurrence of atrioventricular nodal reentrant 
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tachycardia (AVNRT). A prerequisite for AVNRT to occur is the presence of 
electrophysiologically distinct pathways within the AVN14, resulting in slow 
conduction in the so-called slow pathway, unidirectional conduction in the fast 
pathway and a central area of block.  The slow pathway is a common target 
for catheter ablation of AVNRT, and has been described anatomically as the 
inferior nodal extension.15 It has been postulated that the transitional cells and 
nodal extensions are an atrial contribution to the AVN16 or are derived from the 
myocardium of the sinus venosus.2 Interestingly, the inferior nodal extension has 
a similar gene expression profile as the SAN17, and pacemaker activity from the AV 
junction has been attributed to the inferior nodal extension18, thereby suggesting 
a developmental relation between the AVN and the sinus venosus myocardium.
 Islet1 (Isl1), a LIM homeodomain transcription factor that plays an important 
role during cell proliferation, differentiation and survival19, is expressed in the 
sinus venosus myocardium during early stages of development. Genetic lineage 
tracing with an inducible Isl1-Cre revealed important differences in timing of 
addition of cells to the developing heart and AVN. When Cre-recombinase was 
induced with tamoxifen at embryonic day (E)7, a large number of Isl1-positive 
cells was found in the heart at E9. Induction of Cre at E9 and analysis at E11 
revealed far less Isl1-positive cells, with a cluster of cells in the region of the 
developing AVN.20 This could indicate that the AVN develops from multiple 
sources, with contributions at different time points during development. 
Immunohistochemical analysis of ISL1 expression in chick embryos revealed a 
region of ISL1-positive cells in the dorsal atrial wall, just cranial to the AV junction, 
which is known to be the location of the future AVN, leading to the hypothesis of 
a contribution of the sinus venosus myocardium to the AVN.2 However, no cell 
lineage tracing studies independent of gene expression to prove a contribution 
from the sinus venosus myocardium have been performed.
 In the current study, vital dye labeling experiments aimed at studying 
different contributions to the developing AVN were performed, to determine 
the origin of cells contributing to the AVN. First, expression patterns marked by 
double or triple staining with ISL1 (expressed in cardiac progenitor cells), the 
myocardial markers TNNI2 and NKX2-5 and the CCS marker HCN4 were studied 
in sequential stages of chick and mouse development. These results were used as 
a roadmap for targeted vital dye labeling experiments. 
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2. MATERIALS AND METHODS
2.1. IMMUNOHISTOCHEMISTRY
To obtain a developmental series of chicken heart development, fertilized eggs of 
the White Leghorn chicken were incubated at 37°C and 80% humidity. Embryos 
(HH7-31) were excised, staged according to Hamburger and Hamilton criteria21, 
and fixed in 4% paraformaldehyde for 24 hours. Subsequently, they were 
embedded in paraffin and sectioned serially (5µm) for immunohistochemical 
analysis. 
 To confirm the results obtained in chick embryos, immunohistochemical 
analysis was extended to wildtype mouse embryos with a mixed genetic 
background of E10.5, E11.5 and E12.5 (mouse line has been described 
previously22). The morning of the vaginal plug was considered E0.5. Pregnant 
dams were euthanized with CO2 exposure followed by cervical dislocation. 
Processing of embryos after excision was similar to the chicken embryos. Animal 
care was in accordance with national and institutional guidelines and approved 
by the animal experiments committee of the Leiden University Medical Center 
(Permit Number 13067).
 Serial sections were rehydrated and subjected to microwave antigen retrieval 
in citric acid buffer (pH = 6,0) before staining with the primary antibodies. 
Sections were incubated with primary antibodies against ISL1 (Clone 40.2d6, 
1/100, Developmental Studies Hybridoma Bank, Iowa City, Iowa, USA), Troponin 
I, isoform 2 (TNNI2) (SC-15368, 1/200, Santa Cruz Biotechnology Inc., Dallas, 
Texas,  USA), NKX2-5 (SC-8697, 1/500, Santa Cruz Biotechnology Inc., Dallas, Texas, 
USA) and HCN4 (APC-052, 1/2000, Alomone Labs, Jerusalem, Israel) overnight. 
Primary antibodies were diluted in phosphate buffered saline (PBS)-Tween-20 
with 1% Bovine Serum Albumin (A8022, Sigma-Aldrich, St. Louis, Missouri, 
USA) to prevent non-specific binding.  Between subsequent incubation steps all 
slides were rinsed in PBS (2x) and PBS-Tween-20 (1x). To enhance the signal 
of ISL1, Horse-Anti-Mouse (HAM)-Biotin (BA-2000, 1/200, Vector laboratories 
Inc., Burlingame, California, USA) in PBS-Tween-20 was added together with 
normal horse serum (6-S-2000, 1/66, Brunschwig Chemie, Switzerland) for 60 
min. Visualization of the primary antibodies was achieved by incubation with 
fluorescently labeled secondary antibodies, diluted in PBS-Tween-20 (60 min). 
The following antibodies were used: Alexa Fluor® 488 Streptavidin Conjugate 
(S-11223, 1/200), Alexa Fluor® 555 Donkey Anti-Rabbit IgG (A-31572, 1/200) 
and Alexa Fluor® 647 Donkey Anti-Goat IgG (A-21447, 1/200). All secondary 
antibodies were purchased from Life technologies (Carlsbad, California, USA). 
DAPI (D3571, 1/1000, Life technologies, Carlsbad, California, USA) was used as a 
nuclear stain and the slides were mounted with Prolong gold (Life technologies, 
Carlsbad, California, USA). To reduce interfering autofluorescence (HH7-11), 
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small adjustments were made to the above described protocol. Sections were 
blocked (30 min) with a commercially available blocking reagent (Cat. No. 11 
096 176 001, Roche, Mannheim, Germany), which was also used to dilute the 
primary and secondary antibodies. The sections were incubated with the primary 
antibody for 2 hrs. Sections were visualized using a Leica DM 5500 fluorescence 
microscope (Leica microsystems, Illinois, USA). ImageJ was used to process the 
pictures.
2.2. IN SITU HYBRIDIZATIONS
For detection of HCN4 mRNA expression in the developing CCS, in situ 
hybridizations in chick embryos were performed (HH15-23) and analyzed as 
described previously.23  
2.3. LASER CAPTURE MICRODISSECTION PROCEDURE
Laser capture microdissection (LCM) was performed in order to specifically 
isolate tissue of three distinct structures: 1. Myocardial continuity sinus venosus 
and AV canal (SV-AVC); 2. More caudal region of posterior AV canal (AVC); 3. Lateral 
wall right ventricle (RV). Embryos of HH21 were extracted and fixated for 24 hrs 
in 4% paraformaldehyde, embedded in paraffin and serially sectioned at 5µm. 
Sections were mounted on membrane-covered slides (MembraneSlide 1.0 PEN, 
Carl Zeiss Microscopy, Thornwood, NY, USA). Tissue from the different structures 
of interest was dissected using the PALM microbeam (Carl Zeiss Microscopy, NY, 
USA) and RoboSoftware package and subsequently transferred to AdhesiveCaps 
(Carl Zeiss Microscopy, Thornwood, NY, USA). After microdissection, the tissue 
was stored at -80°C. The outline of the dissected tissue was photographed in all 
embryos and examples of the different regions before and after dissection are 
shown in Supplemental Fig. S1.
2.4. RNA ISOLATION, CDNA SYNTHESIS AND QPCR OF LASER 
MICRODISSECTION TISSUE
After microdissection, RNA was isolated using the RecoverAll™ Total Nucleic 
Acid Isolation Kit for FFPE (Ambion, Life technologies, CA, USA). cDNA synthesis 
was performed with the iScript™ cDNA synthesis kit (Bio-rad, Hercules, CA, USA). 
After cDNA synthesis, qPCR was performed for TNNT2, NKX2-5, HCN4 and ISL1. 
For ISL1, a nested approach was necessary in order to detect mRNA expression. 
After cDNA synthesis for ISL1, 15 cycles of pre-amplification were performed 
with 10µl SybrGreen Mastermix (Bio-Rad, Hercules, CA, USA), 8,5µl nuclease 
free water, 0,25µl forward and 0,25µl reverse primer and 1µl of cDNA (final 
volume of 20µl). For the other three genes, no pre-amplification was needed. The 
qPCR was performed with 10µl of SybrGreen Mastermix (Bio-Rad, Hercules, CA, 
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USA), 1µl of forward primer, 1µl of reverse primer, 1µl of cDNA (or 1µl nuclease 
free water as negative control) and 7µl nuclease free water per reaction (final 
volume 20µl). Reactions were carried out in triplicate for each sample. qPCR 
was performed on a Bio-Rad CFX96 real-time system. Melting curve analysis was 
performed to verify single PCR product amplification. Chicken GAPDH was used 
as the reference standard for normalization, and relative differences in mRNA 
expression were determined. The primers used are described in Supplemental 
table 1.
2.5. WHOLE MOUNT ISL1 STAINING
HH21 embryos were extracted and the heart was carefully removed from the 
thorax under the preparation microscope. The heart was fixated in DMSO:100% 
Methanol (ratio 4:1) for 2 hours at 4°C, after which the tissue was rehydrated 
in 75%, 50% and 25% methanol in PBS. After rinsing thoroughly with PBS for 
30 minutes at room temperature, the tissue was permeabilized with PBS-Tween 
for 1 hour. Blocking was performed with PBS-Tween-20 with 1% BSA for 1 
hour at room temperature. The ISL1 primary antibody (Clone 40.2d6, 1/100, 
Developmental Studies Hybridoma Bank, Iowa City, Iowa, USA) was dissolved 
in PBS-Tween-20 with 1% BSA and the tissue was incubated with the antibody 
overnight at 4°C in a shaking plate. The next morning, the tissue was rinsed with 
PBS and incubation with Vectastain ABC staining kit (PK- 6100, Vector Labs) was 
performed for 90 minutes at room temperature. After rinsing with PBS, the tissue 
was incubated for 30 minutes in 3-3’diaminobenzidine-tetrahydrochloride-
dihydrate (DAB) (D5637, Sigma-Aldrich, St. Louis, MO) dissolved in Tris/Maleate 
(pH 7.6). Finally, a fresh solution of DAB with 5µl of H2O2 was added for a brief 
moment (+/- 5 seconds) to the tissue, after which the tissue was thoroughly 
rinsed in PBS to stop the visualization reaction.
2.6. SINGLE-CELL PATCH CLAMP RECORDINGS
Electrophysiological data was obtained by single-cell patch clamp of HH21-22 
chick embryonic cardiomyocytes derived from the continuity between the sinus 
venosus and AV canal and compared to cardiomyocytes from the right ventricle. 
Whole mount ISL1 stained embryos were used to identify the ISL1+ continuity 
between the sinus venosus and AV canal, which aided in specifically dissecting 
this tissue under the preparation microscope (Fig. 6a). As control tissue, a piece 
of right ventricle was collected (Fig. 6a). The dissected tissue was collected in 
1,5ml tubes and 800µl of 0,05% Trypsin (Life technologies, Carlsbad, California, 
USA) was added. The tube was placed in a heated (37°C), shaking (850 rpm) plate 
for 10 minutes. After this, the tubes were vortexed until all tissue was dissociated 
and centrifuged at 1100 rpm for 5 minutes. The supernatant was removed and 
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the cells were resuspended in medium containing DMEM high glucose (Life 
technologies, Carlsbad, California, USA), 10% fetal calf serum (Sigma-Aldrich, St. 
Louis, Missouri, USA), 1% penicillin-streptomycin (Life technologies, Carlsbad, 
California, USA), 1% non-essential amino acids (Life technologies, Carlsbad, 
California, USA) and 1% L-Glutamine (Life technologies, Carlsbad, California, 
USA). Cells were plated on glass coverslips and used for single-cell patch clamp 
recording.
 Recordings were performed on single cardiomyocytes, 1-2 days after cell 
dissociation. Action potential measurements of spontaneously contracting cells 
were recorded. Action potentials were recorded with the perforated patch clamp 
technique using an Axopatch 200B amplifier (Molecular Devices) and were 
filtered (5 kHz) and digitized (40 kHz). Data were acquired with pClamp10.1 
(Axon Instruments) and analysis was performed with custom-made software. 
Potentials were corrected for the estimated change in liquid junction potential. 
Action potentials were recorded at 37°C in Tyrode’s solution. The pipette solution 
contained (mM): K-gluconate 125, KCl 20, NaCl 5, amphotericin-B 0.22, HEPES 
10; pH 7.2 (KOH). The maximal diastolic potential (MDP), maximal upstroke 
velocity (Vmax), action potential amplitude (APA), and action potential duration 
(APD) at 50% and 90% repolarization (APD50 and APD90, respectively) were 
analyzed. Data from 8-9 consecutive action potentials were averaged.
2.7. MICROINJECTION PROCEDURE
A small window was created in the shell to gain access to the embryo (HH15-17). 
A 1:1 solution of two fluorescent dyes (DiI and 5-TAMRA) was used to label and 
follow cells during development. 2.5mg DiI (D-282, Life technologies, Carlsbad, 
California, USA) was dissolved in 50µl DMSO, which in turn was diluted in 950µl 
ethanol (100%). 2.5 mg 5-TAMRA (C-2211, Life technologies, Carlsbad, California, 
USA) was dissolved in 1000µl DMSO. The combined solution was loaded into 
a pulled glass needle and injected in different regions, using a programmable 
microinjector (IM-300 Narishige, Japan) and micromanipulator. 
 Medial labeling was performed by opening the coelomic cavity with 
subsequent injection in the ISL1+/TNNI2+ sinus venosus myocardium (Fig. 1a-
e). To calculate the volume of labeling, all microscopic sections that contained 
DiI/5-TAMRA were photographed and ImageJ was used to calculate the volume 
of labeling. The total volume of labeling and the volume of labeling in the ISL1-/
TNNI2+ atrial myocardium directly bordering the ISL1+/TNNI2+ sinus venosus 
myocardium were calculated for the 14 embryos that were analyzed in the medial 
group 1-2 hours after labeling.
 Lateral, right-sided labeling of the mesenchyme and vessel wall of the right 
cardinal vein (RCV) was performed just caudal to the entrance of the RCV in the 
Sinus venosus myocardium and AV canal development 89
4
sinus venosus (Figure 1f-h). Injection in this region was performed through the 
developing lateral body wall leaving the coelomic cavity intact. This injection site 
was chosen to assure lateral labeling of mesenchymal structures and to minimize 
leakage to other cardiac components. Embryos were collected at selected time 
points (HH15-25) to assess the location of labeling.
Figure 1. Medial and lateral labeling at HH15
a-b. 3D reconstructions of medial labeling, white: myocardium, blue: AV canal myocardium, green: 
ISL1+/TNNI2+ sinus venosus myocardium, red: DiI/5-TAMRA labeling a. Overview of PHT, arrow 
indicates labeling. b. All 14 microinjections are superimposed to clarify extend of total labeling. 
For separate labels see interactive PDF (online 3D PDF S1, available online or at request to the 
authors). No labeling of AV canal myocardium is seen and distance between myocardium of sinus 
venosus and AV canal is present. Labeling is found in mesenchyme RCV (1 in b, 100% of embryos), 
ISL1+/TNNI2+ sinus venosus myocardium (2 in b, 100% of embryos) and a small region of ISL1-/
TNNI2+ myocardium directly bordering the ISL1+/TNNI2+ sinus venosus (3 in b, 64% of embryos). 
c,f.  Directly after labeling demonstrates in ovo medial (c) and lateral (f) location of DiI/5-TAMRA 
(pink, arrow). d,g. DiI/5-TAMRA in mesenchyme RCV present in medial (d) and lateral (g) labeling. 
e,h. DiI/5-TAMRA present in ISL1+/TNNI2+ sinus venosus myocardium in medial labeling (DiI/5-
TAMRA: arrow in e), not in lateral labeling (corresponding DiI/5-TAMRA negative region: arrow 
in h). AVC: atrioventricular canal, EC: endocardial cushion, OFT: outflow tract, PEO: proepicardial 
organ, RCV: right cardinal vein, SV: sinus venosus, V: ventricle. d-e, g-h: white: TNNI2, green: ISL1, 
red: DiI/5-TAMRA, blue: DAPI. Scale bars: 50µm.
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2.8. 3D RECONSTRUCTIONS
AMIRA (Template Graphics Software, Inc.) reconstructions aided in clarifying 
the three-dimensional relationship between different structures. Embryos were 
serially sectioned and immunofluorescently stained for both TNNI2 and ISL1. 
The slides were photographed and processed with Adobe Photoshop CS6. Finally, 
the slides were stacked and aligned and structures of interest were labeled with 
the AMIRA software. A subset of reconstructions was converted to 3D interactive 
PDFs, which are available online or at request to the authors. Different functions 
(e.g. buttons to show, hide or make different structures transparent) were 
included in the interactive PDFs, using Javascript. The scripts that were used 
were previously written and published24 and slightly modified for the current 
PDFs.
Figure 2. ISL1 and TNNI2 co-expression at HH stage 8-12
a. Overview of an HH8 embryo includes foregut and left-sided cardiogenic plate. The boxed region 
is enlarged in b-d. b. Co-expression of TNNI2 and ISL1 in cardiogenic plate (arrowheads in b-d). 
c-d.  Separate channels in grey values. e. Overview of an HH9 embryo, with boxed region enlarged in 
f-h. Co-expression of ISL1 and TNNI2 in majority of cells in cardiogenic plate (arrowheads in f-h). i. 
Overview of an HH12 embryo. Boxed region is shown at higher magnification in j-l. j. ISL1+/TNNI2+ 
myocardium (arrows) is shown at arterial pole of PHT. white arrowheads show ISL1+/TNNI2- 
splanchnic mesoderm. Note lower expression of TNNI2 in ISL1+ cells. Black arrowheads show ISL1-/
TNNI2+ myocardium PHT. k. ISL1 expression is shown. Arrowheads show ISL1+/TNNI2- splanchnic 
mesoderm and arrows show ISL1+/TNNI2+ myocardium of arterial pole. l. TNNI2 expression at 
arterial pole. Arrows show decreased TNNI2 expression in ISL1+ cells. Black arrowheads show 
ISL1-/TNNI2+ myocardium PHT. CC: coelomic cavity, Endo: endoderm, NT: neural tube, PHT: primary 
heart tube, YS: yolk sac. White: TNNI2, green: ISL1, blue: DAPI. Scale bars: 50µm. 
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2.9. STATISTICAL ANALYSIS
Results are expressed as mean ± SEM. Comparisons were made using unpaired 
Student’s t-test (normal distribution) or Mann-Whitney U test when data were 
not normally distributed. P<0.05 was considered statistically significant.
3. RESULTS
3.1. IDENTIFICATION OF AN ISL1+/TNNI2+/HCN4+ 
MYOCARDIAL CONTINUITY BETWEEN SINUS VENOSUS AND 
POSTERIOR PORTION AV CANAL 
This first phase of the study was aimed at analysis of expression patterns of ISL1, 
performing immunostaining at stages HH7-31. The first expression of TNNI2 
was seen by HH8, within the medial borders of the bilateral cardiogenic plates, 
co-localizing with ISL1 (Fig. 2a-d). Strong expression of ISL1 was also found 
in the foregut endoderm (Fig. 2a-c). At HH9, the bilateral plates of mesoderm 
met in the midline, and started to fuse (Fig. 2f). TNNI2 expression increased 
and co-localization with ISL1 was still found in the majority of cells (Fig. 2e-
h). By HH10, the bilateral plates had fused and formed a semitubular structure, 
with the ventral side formed by the TNNI2+ myocardium, and the dorsal side 
bordered by the ISL1+ foregut endoderm. By HH11-12, the heart was almost 
closed posteriorly, forming the primary heart tube. Most cardiomyocytes of 
the tube have lost ISL1 expression (Fig. 2i-j), except for populations of ISL1+/
TNNI2+ cells at the arterial (Fig. 2i-l) and venous pole. 
 Analysis of ISL1 expression in subsequent developmental stages revealed 
ISL1/TNNI2 co-expression in the myocardium of the sinus venosus. At HH14-15, 
the myocardium connecting the atria to the AV canal is negative for ISL1 (Fig. 3a-
f). The AV canal was defined based on morphological criteria, i.e. the presence of 
thick endocardial cushions and less densely organized myocardium underlying 
the cushions (Fig. 3e,i,k). More caudally the sinus venosus myocardium is 
positive for ISL1 and TNNI2 (Fig. 3g-h). Thus, there is initially a region of ISL1-/
TNNI2+ myocardium between the sinus venosus myocardium and the AV canal 
myocardium (Fig. 3b-c). To further clarify the relation between the different 
structures, an interactive PDF of the three-dimensional reconstruction shown in 
Fig. 3 is available online (online 3D PDF S1, available online or at request to the 
authors). At this stage, the right and left venous valve are not evident, yet. 
 During further development, the right venous valve (RVV) becomes 
recognizable as a double myocardial leaflet, of which the inner leaflet (SV luminal 
side) shows co-expression of ISL1 and TNNI2. The outer leaflet is ISL1-/TNNI2+ 
(atrial luminal side) (Fig. 3i-j). An ISL1+/TNNI2+ continuity between the 
myocardium of the sinus venosus and the posterior part of the AV canal becomes 
apparent at HH16-17 (Fig. 3k-l). 
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Figure 3. ISL1 and TNNI2 expression at the venous pole at HH15-16
a-d. 3D reconstructions, HH15 embryo. White: myocardium, blue: AV canal myocardium, green: 
ISL1+/TNNI2+ sinus venosus myocardium, purple: lumen b. Left lateral view showing ISL1-/TNNI2+ 
myocardium (between arrowheads)  between myocardium of AV canal and sinus venosus.  c-d. Right 
lateral view with (in c, part of ventricle and entire OFT are removed to expose right portion of inflow 
tract) and without (in d) myocardium reconstructed, demonstrating distance between sinus venosus 
and AV canal myocardium (between arrowheads). e-f. Transverse section at HH15 of ISL1-/TNNI2+ 
myocardial connection between AV canal (identified based on morphological criteria, i.e. presence 
of thick endocardial cushions and underlying spongious myocardium) and lower region of atrium 
(between arrowheads). g-h. ISL1+/TNNI2+ sinus venosus (including RCV myocardium) which is 
located caudally to connection between atrium and AV canal. i-j. At HH16, RVV is a double leaflet with 
ISL1+/TNNI2+ myocardium in inner leaflet (arrowhead) and ISL1-/TNNI2+ myocardium in outer 
leaflet (arrow). k-l. ISL1+/TNNI2+ continuity between the SV and AV canal (between arrowheads) is 
first seen at HH16.  A: atrium, AVC: atrioventricular canal, EC: endocardial cushion, LCV: left cardinal 
vein, OFT: outflow tract, RA: right atrium, RCV: right cardinal vein, SV: sinus venosus. White: TNNI2, 
green: ISL1, red: NKX2-5, blue: DAPI. Scale bars: 50µm.
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 At HH21, this continuity still shows ISL1 and TNNI2 expression and is located 
between the posterior portion of the AV canal (region of the (putative) AVN) and 
the cranial portion of the sinus venosus at the level of the entrance of the cardinal 
veins in the sinus venosus (Fig. 4c-e). The AV canal is again characterized by the 
presence of thick endocardial cushions with spongious myocardium underlying 
the cushions (Fig. 4g-j). The ISL1+/TNNI2+ area includes the myocardium of the 
SAN, RCV, RVV and LCV, including the left SAN (Fig. 4a-h). The central part of the 
sinus venosus myocardium is connected to the myocardium of the posterior AV 
canal (Fig. 4c,e,g), where ISL1 expression is seen in the AV canal myocardium 
(Fig. 4j-k). An interactive PDF of the 3D reconstruction is available online or at 
request to the authors, which shows in further detail the continuity between the 
ISL1+/TNNI2+ sinus venosus myocardium and the posterior AV canal (online 
3D PDF S2). An ISL1/NKX2-5/TNNI2 triple staining was performed and showed 
a gradient in ISL1 expression from the SV myocardium (strongest expression) 
towards the AV canal myocardium (decrease in expression) (Fig. 4i-l). NKX2-
5 expression showed a similar but opposite gradient (Fig. 4i-l), suggesting 
differentiation of ISL1+/TNNI2+/NKX2-5- sinus venosus cardiomyocytes 
towards NKX2-5+/TNNI2+/ISL1- AV canal cardiomyocytes. During further 
development, ISL1 expression became confined to the myocardial sleeve of the 
RCV at the location of the future SAN (Fig. 4m-p), with no discernible expression 
of ISL1 in the continuity between the myocardium of the sinus venosus and AV 
canal any more. 
 To investigate whether the myocardial continuity between the sinus 
venosus and posterior AV canal indeed had a pacemaker-like phenotype, in situ 
hybridizations were performed in chick embryos for HCN4, which is used as a 
marker for the (developing) CCS.23 The connection between the sinus venosus 
myocardium and the myocardium of the posterior portion of the AV canal 
(Fig. 5a) showed HCN4 expression (Fig. 5b), shown at HH19. To verify the co-
localization of ISL1, TNNI2 and HCN4 in this region in mammals, a triple staining 
for ISL1, TNNI2 and HCN4 was performed in wildtype mouse embryos. ISL1+/
TNNI2+/HCN4+ cells were found in the region of the myocardial continuity 
between the sinus venosus and AV canal (shown at E11.5 in Fig. 5c-f). These 
results indicate that the cells of the myocardial continuity between the sinus 
venosus and posterior AV canal have a pacemaker-like phenotype.
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Figure 4. ISL1+/TNNI2+ continuity between myocardium of sinus venosus and AV canal
a-e. 3D reconstructions, HH21 embryo. white: myocardium, yellow: mesenchyme, blue: AV canal 
myocardium, green: ISL1+/TNNI2+ sinus venosus myocardium. a. Overview of heart. e. Arrowheads 
indicate continuity between sinus venosus and AV canal myocardium. b-d. 3D reconstructions of AV 
canal and sinus venosus myocardium with in white TNNI2 section from AMIRA. b to d is cranial to 
caudal. f-h. Corresponding TNNI2/ISL1 staining. b. Location of SAN and RVV (arrow). f. ISL1+/TNNI2+ 
connection between SAN and RVV (arrow). c.  SAN and RVV are attached to myocardial continuity 
between sinus venosus and AV canal (arrowheads), arrow in g. AV canal identified by presence of 
endocardial cushions and spongious myocardium. d. Connection between LCV and ISL1+/TNNI2+ 
sinus venosus (arrowheads), arrow in h. i-l. ISL1/TNNI2/NKX2-5 staining of myocardial continuity 
between sinus venosus and AV canal. k. Decrease in ISL1 expression from sinus venosus towards AV 
canal. l. Opposite expression pattern for NKX2-5. m-p. ISL1 expression in SAN (arrows) at HH27. 
o-p. Grey values for ISL1 and TNNI2, showing ISL1+/TNNI2+ SAN. AVC: atrioventricular canal, EC: 
endocardial cushion, LA: left atrium, LCV: left cardinal vein, OFT: outflow tract, RA: right atrium, RCV: 
right cardinal vein, SV: sinus venosus. f-p. White: TNNI2, green: ISL1, red: NKX2-5, blue: DAPI. Scale 
bars: 50µm.
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Figure 5. HCN4 expression in myocardial continuity sinus venosus and posterior AV canal
a. TNNI2 stain of HH19 chick embryo. Arrow indicates continuity between sinus venosus myocardium 
and posterior AV canal. b. In situ hybridization shows HCN4 mRNA expression in continuity (arrow). 
c. Merge of ISL1, TNNI2, HCN4 and DAPI staining of E11.5 mouse embryo, showing the myocardial 
continuity between the sinus venosus and posterior AV canal. The ISL1+/HCN4+/TNNI2+ SAN 
(arrowhead) and RVV (arrow) are shown. Note the thick endocardial cushions (asterisks) in the 
AVC. d-f. Higher magnifications of boxed area in c. d. ISL1+/TNNI2+/HCN4+ cells are seen in the 
continuity between sinus venosus myocardium and posterior AV canal myocardium. e-f. grey values 
of ISL1 (e) and HCN4 (f). AVC: atrioventricular canal, LB: long bud, LCV: left cardinal vein, LV: left 
ventricle, OFT: outflow tract, RA: right atrium, RCV: right cardinal vein, SV: sinus venosus. c-f. White: 
TNNI2, green: ISL1, red: HCN4, blue: DAPI. Scale bars: 50µm. 
3.2. CHARACTERIZATION MYOCARDIAL CONTINUITY 
CONFIRMS THE PACEMAKER-LIKE PHENOTYPE
Laser capture microdissection was performed in order to characterize the sinus 
venosus-AV canal continuity (SV-AVC in Fig. 6) and to quantify differences in 
expression levels of TNNT2, NKX2-5, ISL1 and HCN4 in this region. These results 
were compared to the more caudal tissue of the posterior AV canal and tissue 
from the lateral wall of the right ventricle to better identify the phenotype of the 
SV-AVC region.
 Expression of TNNT2 and NKX2-5 was comparable between the different 
samples, confirming the myocardial identity of all tissue samples that were 
collected (Fig. 6b-c). Analysis of HCN4 expression showed the highest relative 
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Figure 6. Characterization myocardial continuity between the sinus venosus and AV canal
a. Whole mount ISL1 staining, posterior view of the heart. Arrows indicate ISL1+ cells in continuity 
sinus venosus and AV canal. Rectangle 1 shows region from which SV-AVC continuity cells were 
collected for patch clamp. Rectangle 2 shows origin of right ventricular cells for patch clamp. b-e. 
mRNA expression after laser capture microscopy (LCM, see Supplemental Fig. S1) of TNNT2, NKX2-
5, HCN4 and ISL1. f-m. Results of single-cell patch clamp experiments. f,j. Representative tracing of 
SV-AVC continuity cells (f, pacemaker-like tracing) and RV cells (j, ventricular-like phenotype). g-i, 
k-m. graphs showing the difference in maximum upstroke velocity (g), frequency (h), amplitude (i), 
APD50 (k), APD90 (l) and maximum diastolic potential (m). * Indicates p<0,05. AVC: AV canal, LCM: 
laser capture microscopy, LV: left ventricle, OFT: outflow tract, RV: right ventricle, SV: sinus venosus, 
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expression in the SV-AVC continuity, with a lower level of expression in the AV 
canal and right ventricle (Fig. 6d). The difference in expression levels between 
the myocardial continuity and the right ventricle was significant (p=0,008). 
There was a trend towards significance in the difference between the continuity 
and the AV canal samples (p=0,056). ISL1 expression was only detectable in the 
samples taken from the SV-AVC continuity (Fig. 6e).
 Single-cell patch clamp was performed to functionally characterize the cells of 
the myocardial continuity between the sinus venosus and AV canal. Whole mount 
ISL1 staining was performed to identify the region of the continuity between the 
sinus venosus myocardium and posterior portion of the AV canal (Fig. 6a). Cells 
from this region were compared to cells from the right ventricle (Fig. 6a). The 
action potential of cells from the SV-AVC continuity showed a pacemaker-like 
phenotype (Fig. 6f), while the action potential of cells from the right ventricle had 
a ventricular-like phenotype (Fig. 6j). The SV-AVC cells had a higher spontaneous 
beating frequency (Fig. 6h), a lower amplitude (Fig. 6i), a shorter APD50% (Fig. 
6k) and APD90% (Fig. 6l), in line with what is expected from pacemaker-like 
cells. The results are summarized in Table 1. 
 Together these results confirm the pacemaker-like phenotype of the cells from 
the myocardial continuity between the sinus venosus and AV canal. Furthermore, 
results show that even during early development, it is possible to distinguish 
different cell populations within the region of the putative AVN.
Electrophysiological 
parameter SV-AVC (n=8) RV (n=6) p-value
Vmax (V/s) 10.32±4 9.45±2 0,873
Frequency (Hz) 4.6±0.3 2.6±0.2 <0,001
APD50% (ms) 52.73±3 88.63±11 0,004
APD90% (ms) 72.79±5 109±11 0,007
Amplitude (mV) 82.66±4.5 101.67±2.8 0,006
MDP (mV) -67±2.7   -71.5±1.3 0,209
APD: action potential duration, MDP: maximal diastolic potential, Vmax: maximal upstroke velocity, 
SV-AVC: cells from myocardial continuity sinus venosus and AV canal, RV: right ventricle.
Table 1. Electrophysiological characteristics.
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Figure 7. Tracing cells after medial labeling of ISL1+/TNNI2+ sinus venosus myocardium
a-c. 3D reconstruction, HH20 embryo. white: myocardium, yellow: mesenchyme, blue: AV canal 
myocardium, green: ISL1+/TNNI2+ sinus venosus myocardium, red: DiI/5-TAMRA a. Overview of 
HH20 heart. b. Detail of continuity (arrowheads) between AV canal and sinus venosus myocardium. 
c. DiI/5-TAMRA labels SAN, RVV and right side myocardial continuity sinus venosus and posterior 
region of the AV canal (arrow). d. Merge of DiI/5-TAMRA, ISL1, TNNI2 and DAPI. boxed area is shown 
at higher magnification in e-g. e. Labeling of continuity myocardium sinus venosus and AV canal  f-g. 
Grey values of the fluorescent signal.  h. Overview of HH25 heart. i. Myocardial continuity at HH25 
(arrowheads). j. Labeling after 48 hrs is similar to 24 hrs and located in myocardial continuity sinus 
venosus and posterior part of the AV canal (arrow).  k. Overview of labeling at HH25. Magnification 
in l-n. l. Shows DiI/5-TAMRA (arrow) in continuity between sinus venosus and AV canal myocardium. 
m-n. Grey values of fluorescent signal. Asterisks in n: background staining. AVC: atrioventricular 
canal, EC: endocardial cushion, LA: left atrium, LCV: left cardinal vein, OFT: outflow tract, RA: right 
atrium, RVV: right venous valve, SAN: sinoatrial node, SV: sinus venosus, V: ventricle. d-g, k-n: red: 
DiI/5-TAMRA, green: ISL1, white: TNNI2, blue: DAPI.  Scale bars:  50µm.
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3.3. LINEAGE TRACING SHOWS INCORPORATION OF SINUS 
VENOSUS MYOCARDIUM IN POSTERIOR REGION AV CANAL
The abovementioned results show the identification of an ISL1+/HCN4+/TNNI2+ 
myocardial continuity between the sinus venosus and posterior AV canal. At 
early developmental stages, ISL1-/TNNI2+ atrial myocardium is positioned 
between the ISL1+/TNNI2+ sinus venosus myocardium and the ISL1-/TNNI2+ 
AV canal myocardium. During further development, ISL1+/TNNI2+ myocardium 
is continuous with the ISL1-/TNNI2+ AV canal myocardium. To further study the 
possible contribution from the ISL1+/TNNI2+ sinus venosus myocardium to the 
posterior portion of the AV canal, lineage tracing experiments were performed. 
In ovo microinjection experiments were performed in chicken embryos with 
vital dyes (DiI-5-TAMRA) aimed at labeling the ISL1+/TNNI2+ sinus venosus 
myocardium at stages when this myocardium is not yet in contact with the AV 
canal (HH14-15). This myocardial labeling was termed medial labeling, since the 
labeling was applied more medial than the second group of labeling performed 
in the mesenchyme outside the sinus venosus myocardium (termed lateral 
labeling). First the results of the medial myocardial labeling will be discussed. 
 To confirm the location of the medial labeling, a group of embryos was 
harvested 1-2 hrs after microinjection (n=14). DiI/5-TAMRA was found in the 
myocardium of the sinus venosus and the myocardium surrounding the RCV, 
both positive for ISL1 and TNNI2 (Fig. 1a-c,e, 14/14 embryos, 100%; in Fig. 1b 
all 14 separate microinjections are superimposed to clarify the extent of the total 
labeling). Labeling was also present in the mesenchyme surrounding the RCV 
(Fig. 1d, 14/14 embryos, 100%). In 9/14 embryos (64%), a small area of labeling 
(on average 5,9% of total labeling) was also found in the ISL1-/TNNI2+ atrial 
myocardium directly bordering the ISL1+/TNNI2+ sinus venosus myocardium, 
but no leakage to the ISL1-/TNNI2+ connection between the inferior region of 
the atrium/sinus venosus and AV canal myocardium or the AV canal itself was 
seen. Limited leakage to other cardiac structures, such as the posterior OFT 
and ventricles was restricted to the upper layer of myocardial cells, while the 
labeling at the sinus venosus myocardium was applied to the full thickness of the 
myocardium. This first group of embryos therefore verified the correct location of 
injection. An interactive PDF of the three-dimensional reconstruction is available 
online, which shows the location of all separate initial microinjections (online 
3D PDF S1, available online or at request to the authors). 
 Analysis of the embryos after 24 hrs of reincubation (n=10, HH19-22) revealed 
DiI/5-TAMRA in the sinus venosus myocardium (9/10 Embryos, 90%), putative 
SAN (10/10 embryos, 100%), RVV (10/10 embryos, 100%), right atrium (7/10 
embryos, 70%) and the continuity between the sinus venosus myocardium and 
the posterior AV canal myocardium (8/10 embryos, 80%) (Fig. 7a-g). The labeled 
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Figure 8. Tracing cells after lateral labeling of RCV mesenchyme
a. Overview, 24 hrs reincubation after labeling wall sinus venosus/RCV. Boxed area shown in b-c. b-c. 
No myocardial labeling, no ISL1+ cells labeled. d. Overview, 48 hrs reincubation. Boxed area shown in 
d-f. d-f. Comparable results. Labeling mesenchyme sinus venosus/RCV, no myocardial labeling. Note 
demarcation (arrow in e) between labeled mesenchyme and sinus venosus myocardium. No ISL1+ 
cells labeled. RCV: right cardinal vein, RV: right ventricle, SV: sinus venosus. Red: DiI/5-TAMRA, green: 
ISL1, white: TNNI2, blue: DAPI. Scale bars:  50µm. 
area was largely positive for ISL1 and TNNI2 (Fig. 7d-g). Two embryos did not 
show DiI/5-TAMRA in the continuity between the myocardium of the sinus 
venosus and AV canal. In one of these embryos, initial labeling was applied more 
cranially, only resulting in labeling of the atrial myocardium. The other embryo 
showed DiI/5-TAMRA in the caudal portion of the sinus venosus myocardium. 
Here, initial injection was applied more caudally than in the 8 embryos that did 
show labeling of the continuity.    
 A third group of embryos was reincubated for 48 hrs (n=4, HH25). DiI/5-
TAMRA was found in the myocardium of the putative SAN (3/4 embryos, 75%), 
the RVV (3/4 embryos, 75%), the sinus venosus myocardium (4/4 embryos, 
100%), right atrium (3/4 embryos, 75%) and the myocardium of the posterior 
continuity between sinus venosus and AV canal (3/4 embryos, 75%) (Fig. 7h-n). 
In one embryo, labeling was not found in the continuity. This is explained by the 
more caudal initial injection that was performed, as was seen in one embryo in 
the second group.
 
3.4. LATERAL LABELING RCV MESENCHYME DOES NOT 
RESULT IN LABELING MYOCARDIUM SINUS VENOSUS OR AV 
CANAL
The above-described results showed that in all embryos, DiI/5-TAMRA was found 
in the mesenchyme of the RCV. The labeled cells that were found in the myocardial 
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continuity between sinus venosus and AV canal can therefore also be derived 
from this mesenchyme. To exclude this possibility, a second group of more lateral 
labeling of the RCV mesenchyme was performed at HH15-17 and the first group 
of embryos was harvested 1-2 hrs after injection (n=6). Analysis showed DiI/5-
TAMRA in the RCV mesenchyme and lateral body wall (6/6 embryos, 100%) (Fig. 
1f-h). None of the analyzed embryos showed leakage to myocardial structures. 
 Analysis after 24 hrs of reincubation (n=5, HH19-21), showed labeling in the 
lateral body wall and TNNI2- RCV mesenchyme in all cases (5/5 embryos, 100%, 
Fig. 8a-c), with no labeling of myocardial structures, such as the myocardium of 
the RCV, RVV or sinus venosus.      
 After 48 hrs of reincubation (n=5, HH24-25), DiI/5-TAMRA was found in the 
TNNI2- mesenchyme of the RCV (5/5 embryos, 100%, Fig. 8d-f). None of the 
embryos showed labeling of the SAN, RVV or sinus venosus myocardium.
 Together, the medial and lateral labeling experiments show that ISL1+/
TNNI2+ myocardium of the sinus venosus is incorporated in the posterior region 
of the AV canal. 
4. DISCUSSION
The adult AVN consists of multiple cell types (i.e. compact nodal cells, transitional 
cells and nodal extensions) with different morphological and electrophysiological 
characteristics. The initiation of AVNRT requires the presence of pathways with 
different electrophysiological characteristics, resulting in slow conduction in 
the so-called slow pathway, unidirectional conduction in the fast pathway and 
a central area of block. Cellular and functional heterogeneity of the node is thus 
a prerequisite for AVNRT to occur. A key finding of the current study was the 
demonstration of incorporation of sinus venosus myocardium in the AV canal in 
the posterior region of the AVN.
 It has been suggested that the transitional cells of the AVN are an atrial 
contribution to the AVN.25 The inferior nodal extension, which acts as the slow 
pathway in AVNRT, has been described as atrial myocardium, based on histologic 
criteria.16 The CCS-LacZ26,27 and HCN4nLacZ28 mice, which were used to visualize 
the developing CCS, demonstrated that the sinus venosus myocardium, that 
includes the SAN at its proximal end as well as the left and right venous valves, 
is connected to the AVN. Analysis of protein expression of HNK-1 in human 
embryos29, mRNA expression of HCN4 in chicken embryos23 and Tbx3 in mice30 
showed the same connection between the sinus venosus myocardium and the AVN. 
More recently, it was established that Isl1+ cardiogenic mesoderm contributed 
to the AVN.20 These results suggest that the sinus venosus myocardium and 
venous valves are connected with the AVN through specialized myocardium of 
the CCS. However, these studies did not show a direct embryonic contribution 
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from the sinus venosus myocardium to the developing AV canal. To overcome 
these limitations, it is necessary to directly label the cells from the sinus venosus 
myocardium and trace these cells during development.  
 Recently, two separate research groups performed vital dye labeling 
experiments and showed a very early contribution (4-6 somite stage in mouse31 
and HH8 in chick32) from a region posterior to the cardiac crescent to the AV canal 
myocardium. Dominguez et al. showed that the majority of cells comprising the 
murine AV canal are derived from an Isl1+ and Mlc2a- pool of cells.31 Bressan et al. 
showed a contribution to the developing AV canal from an even more posteriorly 
located region, which is Isl1- and Nkx2-5-.32 These experiments suggest that the 
AV canal myocardium, and thus the AVN, is derived from a larger population of 
cells than cardiac crescent cells alone. However, these results still do not prove 
the addition of cells from the sinus venosus myocardium to the developing AV 
canal.
 The current study is aimed at the area of myocardial continuity between 
the sinus venosus and AV canal. Expression data show that in this tissue, ISL1 
is strongly expressed in the sinus venosus myocardium and decreases towards 
the AV canal. NKX2-5 expression shows a similar but opposite pattern, with an 
increase in expression towards the AV canal myocardium, suggesting that ISL1+ 
cells are differentiating towards a more restricted cardiac fate in this region. The 
continuity between sinus venosus myocardium and the AV canal also showed 
HCN4 mRNA expression and was identified in murine embryos co-expressing 
ISL1, TNNI2 and HCN4. HCN4 is responsible for the “funny current”, enabling 
cardiomyocytes to depolarize spontaneously and HCN4 is known to be expressed 
in the (developing) CCS.23 The pacemaker–like phenotype of the myocardial 
continuity was confirmed with single-cell patch clamp experiments and by qPCR. 
The different phenotype of this region compared to the more caudal, posterior 
region of the AV canal was demonstrated by the different levels of mRNA 
expression of HCN4 and ISL1. These results suggest the presence of distinct, 
heterogenic cell populations within the region of the putative AVN and indicate a 
contribution of the sinus venosus during the development of the AVN.
 Vital dye labeling of the ISL1+/TNNI2+ sinus venosus myocardium at HH15 
(when this myocardium was not yet in contact with the AV canal) and follow-
up of these cells during further development, showed that part of the sinus 
venosus myocardium becomes incorporated in the posterior region of the AV 
canal myocardium (putative AVN region). As mentioned, it was shown that in 
the region of the developing AVN, different cell populations (i.e. relative high 
expression of HCN4 and ISL1 in the myocardial continuity between the sinus 
venosus and AV canal as compared to the more caudal portion of the posterior 
AV canal) can be distinguished, even early in development.
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 These results combined with the co-expression studies support the hypothesis 
that the definitive AVN is derived from different sources of cells that are added 
at different time points. We hypothesize a relatively late (after HH15, when the 
PHT has been formed and dextral looping has progressed) contribution from the 
sinus venosus myocardium to the developing AVN, which results in the presence 
of multiple cell types in the adult AVN. Furthermore, we postulate that the cells 
from this sinus venosus-AV canal continuity contribute to the nodal extensions 
or transitional cells of the AVN, as the continuity is located posterosuperiorly in 
the AV canal.
 Using a genetic lineage tracing approach in mice, Aanhaanen et al. described 
no contribution of Tbx18+ (used as a marker for the sinus horn myocardium and 
the epicardium) cells to the AVN or AV junction.13 The current study describes 
a contribution from the sinus venosus myocardium to the AV canal. A possible 
explanation for this difference could be the different markers used to identify 
the sinus venosus myocardium. The Tbx18-Cre used will probably label a 
different pool of cells as compared to the ISL1+ cells that were labeled in the 
current study. Furthermore, it has been shown that inefficient recombination 
of the ROSA26R locus33 (the reporter that was used in the Tbx18 -Cre based 
genetic tracing experiments mentioned above was the R26RLacZ mouse) makes it 
difficult to interpret the results. Ma et al. reassessed the fate of Isl1+ and Nkx2-
5+ cells and compared the results of a ROSA26R-based or GATA4-based reporter 
system. They found large differences in recombination domains between the two 
reporter systems, with a far larger recombination domain for the GATA4-based 
reporter experiments.33 These results show that it is difficult to draw conclusions 
from the absence of reporter gene expression.
 Two limitations of the vital dye experiments are the potential leakage of dye to 
adjacent structures and the impossibility to directly correlate the initial labeling 
to the fate of cells at a later time point within the same embryo. Leakage to the 
ISL1-/TNNI2+ atrial myocardium was calculated and showed that only a small 
percentage (on average 5,9%) of labeling was found in this region. Furthermore, 
labeling experiments in a large number of embryos and the high reproducibility 
of injections and pattern of distribution minimized these limitations. 
 In order to describe the dynamics of ISL1 expression, early stages of 
development were analyzed and co-expression of ISL1 and TNNI2 was found in 
the bilateral cardiogenic plates, before formation of the primary heart tube. Cells 
that contribute to the cardiac crescent and primary heart tube are considered 
to be derivatives of the first heart field. Mesodermal cells at both poles of the 
tube which differentiate and are recruited to the heart are considered to be 
derivatives of the second heart field.34 Isl1 is commonly used as a marker for the 
second heart field. However, co-expression of ISL1 and TNNI2 was found in the 
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majority of cells of the bilateral cardiogenic plates (first heart field derived) in 
chick, which is in agreement with expression of ISL1 mRNA in this region.35 As 
described above, Ma et al. showed that the majority of cardiac cells (including 
left ventricular cardiomyocytes) are derived from Isl1+ progenitors.33 This 
shows that Isl1 is not suitable as a second heart field marker.33 These results 
raise the question whether the first and second heart field should be considered 
as truly distinct cell populations, or rather form a continuum and reflect 
different stages of differentiation of progenitor cells with a cardiac fate, as was 
mentioned previously.33,36 Nevertheless, the analysis of ISL1 expression, which 
was performed in the current study, is crucial to identify cardiac progenitors and 
investigate the differentiation state of (pre)cardiac cells. 
 The current study describes co-expression of ISL1 and TNNI2 beyond 
HH12 in regions relevant for normal CCS development, but also in myocardial 
structures known to underlie common arrhythmias. Furthermore, it was shown 
that the myocardial continuity in the upper region of the developing AVN shows 
relative high expression of HCN4 and ISL1. Our data and the results from other 
studies point towards an important link between ISL1 and the CCS. The primary 
pacemaker of the heart, the SAN, retains ISL1 expression until late stages of 
development, whereas in the remaining heart, ISL1 expression is downregulated 
after cells differentiate to working cardiomyocytes.2 Previous inducible Cre-
based genetic tracing experiments showed the contribution of Isl1+ progenitors 
to the SAN and AVN.20 Also, a link between Shox2, a transcription factor essential 
in regulating the SAN gene expression program, and Isl1 has been shown.37 Mice 
lacking Shox2 present with severe bradycardia and defects in SAN development, 
and show downregulation of Isl1 expression in the SAN. The Shox2-mediated 
bradycardia could be rescued by isl1 in a zebrafish model.37 Zebrafish lacking 
isl1 expression show pacemaker dysfunction and the isl1+ cells from the 
inflow portion of the heart reveal pacemaker activity.38 A possible mechanism 
by which ISL1 is involved in CCS functioning is by keeping cells in a primitive 
state, maintaining their pacemaker-like phenotype and preventing them from 
further differentiating towards working myocardium. The CCS consists of 
cells resembling a more primitive myocardium with slow conduction, high 
automaticity, and poor electrophysiological coupling.10 We hypothesize that 
selected clinical arrhythmias could be explained by a local diminished or absent 
downregulation or re-expression of Isl1 resulting in areas with a more primitive, 
CCS-like phenotype, from which arrhythmias originate. Further experiments are 
needed to test this hypothesis.
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5. CONCLUSION
Incorporation of sinus venosus myocardium in the posterior part of the AV 
canal myocardium was demonstrated. It is postulated that the sinus venosus 
myocardium contributes to the nodal extensions or transitional cells of the AVN. 
Multiple sources of cells contributing to the AVN may explain the heterogeneity 
of the node, and form the substrate underlying AVNRT. 
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SUPPLEMENTAL MATERIAL
Supplemental figure S1. Representative images of regions collected by LCM
a-b. The myocardial continuity between the sinus venosus and AV canal is shown (SV-AVC) before 
LCM. The red line indicates the region where the laser will dissect. c-d. The same region is shown 
after dissection of the tissue. e-g. The more caudal posterior AV canal region (AVC,) before (e-f) and 
after (g-h) LCM. i-l. The right ventricular (RV) region where LCM was performed, before (i-j) and 
after (k-l) dissection. AVC: atrioventricular canal, EC: endocardial cushion, LCV: left cardinal vein, 
OFT: outflow tract, PEO: proepicardial organ, RV: right ventricle, SV: sinus venosus. Scale bars: length 
is depicted above bar.  
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LETTER TO EDITOR
Sun et al. report that the dorsal mesenchymal protrusion (DMP) acts as a 
temporary pacemaker during early development, prior to formation of the 
atrioventricular node (AVN).1 We would like to question whether the anatomical 
designation of the DMP used in this paper is correct.  
The DMP was originally described as a mesenchymal protrusion from the dorsal 
mesocardium towards the atrial cavity contributing to the base of the atrial 
septum along with the mesenchymal cap and atrioventricular (AV) cushions 
(see Fig. 1).2 To differentiate between the DMP prior to muscularization (from 
approximately embryonic day (E)13 in mouse), and other structures in the 
AV junction during early development, stainings of myocardial markers are 
essential, which are lacking in the Sun paper.1 In our opinion, the Shox2+ region 
described by Sun et al. as DMP at E11.5 and E12.5 corresponds to CTNI+/
HCN4+/ISL1+ cells of the putative AVN region and not the DMP (CTNI-/HCN4-, 
ISL1+) (see Fig. 1 and refs3,4). HCN4 expression to date has not been described 
in mesenchyme.3–5 Co-expression of HCN4/TBX3 in cells in the AV junction, with 
nodal-like electrophysiological characteristics1 corresponds to the (putative) AVN 
region instead of the DMP, which is in accordance with our own observations.4 
Misnaming the DMP during early development leads to the erroneous conclusion 
that this structure shows pacemaking properties.
Although we do not support the conclusion that the DMP acts as a temporary 
pacemaker, the results described by Sun et al. elegantly show an important role 
for the Shox2-BMP pathway during AVN development.
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Figure 1. Structures in the atrioventricular junction at E11.5
Panels A-E show transverse sections just below the entrance of the pulmonary veins. A. Overview of 
CTNI/HCN4/ISL1 staining. Boxed area is shown in B-E. B. Merge of different channels showing the 
HCN4-/CTNI-/ISL1+ DMP (arrowhead) protruding from the dorsal mesocardium (DM) towards the 
atrial cavity. The close relation with the mesenchymal cap (MC) is shown. C-E. Separate grey values of 
CTNI (C), HCN4 (D), and ISL1 (E). Panels F-J show transverse sections at the level of the base of the 
atrial septum, more caudal to the level shown in panels A-E. F. Overview, with boxed region shown in 
G-J. G. the HCN4-/CTNI-/ISL1+ (low expression of ISL1 at this level) DMP (arrowhead) is continuous 
with the MC, which in turn is continuous with the inferior atrioventricular cushion (iAVC). The arrow 
indicates the HCN4+/CTNI+/ISL1+ region designated by Sun et al. as DMP. However, co-expression 
of markers and the location directly above the iAVC at the base of the right atrium shows that this 
region corresponds to the region of the future AVN. H-J. grey values of CTNI (H), HCN4 (I), and ISL1 
(J). Scalebar in A and F 100µm, other panels 50µm. AS: atrial septum, CTNI: cardiac troponin-I, HCN4: 
hyperpolarization-activated cyclic nucleotide-gated channel 4, ISL1: Islet1, L/RCV: left/right cardinal 
vein, L/RV: left/right ventricle, L/RVV: left/right venous valve, RA: right atrium, sAVC: superior 
atrioventricular cushion.
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RHOA-ROCK signaling regulates cell migration, proliferation, differentiation and 
transcription. RHOA is expressed in the developing cardiac conduction system in 
chicken and mice. In early development, the entire sinus venosus myocardium, 
including both the transient left-sided and definitive right-sided sinoatrial node 
(SAN), has pacemaker potential. Later, pacemaker potential is restricted to the 
right-sided SAN. Disruption of RHOA expression in adult mice causes arrhythmias 
including bradycardia and atrial fibrillation, the mechanism of which is unknown 
but presumed to affect the SAN. The aim of this study is to assess the role of 
RHOA-ROCK signaling in SAN development in the chicken heart.
METHODS AND RESULTS: 
ROCK signaling was inhibited chemically in embryonic chicken hearts using 
Y-27632. This prolonged the immature state of the sinus venosus myocardium, 
evidenced by up-regulation of the transcription factor ISL1, wide distribution 
of pacemaker potential and significantly reduced heart rate. Furthermore 
ROCK inhibition caused aberrant expression of typical SAN genes ROCK1, 
ROCK2, SHOX2, TBX3, TBX5, ISL1, HCN4, CX40, CAV3.1 and NKX2.5 and left-right 
asymmetry genes PITX2C and NODAL. Anatomical abnormalities in pulmonary 
vein development were also observed. Patch clamp electrophysiology confirmed 
the immature phenotype of the SAN cells and a residual left-sided sinus venosus 
myocardium pacemaker-like potential.
CONCLUSIONS: 
RHOA-ROCK signaling is involved in establishing the right-sided SAN as 
the definitive pacemaker of the heart and restricts typical pacemaker gene 
expression to the right side of the sinus venosus myocardium. 
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1. INTRODUCTION
The RHOA-Rho kinase (ROCK1/2) signaling pathway is associated with multiple 
cardiovascular, metabolic and neurodegenerative diseases, and cancer.1 RHOA is 
a member of a family of small GTPases that, together with downstream effector 
kinases ROCK1 and ROCK2, acts as a molecular switch regulating processes like 
cell migration, cytoskeletal reorganization and gene transcription.1, 2 RHOA-ROCK 
signaling has also been linked to early cardiogenesis and embryonic left-right 
asymmetry.3-6 In addition, the function of the cardiac conduction system (CCS) 
likely depends on RHOA-ROCK signaling since (i) adult mice with altered RHOA 
expression present with bradycardia, atrial fibrillation and atrioventricular 
(AV) block7,8 and (ii) expression of RHOA during chicken heart development 
is ultimately restricted to the sinoatrial  node (SAN) and atrioventricular node 
(AVN).9  
 Supraventricular tachycardias (SVTs) are the most common cardiac 
arrhythmias in adults and children.10 SVTs can originate from components 
of the adult CCS, but also from myocardial structures outside the CCS, such as 
the pulmonary venous myocardium.11,12 To date, mechanisms underlying these 
arrhythmias have not been elucidated. Re-expression of embryonic genes 
or failure to mature so that the embryonic phenotype is retained, however 
may account for the development of specific arrhythmogenic sites within the 
heart.9,13 In cardiomyopathy, pathophysiological remodeling occurs through re-
expression of embryonic genes14, a mechanism that could also apply to a specific 
subset of cardiac arrhythmias. 
 During early development, the heart is initially tubular, but loops and expands 
through continuous incorporation of cells from the mesoderm dorsal to the heart 
at the arterial and venous pole. Among the genes expressed by these actively 
proliferating cell populations is the LIM homeodomain transcription factor Islet1 
(Isl1), necessary for proper cellular proliferation, survival and migration.15 Isl1 
has also been linked to the SAN as a direct downstream target of Shox2 and is 
able to rescue the bradycardia in Shox2 mutants.16
 Early in development, the initial pacemaker signal originates from the left 
posterior portion of the venous pole of the heart17, later corresponding to the 
sinus venosus myocardium covering the left cardinal vein. In adults, the SAN is 
located at the entrance of the right superior caval vein (embryonic right cardinal 
vein) in the right atrium (RA). Therefore, a shift in pacemaker location from 
the left towards the right side has to occur. During cardiogenesis, the sinus 
venosus myocardium covers the developing cardinal veins (adult caval veins) 
and includes a functional transient left-sided SAN and the definitive right-sided 
SAN.9,18,19
 The developing sinus venosus myocardium, including the SAN, expresses 
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different genes than the atrial and ventricular working myocardium. These 
include PODOPLANIN20, RHOA9, Shox216, 21, Tbx1822, Tbx323, ISL116, and HCN413 
but NKX2.5 and connexin (Cx) 40 are absent24 (reviewed in 25). In contrast, atrial 
and ventricular myocardium does not express Tbx3 or Shox2 but does express 
NKX2.5.20-22 While most of the key players in SAN differentiation have been 
identified, expression levels within the sinoatrial myocardium of the chicken 
during heart development are largely unknown.
 Although the exact mechanism driving restriction of pacemaker function 
to the right side of the sinus venosus myocardium is unknown, recent studies 
suggest a role for right/left patterning factors like PITX2C. This gene is linked to 
a higher susceptibility for atrial arrhythmias26 and acts as a direct suppressor of 
Shox2 in the left atrium, inhibiting the SAN-specific genetic programme.18,27 
 Based on evidence linking RHOA to the CCS7-9,  we hypothesized that normal 
RHOA-ROCK signaling is essential for proper formation and differentiation of 
the SAN during embryonic development. Here, we disrupted ROCK signaling 
during development of the chicken heart and examined the consequences for 
gene expression and SAN function. We found that RHOA-ROCK signaling is 
important in establishing the right-sided SAN as the definitive pacemaker and 
restricts typical pacemaker gene expression to the right side of the sinus venosus 
myocardium. 
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2. METHODS
A detailed description of Experimental Methods used in this study is provided in 
the Data Supplement at the end of this chapter. 
2.1. RHO-SIGNALING DISRUPTION, CARDIAC 
ELECTROPHYSIOLOGY AND GENE EXPRESSION 
Animal experiments were performed in accordance with institutional guidelines 
of the Leiden University Medical Center. Rho signaling was disrupted by 
addition of the selective Rho kinase (ROCK) inhibitor compound Y-27632 
(688000, Calbiochem, Massachusetts, USA) in ovo after 48 hrs of incubation (~ 
stage HH10/11). 2µl of 100µM Y-27632 or PBS (as control) was added to the 
surface of the embryo. A schematic representation of the experimental setup and 
survival rates of the embryos are provided in Supplemental Fig. 2. Extracellular 
microelectrode recordings and optical mapping recordings were conducted as 
described previously.9,28
 RNA was isolated from control and ROCK inhibited hearts (for HH18-19 whole 
inflow tract portions were used, from HH20 onwards the inflow tract portion 
was divided into the right and the left side to assess gene expression separately) 
and gene expression was analyzed by quantitative Polymerase Chain Reaction 
(qPCR). Embryos were extracted 24 (stage HH18-19;n=6 controls (CTRL);n=8 
ROCK inhibitions (ROCK)), 48 (stage HH21-22;n=7 CTRL;n=9 ROCK) and 96 
(stage HH28-29;n=6 CTRL;n=8 ROCK) hrs after treatment. Chicken gene specific 
primers are provided in Supplemental Table 1.
2.2. MICROELECTRODE ARRAY ON ISOLATED CHICK 
CARDIOMYOCYTES  
To study the direct effect of the ROCK inhibitor on rate and amplitude of 
cardiomyocytes, sinoatrial, atrial and ventricular cardiomyocytes of stage 
HH26-27 chicken embryos were cultured as described previously29 and plated 
on microelectrode arrays (MEA) for electrophysiology. Time point zero was 
recorded before the ROCK inhibitor Y-27632 was added. Data points are displayed 
as % relative to time point zero (before application of inhibitory compound).
2.3. PATCH CLAMP ELECTROPHYSIOLOGY
Patch clamp electrophysiology was conducted on cardiomyocytes isolated from 
right/left or whole sinus venosus myocardium and right ventricular myocardium 
in control and in ovo ROCK-inhibited hearts as previously described.29 
122  Chapter 6 
6
Figure 1. Normal development of the SAN (figure on page 123)
A-D. Posterior views of 3D reconstructions of HH11 (A), HH24 (B),  HH35 (C), and HH42 (D) 
embryonic chicken hearts. NKX2.5-negative myocardium is depicted in lime green, right and left 
cardinal vein (R/LCV) lumen in transparent blue and pulmonary pit or vein in yellow. The numbered 
intersection lines refer to respective sections of the specific embryonic stage. A1-A3. HH11 heart 
showing TNNI2 (A1-A2) but no NKX2.5 (A3) expression in myocardium surrounding the RCV 
(arrow, putative right SAN). A4-A6. Sections showing a cluster of cells medial to the LCV (arrow, 
transient left SAN area) expressing TNNI2 (A4-A5) but no NKX2.5 (A6). B1-B3. HH24 heart showing 
TNNI2 (B1), HCN4 (B2) but no NKX2.5 (B3) expression in the right-sided SAN. B4-B6. Cluster of 
cells medial to the LCV (arrow, transient left-sided SAN) expressing TNNI2 (B3), HCN4 (B5) but no 
NKX2.5 (B6). The right-sided SAN is more compact and shows better myocardial continuity with the 
atrial myocardium than the left-sided SAN (compare B1 with B4). D1-D4. Transverse sections of an 
HH42 chicken embryo depicting the right-sided SAN (arrows) which is TNNI2+ (D1-D2), NKX2.5- 
(D3) and HCN4+ (D4). D5-D8. The majority of the sinus venosus myocardium including the left side 
(arrows) now expresses TNNI2 (D5-D6), NKX2.5 (D7) but no HCN4 (D8). (L/R)A: left/right atrium. 
Scale bars: A-C: 200µm; D: 400µm, A1-D8: 100µm. HH11-31: n=40.
3. RESULTS
3.1. NORMAL SAN DEVELOPMENT: FROM BROAD 
PACEMAKING ACTIVITY TO RIGHT-SIDED RESTRICTION 
Normal development of the SAN in the chicken embryo heart is summarized in 
Fig. 1. Early in development, just as looping of the heart tube has started (HH11), 
the first sinus venosus myocardium could be observed ventral to the cardinal 
veins, evidenced by expression of TNNI2 and absence of NKX2.5 (Fig. 1A, A1-A6). 
A cluster of cells at the entrance of the right cardinal vein (superior caval vein in 
the adult) corresponded to the putative right-sided SAN (Fig. 1A1-A3), whereas 
a cluster on the left side reflected the left-sided SAN (Fig. 1A4-A6). Previously, 
we showed that at these developmental stages the sinus venosus myocardium 
expresses HCN4 mRNA.13 As the heart continued to grow and loop to adopt its 
mature four-chambered structure, the sinus venosus expanded considerably 
(Fig. 1B,C), still encompassing a right and left-sided SAN. Small differences 
between the right and left-sided SAN were already evident: the right-sided SAN 
was more compact than the left (although it still had larger intercellular spaces) 
and showed robust myocardial continuity with the atrial myocardium (compare 
Fig. 1B1-B3 to B4-B6). At pre-hatching stages (HH42), the right side of the sinus 
venosus myocardium was the only region lacking NKX2.5 (Fig. 1D). The fully 
developed right-sided SAN expressed TNNI2 (Fig. 1D1-D2), and HCN4 (Fig. 1D4) 
but not NKX2.5 (Fig. 1D3). In contrast to earlier stages, the myocardium medial 
to the left cardinal vein expressed TNNI2 (Fig. 1D5-D6) and NKX2.5 (Fig. 1D7), 
whereas HCN4 expression (Fig. 1D8) was absent. Thus, although the developing 
SAN occupied a broad area of the heart early in development, it was restricted to 
the right side at later stages.
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Figure 1. Normal development of the SAN (legend on page 122)
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3.2. ROCK INHIBITION AND SAN FUNCTION: PERSISTENT 
IMMATURITY IN FUNCTION AND DEFICIENT 
LATERALIZATION 
The ability of the entire sinus venosus myocardium to generate the first atrial 
activation signal has been previously demonstrated.9, 18, 19 Electrophysiological 
measurements in the current study confirmed the presence of three atrial 
activation patterns during development: right side first activation pattern (RA 
signal precedes left atrium (LA), RA first, Supplemental Fig. 3A-B), left side 
first (LA signal precedes RA, LA first, Supplemental Fig. 3C-D) and concurrent 
activation (no distinction can be made between RA or LA (<1 ms difference), 
Concurrent). These activation patterns were confirmed by optical mapping 
recordings in which three preferential activation sites were observed: left, 
middle and right of the sinus venosus portion of the embryonic heart (Fig. 2A-C).
 In light of restriction of RHOA expression to the SAN at HH289, hearts were 
divided into two groups for analysis: before (<) and at or after (≥) HH28. During 
early stages of normal heart development (<HH28, Fig. 2D) the RA first pattern 
was observed in 62% (63/95) of the cases, the LA first in 18% (18/95) and the 
concurrent pattern in 20% (20/95). Later (≥HH28, Fig. 2D), the RA first pattern 
represented 92% (24/31) of the observed patterns, LA first 4% (1/31) and 
concurrent 4% (1/31). Longitudinal analysis of activation patterns showed a 
significant difference between early and late developmental stages (p=0.014, 
<HH28 vs ≥HH28), demonstrating a shift towards right-sided pacemaking. 
 At early stages of development (<HH28, Fig. 2D), after ROCK signaling was 
inhibited, 39% (12/48) of cases showed the RA first pattern, 26% (8/48) the LA 
first pattern and 35% (11/48) the concurrent pattern. Differences with controls 
were not statistically significant (p=0.061). At later stages (≥HH28, Fig. 2D) ROCK 
inhibition resulted in 57% (8/18) of RA first cases and 21.5% (3/18) of both LA 
first and concurrent cases, significantly different (p=0.03) from the untreated 
group. Longitudinal analysis revealed no significant difference (p=0.099) in 
distribution of atrial activation sites before or after HH28 in the ROCK inhibition 
group.
 During normal heart development, pacemaker cell differentiation could be 
monitored by electrophysiology ex ovo. One of the most striking electrical changes 
was a significant increase in heart rate in RA first hearts ≥HH28 compared to 
LA first hearts (Fig. 2F), compared to <HH28 (Fig. 2E). After ROCK inhibition, 
the heart rate at late stages (≥HH28) of RA first heart was significantly lower 
compared to controls (Fig. 2F). LA first hearts showed a significantly higher 
heart rate compared to its control counterpart and RA first control hearts (Fig. 
2F). Overall, after ROCK inhibition, global pacemaking potential was maintained 
in the entire sinus venosus myocardium. 
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Figure 2. Persistent immaturity in function and deficient lateralization of the SAN
A-C. Optical mapping recordings of the dorsal portion of the heart of HH21 chick embryos showing 
first activation (white asterisk, color code red) of the heart from the left (A), middle (B) or right (C) 
side of the sinus venosus. Each color represents 1ms of propagation. D. Frequency distribution (in % 
of activation pattern) of different atrial activation patterns observed <or ≥ stage HH28 in controls or 
after ROCK inhibition (INH). E. Bar graph depicting significant changes in control heart rate (beats 
per minute, bpm) before stage HH28 between CTRL (n=95) and ROCK INH (n=48). F. Bar graph 
depicting significant changes in heart rate between CTRL (n=31) and ROCK INH (n=18) ≥HH28. L/
RSV: left/right sinus venosus, V: ventricle. χ2 –test was performed for categorical values and two-way 
ANOVA with Bonferroni post-hoc test.*: p< 0.05; **: p< 0.005.
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Figure 3. Hampered lateralization and pacemaker specification in sinoatrial myocardium
A. qPCR analysis of expression genes of interest, right (black bars) vs left (gray bars) sinoatrial 
myocardium, control HH21 chicken embryonic hearts (n=5-7). B. qPCR analysis of expression 
genes of interest, right (black bars) vs left (gray bars) sinoatrial myocardium, control HH29 chicken 
embryonic hearts (n=4-6). Levels shown relative to right side. C,E. qPCR analysis of expression genes 
of interest at stage HH21 after ROCK inhibition (n=4-8) for right (black bars) vs left (gray bars) 
sinoatrial myocardium. D,F. qPCR analysis of genes of interest at stage HH29 after ROCK inhibition 
(n=4-8) for the sinoatrial myocardium. In C and D, levels shown relative to right side. In E and F, levels 
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3.3. ROCK INHIBITION AND SAN DIFFERENTIATION: 
HAMPERED LATERALIZATION AND PACEMAKER 
SPECIFICATION
Based on the electrophysiology results, qPCR analysis was conducted on separate 
right and left portions of the sinoatrial myocardium to assess pacemaker gene 
expression patterns. The identity of the isolated portions was confirmed by 
expression of transcription factors important in SAN differentiation like SHOX221, 
TBX323,  and ISL116, the ion channels necessary for pacemaking HCN4 and HCN130, 
31 and low levels of the SAN inhibitory transcription factor NKX2.524  and gap 
junction protein Connexin (CX) 40, highly expressed in atrial myocardium.18,27
 Early in development, at HH21, control hearts showed that nearly all genes 
studied (i.e. genes of the ROCK pathway, transcription factors important in SAN 
differentiation) were equally expressed between right and left-sided sinoatrial 
myocardium (Fig. 3A). Significant differences encountered at this stage were 
higher expression of NKX2.5 (p=0.0087), TBX5 (p=0.0159), CX40 (p=0.0159), 
CAV3.1 (p=0.0159) and the left-sided identity gene PITX2C18,27 in the left side of 
the sinoatrial myocardium, as expected (p= 0.0023, Fig. 3A).
 Later in development, at HH29, significant differences between the right and 
left sides of the sinoatrial myocardium became more apparent (Fig. 3B). The 
levels of expression of RHOA, ROCK1 and ROCK2 were significantly lower in the 
left side. The genetic profile of the inflow tract at HH29 on the right side of this 
region showed persistent expression of transcription factors and ion channels 
essential for proper SAN function, whereas the left side showed significantly 
lower levels of SHOX2 (p=0.0087), ISL1 (p=0.0173), TBX3 (p=0.0079) and HCN4 
(p=0.0022) and significantly higher levels of CX40 (p=0.0317), and PITX2C 
(p=0.0043) (Fig. 3B). Thus, functional and morphological changes showed that 
the definitive pacemaker of the normal heart will be right-sided.
 At HH21 after ROCK inhibition, expression of ISL1 was significantly higher 
(p=0.0401) and TBX3 significantly lower on the left side of the sinus venosus 
(p=0.0148) (Fig. 3C). At HH29, levels of SHOX2 (p=0.0186), ISL1 (p=0.0293), 
PITX2C (p=0.0007) and CAV3.1 (p=0.0451) were significantly higher in the left 
side compared to the right side (Fig. 3D).
 Gene expression levels after ROCK inhibition were compared to control 
levels. At HH21, differences in gene expression levels after ROCK inhibition 
compared to control became apparent (Fig. 3E). HCN4 (p=0.0293), and 
NKX2.5 (p=0.0031) levels were lower in the left side, and ISL1 (p=0.035) and 
RHOA expression were higher (p=0.037) (Fig. 3E). In the right side, only HCN4 
expression was significantly lower (p=0.0293) while CAV3.1 expression was 
significantly higher in the right side (p=0.0079) (Fig. 3E). At HH29, levels of 
SHOX2 (p=0.0173), and ISL1 (p=0.0079) were significantly higher in the left side 
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whereas TBX5 (p=0.0317) and NODAL (p=0.0043) were significantly lower. In 
the right side, levels of SHOX2 (p=0.008), ISL1 (p=0.02), TBX3 (p=0.0025), HCN4 
(p=0.0007), and CAV3.1 (p=0.0451), important for pacemaker development, 
were low relative to controls. Levels of CX40 (p=0.0095), normally found in atrial 
myocardium, were high (Fig. 3F). In accordance with the functional data, after 
ROCK inhibition, the left-sided SAN region still showed a SAN-like phenotype 
(explaining the maintained pacemaker functionality in the left side) while the 
differentiation of the definitive right-sided SAN area was impaired (explaining 
the decreased heart rate observed in the inhibited hearts).
3.4. ABERRANT SINUS VENOSUS DIFFERENTIATION AND 
ABNORMAL PULMONARY VEIN DEVELOPMENT AFTER ROCK 
INHIBITION
Gene expression analysis revealed abnormal expression of ISL1 after ROCK 
inhibition. During normal heart development, a portion of the sinus venosus 
myocardium including the definitive right-sided SAN expressed ISL1 (Fig. 4A,G) 
as well as a large proportion of the mesodermal cells dorsal to the heart (Fig. 
4C). In controls, ISL1 expression was restricted to the right-sided SAN at late 
stages of differentiation (Fig. 3B,F, compare 4A to 4G). However, after ROCK 
inhibition, this ISL1 balance was disrupted. At HH26 ROCK inhibition resulted 
in an overall increase in ISL1+ sinus venosus myocardium, especially in the left 
portion (compare Fig. 4A to B). This upregulation was still evident at HH29 
(compare Fig. 4G to H), supporting the qPCR results (Fig. 3E and F). 
 Normally, the ISL1+ sinus venosus myocardium is negative for NKX2.5. In 
accordance with the gene expression analysis, ROCK inhibited hearts showed 
an increase in ISL1+/NKX2.5- myocardium on the left side and a decrease on 
the right side (compare Fig. 4D to F). At HH26, this increase in ISL1+ cells in 
ROCK inhibited hearts was also observed in the mesoderm dorsal to the heart, 
where the pulmonary vein is developing (compare Fig. 4C to Fig. 4E). Later in 
development (HH29), in 4/5 cases ROCK inhibition caused aberrant positioning 
of the entrance of the common pulmonary vein into the left atrium, including one 
case in which the right pulmonary veins entered the right portion of the sinus 
venosus (Fig. 4H).
3.5. THE EFFECT OF ROCK INHIBITION ON HEART RATE IS 
SPECIFIC FOR THE SINOATRIAL CARDIOMYOCYTES
Since ROCK inhibition was applied to the entire heart, we next examined 
whether effects observed on SAN function and development were specific for the 
sinoatrial myocardium. MEA experiments were performed on isolated sinoatrial 
and atrial (only appendages) cells of HH26-27 control and ROCK-inhibitor 
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Figure 4. Aberrant sinus venosus differentiation and pulmonary vein formation after 
inhibition of ROCK signaling
Posterior view of 3D reconstructions of HH26 control (A) and ROCK inhibition (B). ISL1+/TNNI2+ 
myocardium is depicted in purple, right and left cardinal vein (R/LCV) lumen in transparent blue and 
pulmonary pit or vein in yellow. ISL1 staining of a HH26 control (C) and ROCK inhibition (E) heart 
showing ISL1 expression in non-myocardial area surrounding the lumen of the pulmonary vein (*). D 
and F show posterior views of the same 3D reconstruction as in A and B but with the NKX2.5 negative 
myocardium in lime green. Posterior view of 3D reconstructions of HH29 control (G) and ROCK 
inhibition (H) sinus venosus with the same color coding as in A-B. Dotted line in 3D reconstructions 
separates the right from the left sinus venosus portions. L/RA: left/right atrium, L/RCV: left/right 
cardinal vein. Scale bars: A-B, G-H, G1-G2, H1-H2: 200µm, C-D: 100µm.
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treated embryonic chicken hearts. Results showed a decrease in heart rate 
(Fig. 5A) when ROCK signaling was inhibited in sinoatrial cardiomyocytes, but 
no effect on heart rate in atrial cardiomyocytes was observed (Fig. 5B). ROCK 
inhibition did affect signal amplitude in both sinoatrial and atrial cardiomyocytes 
(Supplemental Fig. 4). As an internal control, the same experiment was 
performed on ventricular cardiomyocytes and no effect on rate or amplitude was 
observed (Supplemental Fig. 5). This showed that the effect of inhibiting ROCK 
signaling was specific for the sinoatrial myocardium including the developing 
SAN.
3.6. ROCK INHIBITION DELAYS ACTION POTENTIAL 
MATURATION AND CAUSES PERSISTENT PACEMAKER 
POTENTIAL ON THE LEFT SIDE
To assess the electrophysiological maturation status of sinus venosus 
cardiomyocytes after ROCK inhibition, patch clamp electrophysiology was 
performed at HH29 (Fig. 5C-J). During normal development, maturation of the 
action potential was observed (compare Fig. 5C (HH29) to Fig. 5E (HH20)). After 
ROCK inhibition, the action potential of sinoatrial cardiomyocytes resembled 
that of HH20 sinoatrial cardiomyocytes more closely than HH29 untreated 
sinoatrial cardiomyocytes (Fig. 5C-E). This immaturity was confirmed by a 
significant decrease in maximal upstroke velocity (dV/dT, p=0.0035, Fig. 5F), 
action potential amplitude (p=0.011, Fig. 5H) and resting membrane potential 
(p=0.037, Fig. 5J), which bore more resemblance to early HH20 sinoatrial 
cardiomyocytes. 
 Right-left sinoatrial differences were also assessed after ROCK inhibition (Fig. 
6). Immaturity was observed in both right and left-sided sinoatrial cardiomyocytes 
after ROCK inhibition (Fig. 6A-D). However, after ROCK inhibition, sinoatrial 
cardiomyocytes from the left side showed characteristics similar to that of the 
right side (definitive pacemaker), in concordance with the right-sided phenotype 
observed with qPCR. The action potential duration (APD90) was significantly 
increased (p=0.046) and the significant difference with the control group when 
compared to the right side (p<0.0001) was no longer apparent (p=0.307, Fig. 
6F). The action potential amplitude was significantly lower on both sides after 
inhibition (p=0.014 for right and p<0.0001 for left, Fig. 6G) and the maximum 
diastolic potential significantly lower in the left-sided sinoatrial cardiomyocytes 
compared to control (p=0.0016). 
 Overall, the left-sided sinoatrial cardiomyocytes shared more properties of 
the right side after ROCK inhibition, indicative of persistent pacemaker potential 
on the left side.
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Figure 5. ROCK inhibition reduces the heart rate specifically in sinoatrial cardiomyocytes
A. % Of rate variation compared to time point zero (0) of sinoatrial cardiomyocyte cell cultures at 
various time points (up to 240 min) after treatment with ROCK inhibitor (ROCK INH; n=9) or PBS 
(CTRL; n=7). B. % Of rate variation compared to time point zero (0) of atrial cardiomyocytes (with 
no SAN cardiomyocytes) after treatment with  ROCK inhibitor (ROCK INH; n=7) or PBS (CTRL; n=7). 
C-E. Representative tracings of sinoatrial cardiomyocytes from HH29 control (C, HH29 CTRL), HH29 
ROCK inhibition (D, HH29 INH) and HH20 control (E, HH20 CTRL). 17-19 cells analyzed per group. 
F-J. Scatter plots showing maximum upstroke velocity (F), action potential duration (APD)90 (G), 
amplitude (H), frequency (I) and maximum diastolic potential (J). One or two-way ANOVA analyses 

























































































































Micro-Electrode Array (MEA) Electrophysiology - HH26
Patch Clamp Electrophysiology - Embryonic Sinoatrial Cardiomyocytes
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Patch Clamp Electrophysiology - HH29 Sinoatrial Cardiomyocytes 
Figure 6. Right-left differences in sinus venosus cardiomyocytes after ROCK inhibition
A-D. Representative tracings of sinoatrial cardiomyocytes from right control (A), right ROCK 
inhibition (B), left control (C) and left ROCK inhibition (D). 17 to 19 cells were analyzed per group. 
E-I. Scatter plots showing maximum upstroke velocity (E), action potential duration (APD)90 (F), 
amplitude (G), frequency (H) and maximum diastolic potential (I). One-way ANOVA with Bonferroni 
post-hoc test was performed.*, p<0.05; ** p<0.01; ***, p<0.001; ****, p<0.0001.
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4. DISCUSSION
In this study, changes in function and gene expression in the SAN region before 
full development of the definitive right-sided SAN were described. Rho kinase 
inhibitors wield a dual effect on the developing SAN. On the one hand, ROCK 
inhibition results in immaturity of the right-sided SAN and prolonged pacemaker 
potential of the transient left-sided SAN, reflecting overall immaturity of the 
sinus venosus myocardium. On the other hand, it results in gap junction and 
ion channel remodeling of the developing SAN, impairing proper conduction 
through this myocardium.
4.1. ROCK SIGNALING AND LATERALIZATION OF THE SAN
Left-right (LR) asymmetry is observed in the entire body plan; establishing 
this normal asymmetry correctly is essential in determining the position and 
structure of internal organs, including the heart. Abnormalities in LR asymmetry 
lead to laterality disorders including complex congenital heart diseases.32,33 
Asymmetric expression of NODAL, LEFTY and members of the PITX2 gene family 
in the lateral plate mesoderm are essential for proper LR-asymmetry. This 
asymmetry is likely established early in development by the pre-determined 
antero-posterior  and dorso-ventral axis in the embryonic plate.33 Recently it was 
demonstrated that RHOA-ROCK signaling is involved in LR-asymmetry. ROCK2B 
knockdown in zebrafish resulted in abnormal asymmetric gene expression in 
the lateral plate mesoderm and abnormal LR-patterning in organs.6 In mouse 
and chicken, disruption of ROCK signaling using the small molecule inhibitor 
Y-27632 results in cardiac defects and bilateral expression of NODAL in the 
lateral plate mesoderm in chicken embryos.3 
 Although Y-27632 has inhibitory effects on protein kinases other than 
ROCK1/2, its affinity for Rho kinases is more than 200-fold higher.3,34 The 
present study showed that treatment with Y-27632 resulted in lower levels of 
ROCK2 expression. However, further research is required to assess whether the 
effect of Y-27632 on SAN development is exclusively through downregulation of 
ROCK1/2. Chicken embryos studied here showed abnormal levels of NODAL in the 
left side of the sinoatrial myocardium. Thus, RHOA-ROCK signaling may play an 
important role in determining LR-asymmetry early in development, specifically 
in establishing right-sidedness in the sinus venosus myocardium, important 
for proper establishment of the right-sided SAN as definitive pacemaker of the 
heart. 
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4.2. ROCK SIGNALING AND SAN DIFFERENTIATION: GENE 
TRANSCRIPTION REGULATION AND FUNCTION
Inhibition of ROCK signaling during early developmental stages resulted in 
immature sinus venosus myocardium and abnormal SAN gene expression 
patterns. The definitive right-sided SAN is inefficient and its transient left-sided 
part  retained its pacemaker potential. This results in impaired SAN function 
reflected by bradycardia at older developmental stages and in an immature area 
prone to arrhythmias, including structures with known arrhythmogenic potential 
like the pulmonary veins.11, 12 Limited SAN function was already reported in mice 
with aberrant ROCK signaling, but the mechanism remains unknown.7, 8 Based on 
results presented here, abnormal SAN function reflects abnormal differentiation 
of the SAN myocardium. A complex genetic transcriptional network involved 
in SAN differentiation was established over the past decade. However, new 
interactions and key players in SAN development keep arising. Among these 
are the transcription factors Tbx323, Shox221,35, Nkx2.524, Pitx2c36 and Isl116,37 
(reviewed in25). These are linked since they can exert inhibitory or activating 
effects on each another in complex feedback loops. Emerging evidence supports 
a role for RHOA-ROCK signaling in regulation of molecular pathways involved 
in early cardiogenesis.3,5 More specifically Rho-Kinase inhibitors can either 
impair5 or promote38 cardiac differentiation in vitro altering the expression of 
key genes in early cardiac lineages like GATA4, ISL1 and TBX5.5, 38 In our study, at 
late developmental stages, low levels of ROCK1 and ROCK2 in the right portion 
of the sinoatrial myocardium were accompanied by low levels of expression of 
key transcription factors necessary for proper SAN differentiation (ISL1, SHOX2, 
TBX3, and HCN4, Fig. 3). Myocardial transcriptional targets of the RHOA-ROCK 
pathway are SRF, GATA4, α-ACTIN, TBX5 and ISL1.3,5,38 This signaling pathway 
may be involved in regulating the transcriptional network necessary for proper 
SAN differentiation, since dysregulation of this pathway in adult mice leads to 
several CCS abnormalities.7,8 ROCK can control the activity of LIM kinases1 and can 
therefore regulate proteins containing LIM domains, such as ISL1. A direct effect 
of ROCK on ISL1 expression has yet to be discovered. The dysregulation of ISL1 
expression is observed in both the myocardial (TNNI2+) as well as the TNNI2- 
cell population dorsal to the heart. Expression of Isl1 in the developing SAN (i.e. 
the myocardial population) is important for proper SAN differentiation37 and 
function.16 Putative binding sites for Isl1 were identified within the regulatory 
regions of Tbx3 and Hcn4, suggesting a novel regulatory function of Isl1 within 
the SAN gene program.37 
 ISL1 expression in the mesenchymal population is important for normal 
pulmonary vein development.39 This is interesting in the light of the 
arrhythmogenic potential attributed to the pulmonary venous myocardial 
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sleeves, as well as the potential involvement of the RHOA-ROCK signaling 
pathway in anomalous pulmonary venous connections.12 A well-kept Shox2 and 
Nkx2.5 balance has recently been described as the mechanism that ensures the 
non-pacemaker phenotype of the pulmonary venous myocardial sleeve during 
development.40 In this study, SHOX2 and ISL1 are abnormally expressed in the 
venous pole of the heart, potentially leading to an increased arrhythmogenic 
potential due to abnormal/insufficient differentiation.
 To ensure coordination between propagation of the pacemaking signal and 
contraction of the chambers, electrical heterogeneity of the myocardium is 
required. This is accomplished by differential expression of connexins and ion 
channels within the chambers.41 For instance, high levels of Cx40 expression 
in the atrial myocardium ensure rapid propagation of the electrical impulse 
from the SAN to allow for simultaneous atrial contraction.21,24,27 The abnormal 
conduction through the sinus venosus myocardium found in this study could 
be due to the effect of RHOA-ROCK signaling on ion channel expression or 
activity. This could account for the electrophysiological differences observed 
in SAN electrophysiology between whole-heart and single-cell measurements. 
Altered Rho-signaling has been associated with abnormalities in expression 
of Cx408 and 4342, and L-type Ca2+ channels.43 Expression of Cx40 was altered 
after Rho-kinase inhibition, resulting in high expression in the right-sided SAN 
(Fig. 3). In the chick heart, expression of connexins (40, 43, and 45) is different 
than in mammals.44 Expression of all 3 connexins was studied but only Cx40 is 
of relevance in the developing chick SAN. Given the direct regulatory role of the 
RHOA-ROCK pathway on Cx43 expression in myocardial cells, this pathway could 
be involved in regulating Cx40 expression during development. In the mouse 
heart, L-type Cav1.2 and T-type Cav3.1 Ca2+ channels are highly expressed 
in the SAN.45 Since RHOA has been found to regulate L-type Ca2+ currents in 
ventricular cardiomyocytes43 and mice lacking T-type Cav3.1 Ca2+ channels 
show bradycardia45, we studied its expression pattern in the developing SAN and 
the effects of ROCK inhibition. After ROCK inhibition, expression levels of Cav3.1 
were altered, specifically in the right-sided SAN (Fig. 3). Additional experiments 
are necessary to unravel the mechanism by which RHOA can regulate Cav3.1 
expression and/or activity, as observed in ventricular cardiomyocytes for 
Cav1.2.43
4.3. RHOA-ROCK SIGNALING IN HUMAN DISEASE
Human genetic studies have linked abnormal RHOA-ROCK signaling with several 
congenital heart abnormalities. Specifically, low frequency variants in the 
ROCK1 gene have been associated with a higher risk of developing tetralogy of 
Fallot.46 Mutations in the protein phosphatase SHP-2 have been linked to Noonan 
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and Leopard syndrome, both frequently associated with congenital heart 
abnormalities like pulmonary valve stenosis, hypertrophic cardiomyopathy or 
conduction abnormalities. Missense mutations in SHP-2 in these patients cause 
hyperactivation of the RHOA-ROCK pathway.47 Additionally, trisomy 18 and 21 
foetuses show higher levels of ROCK1 RNA, and the ROCK1 gene is located on 
chromosome 18 in humans.48 RHOA was found to regulate Cx43 expression, 
providing a plausible disease mechanism for these patients.42 These data suggest 
a role for RHOA-ROCK signaling in human cardiac diseases.
Overall, RHOA-ROCK signaling is essential for establishing the right-sided SAN as 
definitive pacemaker of the adult heart. Abnormal RHOA-ROCK signaling results 
in an immature sinus venosus myocardium, including the SAN, and ectopic 
maintenance of a pacemaker phenotype in the left-sided sinus venosus. 
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DATA SUPPLEMENT
ANIMAL PREPARATION AND RHO SIGNALING DISRUPTION
Animal experiments were performed in accordance to institutional guidelines 
of the Leiden University Medical Center, national guidelines and Directive 
2010/63/EU of the European Parliament on the protection of animals used 
for scientific purposes. Fertilized White Leghorn chicken eggs were incubated 
horizontally at 37°C (80% humidity). Rho signaling was disrupted by addition 
of the selective Rho kinase (ROCK) inhibitor compound Y-27632 (688000, 
Calbiochem, Massachusetts, USA) in ovo after 48 hrs of incubation (~HH10-
11). First, a window in the egg was made and the extraembryonic membranes 
were carefully opened. 2µl of 100µM Y-27632 or PBS was added to the surface 
of the embryo at a singular moment. qPCR analysis after 24 hrs of reincubation 
confirmed downregulation of ROCK2 (p-value<0.05), with a trend towards lower 
expression of RHOA (Supplemental Fig. 1). A schematic representation of the 
experimental setup is provided in Supplemental Fig. 2. Y-27632 has a half-life of 
12-16 hrs.1 Embryos were extracted 1-4 days post-intervention, staged according 
to standard criteria2 and euthanized by decapitation. For ex ovo extracellular 
microelectrode recordings hearts were isolated. The same experiments were 
performed for RNA isolation and for patch clamp electrophysiology. Survival 
rates of embryos treated with ROCK inhibitor was significantly different as 
compared to controls embryos (p=0.013, Supplemental Fig. 2).
EX OVO ELECTROPHYSIOLOGICAL RECORDINGS
To assess the effects of ROCK inhibition on sinoatrial node development, ex 
ovo electrophysiological recordings were conducted in 168 control and ROCK 
inhibited embryonic hearts (HH16 to HH31) during superperfusion with 
oxygenated Tyrode solution as previously described.3 Briefly, hearts were placed 
in a temperature-controlled fluid-heated superperfused tissue bath (37±0.5°C), 
fixed with a wire through non-cardiac tissue near the outflow tract and allowed 
to equilibrate for 10 min. Heart rates (beats per minute, bpm) below the standard 
for their stage of development were excluded.3 Tungsten recording electrodes 
were placed on the right atrium (RA) (near the entrance of the right cardinal 
vein), left atrium (LA) (near the entrance of the left cardinal vein), on the left 
side of the ventricular apex (V), and a reference electrode in the tissue bath. The 
electrical activity was confirmed visually by mechanical activity (contraction) 
of the atria and ventricles. A difference of ≥ 1ms in local depolarization time 
between the recording electrodes was considered significant.  An example of 
an electrical recording is depicted in Supplemental Fig. 3. Heart rates were 
measured between two atrial signals. Interatrial conduction time was measured 
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as miliseconds (ms) between the RA and LA signal. Analysis was performed 
in two separate groups: <HH28 between control (n=95) and ROCK inhibition 
(n=48) and ≥HH28 between control (n=31) and ROCK inhibition (n=18).
OPTICAL MAPPING RECORDINGS
Optical mapping recordings were conducted as previously described.3-5 Briefly, 
freshly isolated hearts from embryonic stages HH21-22 (n=9 chick embryos)
were dissected in ice-cold Tyrode solution (to prevent any post-mortem 
ischemic damage) with the following composition: NaCl 145 mmol/l, KCl 
5.9 mmol/l, CaCl2 1.1 mmol/l, MgCl2 1.2 mmol/l, glucose 11 mmol/l, HEPES 
5 mmol/l; pH = 7.4. Hearts were isolated with abundant non-cardiac outflow 
tract tissue for fixation in the tissue bath and intact inflow tract region to ensure 
spontaneous pacemaking activity. These hearts were stained with 2.5 μmol/l 
di-4-ANEPPS (Invitrogen) for 10 minutes. Motion control was accomplished 
with 0.1μM blebbistatin (Sigma) and by pinning the heart by the non-cardiac 
outflow tract tissue to the bottom of the dish. The Ultima L high-speed camera 
and software were used for data acquisition and analysis  was performed using 
the BV Analyzer software.3-5
IMMUNOHISTOCHEMISTRY AND NON-RADIOACTIVE IN SITU 
HYBRIDIZATION
For immunohistological analysis thoraxes were fixed in 4% paraformaldehyde 
for 24 hrs, embedded in paraffin and serially sectioned. Immunohistochemical 
stainings were conducted (HH16-HH31, n=40) as described3 for primary 
antibodies: anti-TNNI2 (goat polyclonal antibody, sc-8118, Santa Cruz, 1/400), 
anti-NKX2.5 (goat polyclonal antibody, sc-8697, Santa Cruz, 1/4000), and 
anti-ISL1 (mouse monoclonal antibody, clone 39.4D5, Developmental Studies 
Hybridoma Bank, 1/400). Slides were incubated with biotin-conjugated 
secondary antibodies specific to the appropriate species (goat-α-rabbit (BA-
1000); horse-α-goat (BA-9500), horse- α-mouse (BA-2000), all from Vector 
Labs), visualized by incubation with 3-3’diaminobenzidin tetrahydrochloride 
(DAB, D5637, Sigma-Aldrich), and counterstained with haematoxylin (0.1%, 
Merck). Nonradioactive in situ hybridization analysis for HCN4 was conducted 
with a digoxigenin-labeled antisense RNA probe in 10µm embryo sections as 
described previously.6 Briefly, a cDNA fragment corresponding to HCN4 amino 
acids 400–602 was used as template and digoxigenin-labeled probes were 
generated. A sense RNA probe was used as a negative control.
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3D RECONSTRUCTIONS
3D reconstructions of atrial and ventricular myocardium of TNNI2-stained serial 
sections of HH11, HH24, HH26, HH29, HH35 and HH42 embryos were made 
as previously described7 using the AMIRA v5.0 Software Package (Template 
Graphics Software, San Diego, USA). In the HH26 and HH29 reconstructions, 
ISL1-positive myocardial expression observed in immediate sister sections was 
superimposed. In the rest of the reconstructions, NKX2.5 negative myocardium 
observed in immediate sister sections was superimposed. 
 
RNA ISOLATION, CDNA SYNTHESIS, REVERSE TRANSCRIPTASE 
PCR AND REAL TIME QPCR
Chicken embryos treated with 2µl of 100µM Y-27632 or PBS (as described 
before) were cultivated for RNA isolation. Embryos were extracted between 24 
(stage HH18-19; n=6 controls (CTRL); n=6-7 ROCK inhibition (ROCK)), 48 (stage 
HH21-22; n=5-8 CTRL; n=4-8 ROCK) and 96 (stage HH28-29; n=4-8 CTRL; n=5-8 
ROCK) hrs after treatment with the inhibitor for real time qPCR analysis. RNA was 
isolated from individual inflow tract regions of embryonic chicken hearts using 
the RNeasy Micro Kit (Qiagen) and treated with DNAse-I (Qiagen) according to 
the manufacturer’s protocol. 200ng of RNA was reversely transcribed into cDNA 
using Superscript II reverse transcription-polymerase and random primers 
(Invitrogen). For HH18-19 specimens, whole inflow tract portions were used. 
From HH20 onwards, the inflow tract portion was divided into the right and the 
left side to assess gene expression separately. 
 For qPCR analysis, chicken gene specific primers for the genes of interest 
are shown in Supplemental Table 1. Primers for HCN4, HCN1 and GAPDH have 
been already validated.6 For each qPCR reaction 1µl of cDNA was used in a final 
volume of 20µl. Reactions were carried out in triplicate for each sample. Negative 
controls were reactions containing H2O instead of cDNA. qPCR was performed on 
a Bio-Rad CFX96 Real Time System and a melting curve was produced to verify 
single qPCR product amplification. Efficiency of the PCR reaction was tested using 
a standard curve synthesized from a dilution series of cDNA. Chicken GAPDH 
was used as the reference standard for normalization and relative quantification 
of differences in mRNA expression was determined. Results were analyzed 
using Graphpad Prism software and are shown as fold change compared to the 
definitive right-sided SAN when showing only the control data or as fold change 
compared to the control group when showing the ROCK inhibition data. In the 
Supplemental Excel file (available online or at request to the authors), all raw 
qPCR values are provided. Furthermore, a step-by step overview is provided for 
the calculations that were performed. 
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The following steps were performed:
1. First, for every gene separately, the right (see Supplemental qPCR data & 
Fig. 3A-3D) or the control (see Supplemental qPCR data & Fig. 3E-F) average 
gene expression value was set to 1. This was achieved by dividing (for all genes 
separately) the values of either the right (Supplemental qPCR data & Fig. 3A-
3D) or control (Supplemental qPCR data & Fig. 3E-3F) embryos by the average 
of the corresponding group. This results in an average value of expression of 
1, and this value is used to calculate the fold change of expression for either 
the left side (Supplemental qPCR data & Fig. 3A-3D) or the inhibition group 
(Supplemental qPCR data & Fig. 3E-F).
2. To calculate the fold change between either the right vs the left side 
(Supplemental qPCR data & Fig. 3A-3D) or the control vs the inhibition 
(Supplemental qPCR data & Fig. 3E-F), for every gene the seperate values of 
the left side (Supplemental qPCR data & Fig. 3A-D) or the inhibition group 
(Supplemental qPCR data & Fig. 3E-F) were divided by the average of either 
the right side (Supplemental qPCR data & Fig. 3A-D) or the control group 
(Supplemental qPCR data & Fig. 3E-F). 
3. These values (see also Supplemental qPCR data file, which also shows which 
values were used for the final statistical analysis) were used to perform Mann-
Whitney U-tests in Graphpad. These values were also used to plot the graphs.   
Missing data in the online Excel file is explained by a limited amount of cDNA 
available to perform qPCR (i.e. insufficient material to perform qPCR analysis for 
all the genes per embryo).
CELL CULTURE AND MICROELECTRODE ARRAY (MEA) 
ELECTROPHYSIOLOGY
To study the direct effect the ROCK inhibitor has on rate, sinoatrial, atrial (only 
appendages) and ventricular cardiomyocytes of HH26-27 chicken embryos 
were cultured as described previously8 and plated for MEA electrophysiology. 
A total of 5 separate experiments were conducted. Each experiment consisted 
of a cardiomyocyte isolation of sinoatrial, atrial or ventricular cardiomyocytes 
pooled from 15-25 embryonic chicken hearts and plated into a minimum of 2-4 
separate MEA chips. Experiments were always carried out with a control and 
treated group in parallel (n=7-9 per group). The culture medium used was our 
cardiomyocyte medium which contains DMEM high glucose (Life technologies, 
Carlsbad, California, USA), 10%  fetal calf serum (Sigma-Aldrich, St. Louis, Missouri, 
USA), 1% penicillin-streptomycin (Life technologies, Carlsbad, California, USA), 
1% non-essential amino acids (Life technologies, Carlsbad, California, USA) 
and 1% L-Glutamine (Life technologies, Carlsbad, California, USA). MEA chips 
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were plasma-cleaned and coated with fibronectin for 1 hour at 37°C. 80,000 to 
100,000 isolated cardiomyocytes were plated on standard 60 electrode MEAs. 
After allowing the cells to settle and grow for 48 hours after plating, recordings 
were conducted using MEA1060INV MEA amplifier (Multi Channel Systems, 
Reutlingen, Germany) as described before.9 Time point zero was recorded 
before the ROCK inhibitor Y-27632 (688000, Calbiochem, Massachusetts, USA) 
was added. Medium was refreshed in the MEAs with medium containing a final 
concentration of 10µM of Y-27632. Measurements were recorded at specific 
time intervals after inhibition (between 10 minutes and 4 hours after application 
of the inhibitor). During the recordings, temperature was kept at 37°C. Data 
were recorded using QT-screen (Multi Channel Systems,) and analyzed with 
QT-analyzer (Multi Channel Systems). Rate data from 3 independent electrodes 
were averaged using Graphpad Prism software. Data points are displayed as % 
relative to time point zero (before application of inhibitory compound).
PATCH CLAMP ELECTROPHYSIOLOGY
Patch clamp electrophysiological studies were performed on cardiomyocytes 
isolated from right/left or whole sinus venosus myocardium and right 
ventricular myocardium in control and in ovo ROCK-inhibited hearts as 
previously described.10 A total of 3 separate experiments were performed. In 
each experiment sinus venosus or ventricular cardiomyoctes were isolated from 
a pool of 15-25 embryonic chicken hearts. Sinus venosus myocardium tissue 
was isolated the same way as for the qPCR analysis, maintained as a whole or 
divided into a right and a left portion. Tissue from the right ventricular free 
wall was isolated as internal control. The tissue was dissociated using 0.05% 
Trypsin (Life technologies, Carlsbad, California, USA) shaking (850 rpm) at 37°C, 
vortexed and then centrifuged for 5 minutes at 1100rpm (114g). The pellet was 
resuspended in our DMEM cardiomyocyte medium (with DMEM high glucose 
(Life technologies, Carlsbad, California, USA), 10% fetal calf serum (Sigma-
Aldrich, St. Louis, Missouri, USA), 1% penicillin-streptomycin (Life technologies, 
Carlsbad, California, USA), 1% non-essential amino acids (Life technologies, 
Carlsbad, California, USA) and 1% L-Glutamine (Life technologies, Carlsbad, 
California, USA)). The cells were plated on glass coverslips. Recordings were 
performed on cardiomyocytes 24 hours after isolation at 37°C in Tyrode’s 
solution of the following composition: NaCl 140 mM; KCl 5.4 mM; CaCl2 1.8 mM; 
MgCl2 1.0 mM, D-Glucose 5.5 mM; HEPES 5.0 mM adjusted to pH 7.4 with NaOH 
(all components from Sigma-Aldrich USA). Action potentials were recorded on 
spontaneously contracting cells with the perforated patch clamp technique using 
an Axopatch 200B amplifier (Molecular Devices Axon Instruments, USA) at 5 kHz 
in the fast current clamp mode. Cut-off seal resistance of 2GOhm or higher was 
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selected for further analysis. Data acquisition was obtained with DigiData 1550 
under control of Clampex 10.0 software (Molecular Devices Axon Instruments, 
USA). Pipets had a resistance of ~2.4 MOhm and the buffer composition was the 
following: K-gluconate 125 mM; KCl 20 mM; NaCl 5 mM; HEPES 10 mM adjusted 
to pH 7.3 with KOH. Before measuring, Amphotericin-B (light protected, Sigma-
Aldrich, USA) at a final concentration of 3μl/ml in DMSO was added. 
 The data was analyzed with custom developed software (L.G.J.T. under 
Labview development software, National Instruments, Austin, Texas, USA). A 
total of 17 to 19 cells were analyzed separately per treatment group. The Action 
Potential Duration (APD), maximal upstroke velocity (dV/dT), action potential 
amplitude, resting membrane potential and the spontaneous beating frequency 
were quantified. 
STATISTICAL ANALYSIS
Data were analyzed using GraphPad Prism software (GraphPad Software, La 
Jolla, California, USA). Multiple comparisons between groups for the qPCR 
results were analyzed with the non-parametric Mann-Whitney U-test (P<0.05 
was considered to be statistically significant). Additional one or two-way ANOVA 
analysis was performed with Bonferroni post-hoc tests in the data obtained from 
the MEA and patch clamp electrophysiology. For comparison of the activation 
pattern (categorical variable) χ2 –test was performed. A p-value <0.05 was 
considered significant. Results are shown as mean ± SEM. 
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Supplemental Figure 2. ROCK inhibition results in higher mortality rates in embryos 
A. Experimental setup of use of Rho-kinase inhibitor Y-27632. B. Survival curve of chick embryos 
after treatment with PBS (control) or with Y-27632 (ROCK inhibition). *p<0.05.
Supplemental Figure 1. ROCK2 expression is reduced 24 hours after ROCK inhibition
qPCR analysis of induced gene expression changes for RHOA, ROCK1  and ROCK2  24 hours after 
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Sinoatrial cardiomyocytes Atrial cardiomyocytes
Supplemental Figure 4. ROCK inhibition results in a lower signal amplitude of sinoatrial 
cardiomyocytes 
A. % Of amplitude variation compared to time point zero (0 min) of sinoatrial cardiomyocyte cell 
cultures at various time points (up to 240 min) after treatment with Y-27632, ROCK inhibitor (ROCK 
INH) or with PBS (control, CTRL). B. % Of amplitude variation compared to time point zero (0) of 
atrial cardiomyocytes (with no SAN cardiomyocytes) after treatment with ROCK inhibitor Y-27632 
(ROCK INH) or with PBS (control, CTRL).*p< 0.05. n=7-9 per group (15-25 embryonic hearts pooled 
per MEA culture).
Supplemental Figure 3. Right and left-sided atrial activation patterns are observed throughout 
development
A-B. Representative example of a recording of an HH23 chicken heart showing pacemaking dominance 
in the right atrium (RA). B. Magnification of the atrial signals showing the RA signal preceding the 
left atrial (LA) signal by 3ms. C-D. Representative example of a recording of a chicken heart at HH24, 
showing pacemaking dominance in the LA. D. Magnification of the atrial signals showing the LA 
signal preceding the RA signal by 6ms.
148  Chapter 6 
6










































































Micro-Electrode Array (MEA) Electrophysiology - HH26
Patch Clamp Electrophysiology
  




































































































































Supplemental Figure 5. ROCK inhibition does not affect electrophysiology ventricular 
cardiomyocytes
A. % Of rate variation compared to time point zero (0 min) of ventricular cardiomyocyte cell cultures 
at various time points (up to 240 min) after treatment with Y-27632, ROCK inhibitor (ROCK INH, 
n=10) or with PBS (control, CTRL, n=5). B. % Rate of amplitude variation compared to time point 
zero (0) of ventricular cardiomyocytes after treatment with ROCK inhibitor Y-27632 (ROCK INH) or 
with PBS (CTRL). C-D.  Representative tracing of right ventricular cardiomyocytes from HH29 control 
(C, HH29 CTRL, n=10) and HH29 ROCK inhibition (D, HH29 INH, n=13). E-I. Scatter plots showing 
maximum upstroke velocity (E), action potential duration (APD)90 (F), amplitude (G), frequency (H) 
and maximum diastolic potential (I). ***p<0.001.
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The RHOA-ROCK signaling pathway is involved in numerous developmental 
processes, including cell proliferation and migration. RHOA is expressed in 
the atrioventricular node (AVN) and altered expression of RHOA results in 
atrioventricular (AV) conduction disorders in mice. The current study aims to 




RHOA-ROCK signaling was inhibited chemically in avian embryos. Ex ovo 
microelectrode recordings showed first to third degree AV block. Morphological 
examination revealed hampered development of the myocardial continuity 
between the sinus venosus and posterior AV canal, including the AVN region. 
Laser capture microdissection and subsequent qPCR of tissue collected from this 
region revealed disturbed expression of HCN1, ISL1 and SHOX2.
CONCLUSIONS:
RHOA-ROCK signaling is essential for normal morphological development and 
gene expression patterns of the myocardial continuity between the sinus venosus 
and posterior region of the AV canal, including the AVN region. Disturbing the 
RHOA-ROCK signaling pathway results in AV block. This is, at least in part, 
explained by the abnormal morphology of the AV transition and disturbed 
gene expression of key genes involved in normal CCS functioning. The RHOA-
ROCK inhibition model can be used to further study the pathophysiology and 
therapeutic strategies for AV block. 
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1. INTRODUCTION
A proper functioning atrioventricular node (AVN) is essential for normal impulse 
propagation from the atria towards the ventricles, after allowing a delay of the 
electrical activation in the AVN. This delay must be long enough to ensure proper 
filling of the ventricles, and short enough to ensure maintenance of a sufficient 
heart rate. Disturbance of AV conduction may result in different degrees of AV 
block, ranging from first degree to complete (third degree) block requiring 
pacemaker implantation. The mechanisms of these different forms of AV block 
are still insufficiently understood. The AVN is a morphologically and functionally 
complex structure, consisting of multiple cell types. The compact portion of the 
node is covered by transitional cells with nodal extensions running towards the 
vestibules of the mitral and tricuspid valves.1,2 
 The exact origin of these different components of the AVN remains to be 
elucidated. It was suggested that at least the compact portion of the AVN is 
derived from the transcription factor T-box (Tbx)2+ myocardium of the AV 
canal.3 We recently described another region that appears to be involved in AVN 
development.4 This region consists of a myocardial continuity that is situated 
between the sinus venosus myocardium (containing the definitive right-sided 
and a transient left-sided sinoatrial node (SAN)), and the AVN, encompassing its 
posterior part. This area is characterized by expression of Islet1 (ISL1, marker for 
(pre)cardiac mesoderm and undifferentiated myocardium5), Troponin-I, isoform 
2 (TNNI2, myocardial marker) and hyperpolarization-activated cyclic nucleotide-
gated channel 4 (HCN4, marker for the (developing) CCS6).4 In previously 
performed cell tracing studies, incorporation of the sinus venosus myocardium in 
the posterior region of the putative AVN (the region of the myocardial continuity) 
was shown.4 This is in line with genetic tracing experiments of Isl1+ progenitors, 
which showed a contribution of Isl1+ progenitors to the AVN.5 A dual origin 
for AVN cells (i.e. AVN cells deriving from the AV canal and the sinus venosus 
myocardium) helps to explain the cellular heterogeneity of the AVN region.
 Further functional and genetic characterization of the continuity between the 
sinus venosus and AV canal showed that cells from this region had a pacemaker-
like phenotype, which again implies a role for this region in CCS functioning.4 
However, whether this region is directly involved in normal and abnormal AV 
conduction was not studied. 
 The AVN region shows expression of the Ras homolog gene family, member 
A (RHOA). Expression is initially broadly present during development, but 
becomes  restricted to the sinus venosus (including the SAN) during further 
development.7 RHOA is a member of the family of Rho kinases, which are small 
GTPases, known to play an important role in cell migration, cell proliferation 
and apoptosis.8 Interestingly, Rho-Kinase inhibitors have been shown to either 
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impair9 or promote10 cardiac differentiation in vitro altering the expression of key 
genes in early cardiac lineages like GATA4, ISL1 and TBX5.9,10 Normal RHOA-ROCK 
signaling is essential for normal development and functioning of the SAN, the 
pacemaker of the heart.11 Inhibiting the RHOA-ROCK pathway in chick resulted in 
an immature right-sided SAN with residual pacemaker potential of the left-sided 
sinus venosus myocardium, indicating that the RHOA-ROCK pathway is crucial 
for establishing the SAN. In addition, it has been shown that cardiac specific 
overexpression of RHOA in mouse results in bradycardia, atrial fibrillation, 
first and second degree atrioventricular block and AVN dysfunction.12 It was 
hypothesized that disruption of RHOA signaling affects the function of cardiac ion 
channels.12 Interestingly, similar results were obtained when expression of RHOA 
was downregulated.13 This indicates that strict regulation of RHOA expression 
is necessary for normal functioning of the AVN. However, these studies were 
performed in postnatal mice. The role of RHOA in developmental processes 
leading to AV conduction disturbances was not investigated. Furthermore, the 
morphology of the AV conduction axis after RHOA disruption has not been 
studied. 
 The current study aimed to first generate a novel model system to investigate 
AV conduction disturbances during development in chick embryos by in ovo 
inhibition of the RHOA-ROCK signaling pathway. Second, since RHOA is involved 
in cellular migration, it was hypothesized that AV block after RHOA inhibition 
may relate to a maldevelopment of the myocardial continuation between the 
sinus venosus and the AV canal (further referred to as SV-AVC continuity). 
Furthermore, we investigated RNA expression of a panel of key cardiac and 
conduction system genes in the region of the SV-AVC continuity and putative AVN 
after RHOA inhibition.
2. METHODS
A schematic representation of the experimental setup is provided in 
Supplemental Fig. 1.
2.1. EXPERIMENTAL PREPARATION
Fertilized White Leghorn chicken eggs were incubated horizontally at 37°C 
and 80% humidity, until they reached the desired developmental stage. 
Staging of embryos was performed according to the Hamburger and Hamilton 
(HH) criteria.14 Embryos were either used as control or used for experiments 
as described in the following sections. After extraction from the egg, embryos 
were staged and euthanized by decapitation, and processed as described below. 
All animal experiments were in accordance with national and institutional 
guidelines.
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2.2. IN OVO ROCK INHIBITION
The chick embryo is readily accessible for microsurgical procedures and follow-
up after intervention is relatively easy. Inhibition of ROCK signaling was achieved 
as previously described.11 Briefly, the Rho-kinase inhibitor compound Y-27632 
(688000, Calbiochem, Massachusetts, USA) was administered in ovo once at 
~HH10-11. ROCK inhibition was achieved by administering 2µl of 100µM 
Y-27632 directly to the surface of the embryo, or by placing heparin acryl beads 
loaded with compound at both sides of the inflow portion of the heart. As a 
control, PBS was administered directly to the surface of the embryo. After the 
procedure, eggs were reincubated and embryos were extracted from the egg at 
the desired time points. 
2.3. EX OVO EXTRACELLULAR MICROELECTRODE 
RECORDINGS
Recordings were conducted in control (n=29) and ROCK inhibited (n=20) hearts 
(HH28-30) as described previously.7,15,16 Hearts were placed in a temperature-
controlled (37±0.1°C) superperfused (oxygenated Tyrode) tissue bath and 
allowed to equilibrate for 10 min. Heart rates (beats per minute, bpm) below 
the standard for their stage of development were excluded.7 Tungsten recording 
electrodes were placed on the right atrium (RA) (near the entrance of the right 
cardinal vein), left atrium (LA) (near the entrance of the left cardinal vein), on 
the left side of the ventricular apex (V), and a reference electrode in the tissue 
bath. The time between the RA electrode and V electrode was considered the AV 
conduction time.
2.4. IMMUNOHISTOCHEMISTRY
Thoraxes of control (n=4) and ROCK inhibited (n=5) embryos of HH29-30 
(corresponding with the stages used for microelectrode recordings) were 
fixed in 4% PFA for 24 hrs, embedded in paraffin and serially sectioned. 
Immunohistochemical stainings were conducted as described4,7 for primary 
antibodies: anti-TNNI2 (goat polyclonal antibody, sc-8118, Santa Cruz, 
1/400), anti-TNNI2 (rabbit polyclonal antibody, SC-15368, 1/200; Santa 
Cruz Biotechnology Inc., Dallas, TX, USA), and anti-ISL1 (mouse monoclonal 
antibody, clone 40.2d6, 1/100, Developmental Studies Hybridoma Bank, Iowa 
City, Iowa, USA). Slides were incubated with biotin-conjugated secondary 
antibodies (except for immunofluorescent staining of TNNI2, which was directly 
visualized with secondary antibody) specific to the appropriate species (horse-
α-mouse (BA-2000) goat-α-rabbit (BA-1000); horse-α-goat (BA-9500), all from 
Vector Labs), and visualized by either incubation with 3-3’diaminobenzidin-
tetrahydrochloride (DAB, D5637, Sigma-Aldrich) or fluorescently labeled 
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secondary antibodies (Alexa Fluor® 488 Streptavidin Conjugate (S-11223, 1/200) 
and Alexa Fluor® 647 donkey anti-goat IgG (A-21447, 1/200), all purchased from 
Life Technologies (Carlsbad, CA, USA)). Slides were either counterstained with 
haematoxylin (0.1%, Merck) or DAPI (used as a nuclear stain, D3571, 1/1000; 
Life Technologies).
2.5. 3D RECONSTRUCTIONS
3D reconstructions were made based on TNNI-stained serial sections of HH29-
30 embryos which were representative for i. the control heart, ii. the mild 
phenotype, and iii. the severe phenotype. The AMIRA v4.0 software package 
(Template Graphics Software, San Diego, CA) was used as previously decribed.17 
2.6. VITAL DYE LABELING STUDIES
Labeling of the sinus venosus myocardium with DiI/5-TAMRA was performed 
at HH15 as described previously.4 Briefly, after windowing the egg the coelomic 
cavity was opened and the DiI/5-TAMRA was injected in the sinus venosus 
myocardium using a programmable microinjector (IM-300, Narishige, Tokyo, 
Japan) and micromanipulator. After injection of the vital dyes, 2µl of 100µM 
Y-27632 (n=5) or PBS (n=4) was injected into the pericardial cavity. Analysis of 
cellular fate was performed after 24 hrs of reincubation (HH19-20).
2.7. LASER CAPTURE MICRODISSECTION PROCEDURE
Laser capture microdissection (LCM) was performed in control (n=5) and ROCK 
inhibited (n=5) embryos at HH30-31 (corresponding with microelectrode 
recordings and immunohistochemical data) as described previously.4 Two 
specific regions were isolated. First, the medial portion of the continuity between 
the sinus venosus myocardium and the posterior AV canal was isolated. The 
medial portion of the SV-AVC continuity is situated where the right venous valve 
(RVV) attaches to the base of the atrial septum (“SV-AVC”, control: Fig. 1A-D, 
ROCK inhibition: Fig. 1I-L). The second set of samples collected was from the 
region of the (putative) AVN, which is situated just distal to the SV-AVC continuity 
(“AVN region”, control: Fig. 1E-H, ROCK inhibition: Fig. 1M-P). After isolating the 
tissue using LCM, the tissue was stored at -80oC.
2.8. RNA ISOLATION, CDNA SYNTHESIS AND QPCR OF LASER 
MICRODISSECTION TISSUE
Gene expression of the following key genes was analyzed: 1. myocardial 
marker Troponin T, isoform 2 (TNNT2); 2. NK2 homeobox 5 (NKX2-5), which 
is expressed in the cardiac mesoderm during early cardiac development and 
remains expressed in atrial and ventricular cardiomyocytes during adulthood. It 
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pathway
A-D. Control heart (HH30) before (A-B) and after (C-D) dissection of the myocardial continuity 
between sinus venosus and posterior AVC (SV-AVC). Boxed area in A and C are shown at higher 
magnification in resp. B and D. The excised region is located in the area where the right venous valve 
(RVV) attaches to the lower border of the atrial septum (arrows in B and D). E-H. Same heart before 
(E-F) and after (G-H) dissection of the region of the putative AVN. Boxed area in E and G are shown at 
higher magnification in resp. F and H. The excised region (arrows in F and H) is located just beneath 
the SV-AVC continuity (asterisk in F and H). Note the small strip of tissue that is located between the 
SV-AVC continuity and the AVN region. This was done to isolate different regions of tissue.  I-L. Heart 
after ROCK inhibition, HH31, before (I-J) and after (K-L) dissection of the same region as in A-D (SV-
AVC continuity). Boxed area in I and K are shown at higher magnification in resp. J and L. The excised 
region is indicated by arrows in J and L.  M-P. Same heart (after ROCK inhibition) before (M-N) and 
after (O-P) dissection of the same region as in E-H (putative AVN region). Boxed area in M and O are 
shown at higher magnification in resp. N and P. The excised region is indicated by arrows in N and P. 
Excised SV-AVC tissue is marked by an asterisk in N and P. LV: left ventricle, RA: right atrium, RV: right 
ventricle, RVV: right venous valve, SV: sinus venosus.    
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is not expressed in the myocardium of the sinus venosus18; 3. hyperpolarization-
activated cyclic nucleotide-gated channels (HCN)1 and 4, which are responsible 
for the “funny-current”, also known as the pacemaker current and are used as 
markers for the (developing) CCS6,19,20; 4. T-box transcription factors (TBX)3 and 
18. TBX3 is a transcriptional repressor which delineates the CCS and is essential 
for CCS function.21,22 TBX18 is a marker for the sinus venosus and is essential for 
development of the venous pole and SAN23,24; 5. the short stature homeobox 2 
(SHOX2) gene, which is also essential for SAN development.25,26 
 RNA was isolated with the RecoverAll™ Total Nucleic Acid Isolation Kit for 
FFPE (Ambion, catalog number AM1975, Life technologies, CA, USA). cDNA 
synthesis was generated using the iScript™ cDNA synthesis kit (Bio-rad, Hercules, 
CA, USA). For all genes, a nested approach was used as described4, except for 
GAPDH and TNNT2. 10 Pre-amplification cycles were performed, using 10µl Sybr-
Green Mastermix (Bio-Rad), 8.5µl nuclease-free water, 0.25µl forward and 0.25µl 
reverse primer and 10µl of cDNA (final volume of 20µl). qPCR was performed 
with for each reaction 5µl of SybrGreen Mastermix (Bio-Rad, Hercules, CA, USA), 
0,5µl of forward primer, 0,5µl of reverse primer, 0,5µl of cDNA (or 0,5µl nuclease 
free water as negative control) and 3,5µl nuclease free water (final volume 10µl). 
Reactions were carried out in triplicate for each sample. qPCR was performed 
on a Bio-Rad CFX384 real-time system. Melting curve analysis was performed to 
verify single PCR product amplification. Chicken GAPDH was used as the reference 
standard for normalization, and relative quantification of differences in mRNA 
expression was determined. The primers used are described in Supplemental 
table 1.
2.9. STATISTICAL ANALYSIS
Data was analyzed with SPSS software (SPSS, Inc, Chicago, Ill). AV intervals were 
compared between groups with a 2-tailed Student's t test for normally distributed 
values. Levels of gene expression were compared using the Mann-Whitney U-test 
(non-normal data). A p-value <0.05 (2-tailed) was considered significant. Results 
are presented as mean ± SEM.
3. RESULTS
3.1. DISRUPTION OF THE ROCK PATHWAY RESULTS IN 
PROLONGED AV CONDUCTION TIME AND AV BLOCK
Ex ovo extracellular microelectrode recordings were performed at HH28-31 
to investigate the effect of early ROCK inhibition on AV conduction in chick 
embryonic hearts. All control hearts showed a spontaneous, regular sinus rhythm, 
with atrial activation prior to ventricular activation for all contractions (Fig. 2A). 
After ROCK inhibition, the mean time between atrial and ventricular activation 
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(termed AV time) for the whole group was prolonged (control: 93.66±12.56 
milliseconds, ROCK inhibition: 106.5±13.56 milliseconds, p=0.0031, Fig. 2B). 
Prolongation of the AV time is comparable to what is observed in first degree AV 
block.27 Furthermore, after ROCK inhibition, 7/20 (35%) of the hearts displayed 
second (Wenkebach and Mobitz type) as well as third degree AV block27 (see Fig. 
2C-E and figure legend for details). These results show that AV conduction is 
abnormal after ROCK inhibition in chick, confirming previous results found in 
postnatal mice.12,13 
         
3.2. ROCK INHIBITION RESULTS IN DEFECTIVE DEVELOPMENT 
OF THE MYOCARDIAL CONTINUITY BETWEEN THE SINUS 
VENOSUS AND AV CANAL IN CHICK EMBRYONIC HEARTS
Next, we sought an explanation for the observed AV conduction disturbances. 
Previous work showed that during normal cardiac development, the sinus 
venosus myocardium is incorporated in the posterior region of the AV canal.4 
This myocardial continuity is situated in the region where the right venous valve 
(RVV) attaches to the lower rim of the atrial septum (putative AVN region).4,28  
 First, the morphology of the SV-AVC continuity after ROCK inhibition was 
studied. Examination of control hearts (n=4) showed the myocardial continuity 
between the sinus venosus myocardium (including the SAN, RVV, LVV and 
myocardium surrounding the cardinal veins) and the posterior region of the AV 
canal (putative AVN region), which in turn was continuous with the AV bundle 
(Fig. 3A-F and figure legend for detailed description). 
 After ROCK inhibition (n=5 analyzed), two phenotypes, that were designated 
“mild” and “severe”, were seen.  In the “mild” phenotype (3/5, 60%), the myocardial 
continuity could still be recognized. However, the continuity appeared smaller 
and the connection with the sinus venosus myocardium was displaced laterally 
and to the right (Fig. 3G-L). A putative AVN region was distinguishable from the 
rest of the myocardium, similar to controls.  
 In the “severe” phenotype (2/5, 40%), the myocardial continuity between 
the sinus venosus and posterior AV canal was further displaced laterally 
and rightwards and consisted of only a strand of myocardial tissue, which 
was connected to the ventricular septum (Fig. 3Q). In contrast to the “mild” 
phenotype, the putative AVN was not distinguishable from the surrounding 
myocardium (Fig. 3M-R). These results show that after ROCK inhibition, the 
morphology of the AV conduction pathway is abnormal. Different phenotypes are 
present, indicating a variable degree of inhibition of the RHOA-ROCK pathway. 
This could explain the variable AV conduction disturbances that were found.



















A - Sinus rhythm
C - Wenkebach type AV block (2nd degree)
D - Mobitz type AV block (2nd degree)



























Figure 2. ROCK inhibition results in AV conduction disturbance
A. Normal AV conduction, atrial activation followed by ventricular activation. Time between 
subsequent ventricular activation waves is constant (309-310 milliseconds (ms)). B. AV time 
significantly prolonged after ROCK inhibition (**, p=0.0031). C. Example of Wenkebach type (second 
degree, type I) AV block, characterized by gradual prolongation of AV time, followed by complete 
AV block (asterisk). D. Example of Mobitz type (second degree, type II) AV block, characterized 
by sudden AV block (asterisk), without prolongation of AV time. E. Example of third degree AV 
block, characterized by dissociation between atrial and ventricular activation. Time between atrial 
activation constant (331-335ms), with variable AV time (219-256 ms). Note the low ventricular 
escape rhythm (+/- 20 beats per minute). A=atrial electrode, V=ventricular electrode.  
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Figure 3. Development of the myocardial continuity between  sinus venosus and posterior 
region of the AV canal is disturbed after ROCK inhibition (legend on page 162) 
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3.3. ROCK INHIBITION DOES NOT INTERFERE WITH 
INCORPORATION OF SINUS VENOSUS MYOCARDIUM IN THE 
POSTERIOR AV CANAL
In previous vital dye labeling studies, cells labeled with fluorescent dyes injected 
in the sinus venosus region could be traced to the posterior region of the AV 
canal, which corresponds to the region where the putative AVN develops.4 As 
the RHOA-ROCK signaling pathway plays an important role during cell migration, 
proliferation, and motility8,29, we hypothesized that inhibition of RHOA-ROCK 
signaling results in disturbed incorporation of the sinus venosus in the posterior 
AV canal, leading to disturbed AV conduction. To test this, the sinus venosus was 
labeled with vital dyes and labeling was assessed after 24 hrs of subsequent 
development. 
 In the control hearts (n=4), vital dye was seen in the region of the ISL1+/
TNNI2+ myocardial continuity between the sinus venosus and the posterior AV 
Figure 3. Development of the myocardial continuity between the sinus venosus and posterior 
region of the AV canal is disturbed after ROCK inhibition (figure on page 161)
A-C. 3D reconstructions (see below for color coding), control heart, HH29.  Ventral (A) and dorsal (B) 
view. The sinus venosus (SV) myocardium, consisting of the myocardium of the SAN, the myocardium 
surrounding the cardinal veins and myocardium of the coronary sinus is shown in green. A ventral 
detail of the myocardial continuity between the SV and the posterior AV canal is provided in C 
(arrowheads).  The putative AVN is shown (asterisk in C). D-F. Representative transverse sections 
of the same HH29 embryo, from cranial (D) to more caudal (F). The SV myocardium is shown. The 
myocardial continuity (arrowheads in E) between the sinus venosus and the putative AVN (dotted 
area with asterisk in E) is easily recognizabe. G-I. 3D reconstructions of the “mild phenotype” after 
ROCK inhibition, showing a smaller putative AVN region (asterisk in I). J-L. Representative transverse 
sections of the “mild phenotype”, showing disturbed morphology of the myocardial continuity 
(compare arrows in E with arrows in K). Note the lateral displacement of the myocardial continuity 
between the SV and AV canal. Putative AVN is recognizable (dotted area with asterisk in K). M-O. 
3D reconstructions of the “severe phenotype” after ROCK inhibition. The myocardial continuity is 
displaced laterally and is positioned more to the right (arrowheads in O and Q) and the putative 
AVN region (asterisk in O) is not recognizable. P-R. Representative transverse sections of the same 
embryo. Note the lateral and rightward displacement of the myocardial continuity (arrowheads in 
Q). The putative AVN is not recognizable and the connection between the sinus venosus and the 
posterior AV canal is smaller as compared to uninhibited hearts. Color coding 3D reconstructions: 
blue: lumen sinus venosus, right atrium, right ventricle and pulmonary artery; red: lumen left atrium, 
left ventricle, aorta; green: sinus venosus myocardium, yellow: mesenchymal tissue; light blue: 
pulmonary veins; transparent grey: myocardium. AVB: atrioventricular bundle, AVC: atrioventricular 
cushion, CS: coronary sinus, Ao: aorta, IVS: interventricular septum, LA: left atrium, LCV: left cardinal 
vein, LV: left ventricle, OFT: outflow tract, PV: pulmonary veins, RA: right atrium, RCV: right cardinal 
vein, RV: right ventricle, RVV: right venous valve, SAN: sinoatrial node, SV: sinus venosus. Scale bars: 
100µm.
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canal (Fig. 4A-D). After inhibition of the RHOA-ROCK pathway (n=5), no apparent 
morphological abnormalities were observed at HH20. Labeling was comparable 
to the control hearts. In the inhibited embryos, labeling was also present in the 
SV-AVC continuity (Fig. 4E-H), indicating that ROCK inhibition at HH15 does 
not interfere with incorporation of cells of the sinus venosus myocardium to the 
posterior region of the AV canal.  
3.4. ROCK INHIBITION RESULTS IN ALTERED GENE 
EXPRESSION IN THE POSTERIOR AV CANAL
To investigate whether gene expression was disturbed after inhibition of 
the RHOA-ROCK pathway, qPCR was performed on specific regions of the 
heart at HH30-31 (corresponding with microelectrode recordings and 
immunohistochemical data) in control hearts and after ROCK inhibition. 
 ROCK inhibition resulted in alterations in gene expression in both regions 
extracted by LCM. In both groups of tissue (“SV-AVC” and “AVN region”), 
expression of TNNT2 and NKX2-5 (both expressed in high levels in myocardium) 
was comparable between control and ROCK inhibited embryos, confirming the 
myocardial identity of the isolated tissue (Fig. 5A-B). In the “SV-AVC” group, 
HCN1 expression was detected in 4/5 (80%) of the control samples, whereas 
only 2/5 (40%) of the inhibited samples showed a detectable level of HCN1 (Fig. 
5A). The other genes showed no clear difference in expression between the two 
groups (Fig. 5A).
Figure 4. Incorporation of the sinus venosus myocardium in the posterior region of the AV 
canal is normal after ROCK inhibition
A. Overview of vital dye labeling after 24h in a control heart. The boxed area is shown at greater 
magnification in (B-D) B. Arrow shows ISL1+/TNNI2+ SV-AVC continuity with DiI/5-TAMRA labeling 
present in the continuity. Seperate grey values are shown for ISL1 (C, arrow = continuity) and DiI/5-
TAMRA (D, arrow = continuity).  E. Overview of labeling after ROCK inhibition. General morphology 
showed no apparent abnormalities at HH20. Boxed area is shown at greater magnification in (F-H). F. 
DiI/5-TAMRA is present in the SV-AVC continuity (arrows in F-H). Grey values for ISL1 (G) and DiI/5-
TAMRA (H). A: atrium, EC: endocardial cushion, LCV: left cardinal vein, OFT: outflow tract, SV: sinus 
venosus. Scale bars: 50µm.
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CTRL 100% 100% 80% 80% 100% 100% 80% 
INH 100% 100% 100% 40% 100% 100% 80% 
CTRL 100% 100% 100% 20% 100% 100% 20% 
INH 100% 100% 100% 40% 100% 100% 60% 
A 
B 


































Figure 5. Disturbed gene expression after ROCK inhibition 
A. qPCR results of tissue collected from the “SV-AVC” for the different genes of interest. The table 
underneath the graph shows the percentage of embryos in which expression of the corresponding 
gene could be detected. HCN1 expression was found in 80% of control “SV-AVC” samples, compared to 
only 40% of samples after ROCK inhibition. B. qPCR results of tissue collected from the “AVN region” 
for the different genes of interest as in A, with the embryo percentage of the observed expression 
shown in the table underneath. SHOX2 was found in 20% of control “AVN region” samples compared 
to 60% of “SV-AVC” samples. Expression appeared to be upregulated. Expression of ISL1 was not 
shown in this figure, since none of the control embryos showed ISL1 expression.
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 In the “AVN region” samples, no ISL1 expression was detectable in the control 
group. However, in 2/5 (40%) of the ROCK inhibited samples, ISL1 expression 
was detectable. SHOX2 expression was detectable in 1/5 (20%) of the control 
hearts, compared to 3/5 (60%) of the inhibited samples (Fig. 5B). Expression 
appeared to be highly upregulated after ROCK inhibition (Fig. 5B). Unfortunately, 
statistical analysis was either not possible due to small numbers or showed no 
significant differences. However, the results do suggest abnormal differentiation 
of the AVN region after ROCK inhibition.
4. DISCUSSION
Understanding the developmental processes ultimately resulting in the mature 
AVN, is crucial to understand arrhythmias and conduction disturbances arising 
from this structure. Here we describe i. RHOA-ROCK inhibition in chick embryos 
as a novel model to study AV conduction disturbances; ii. Disturbed morphology 
of the myocardial continuity between the sinus venosus and the putative AVN 
in this model; iii. Altered gene expression in this region after disturbing RHOA-
ROCK signaling.
 Based on the findings in the current study, several explanations of the 
observed AV conduction disorders are possible. Morphological investigation 
of the AV transition after disturbing RHOA-ROCK signaling showed disturbed 
development of the myocardial continuity between the sinus venosus and the 
posterior region of the AV canal. Previous work showed that this continuity 
expresses HCN4 and ISL1 (both protein and mRNA), which are both important 
for normal functioning of the CCS.4 Furthermore, cells extracted from this region 
showed a pacemaker-like electrophysiological phenotype, so it was concluded 
that this region is part of the CCS and likely plays a role in AV conduction.4 
 In the current study it was shown that ROCK inhibition results in a hypoplastic 
and laterally displaced SV-AVC continuity. In several hearts the AVN area could 
not be recognized at all. These morphological findings may well be related to the 
observed AV conduction disturbances. Stroud et al. described different degrees 
of AV conduction disturbances including AV block in cGATA6-Cre/Alk3-mice. 
Examination of the morphology of the AVN revealed an abnormally stretched 
and loosely organized AVN30, indicating that abnormalities in morphology of the 
AVN coincide with AV conduction disturbances. 
 Although Rho-kinases are involved in cell motility8, ROCK inhibition at HH15 
did not interfere with incorporation of sinus venosus cells in the putative AVN 
region, as labeled cells could be traced towards the SV-AVC continuity. Cell tracing 
was performed at HH15, since this setup was previously validated. Incorporation 
of sinus venosus myocardium in the putative AVN region was confirmed with 
these experiments.4 
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 In addition to aberrant development of the myocardial continuity between the 
sinus venosus and posterior AV canal and the putative AVN, gene expression was 
also disturbed. In the continuity between the sinus venosus and the posterior AV 
canal, HCN1 expression was present in a higher percentage of control embryos as 
compared to ROCK inhibited embryos. The HCN1 channel is expressed in the SAN 
and AVN19 and mice deficient for HCN1 display a phenotype resembling sick sinus 
syndrome31, which suggests that HCN1 is important for normal CCS functioning, 
and might help to explain the AV conduction disturbances after ROCK inhibition.
 In the AVN region, SHOX2 expression was found in a higher percentage of 
embryos, and ISL1 was re-expressed after ROCK inhibition. Expression of SHOX2 
was increased after ROCK inhibition. These results correspond with previous 
data.10,11 It was previously shown that ROCK inhibition resulted in disturbed 
lateralization of the SAN, with increased pacemaker potential at the left side 
of the sinus venosus myocardium and a more immature right side of the sinus 
venosus myocardium (the location where the SAN normally develops).11
 Upregulation of SHOX2 in the region of the AVN may be of interest to explain 
the observed phenotype. Shox2 is important for normal development of the 
venous pole of the heart, including the SAN.25,26 To date, focus has predominantly 
been on development of the SAN and the majority of studies have been 
performed in models where expression of Shox2 is disturbed. However, previous 
work showed Shox2 expression in the AV junction.32 Furthermore, Shox2 plays 
an important role in normal electrophysiological functioning within the AV 
junction.33 Overexpression of Shox2 in embryonic stem cells resulted in enhanced 
automaticity and an increase in pacing-ability of these cells.34. This is in line 
with the observed re-expression of ISL1 in the putative AVN. ISL1 is expressed 
in the developing SAN and is necessary for normal SAN development.35,36 The 
increase in expression of SAN related genes (ISL1/SHOX2) in the region of the 
putative AVN might result in a more immature phenotype of the AVN, resulting 
in AV conduction disturbances. Furthermore, altered intercellular coupling and 
electrophysiological characteristics in this region could be of importance. ROCK 
inhibition hampers Connexin (Cx) 40 expression in the sinus venosus.11 Cx40 
is one of the major gap junction proteins.37 These proteins are responsible for 
intercellular coupling, necessary for normal propagation of the action potential.37 
Altered differentiation and intercellular coupling in the region of the putative 
AVN might explain the observed AV conduction disorders after ROCK inhibition.  
 Finally, we described a “mild” and “severe” phenotype after ROCK inhibition. 
mRNA expression could only be tested in the “mild” phenotype, since the AVN 
region was not recognizable in the “severe” phenotype. Gene expression is 
expected to be more severely affected in the group with the “severe” phenotype, 
but quantification was not possible.
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5. CONCLUSIONS
RHOA-ROCK signaling is essential for normal development of the myocardial 
continuity between the sinus venosus and posterior region of the AV canal, 
including the AVN region. Disturbing the RHOA-ROCK signaling pathway results 
in AV block, which, at least in part, can be explained by the abnormal morphology 
of the AV transition and abnormal differentiation of the putative AVN after 
inhibition. 
 The AV conduction disturbances found after ROCK inhibition mimic the 
classic clinical types of AV block (1st to 3rd degree AV block were found). This 
AV block model can therefore be used to further investigate the development 
of AV conduction disturbances and to study the effects of therapeutic strategies 
(including pharmacological interventions) aimed at treating these common 
clinical arrhythmias. 
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Supplemental Figure 1. Schematic representation of experimental setup
Two sets of time points were chosen for the experiments. A. Embryos were treated with either PBS 
or Y-27632 at HH10/11 (day 2 of incubation). The embryos were extracted at HH28-31 (day 6 of 
incubation) for electrophysiology (EP, microelectrode recordings), immunohistochemistry (IHC) or 
laser capture microdissection (LCM). B. Embryos were treated with either PBS or Y-27632 and the 
sinus venosus myocardium was labeled with vital dye at HH15 (2.5 days of incubation). The embryos 
were extracted at HH 19-20 (3.5 days of incubation) and the fate of the labeled cells was analyzed. 
SUPPLEMENTAL MATERIAL 
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ABSTRACT
The cardiac autonomic nervous system (cANS) modulates the heart rate, 
contraction force and conduction velocity. The embryonic chicken heart already 
responds to epinephrine prior to establishment of the cANS. The aim of this 
study was to define the regions of the heart that might participate in modulating 
the early autonomic response to epinephrine. Immunofluorescence analysis 
revealed expression of neural markers tubulin beta-3 chain and neural cell 
adhesion molecule in the epicardium during early development. In addition, 
expression of the β2 adrenergic receptor, the receptor for epinephrine, was found 
in the epicardium. Ex ovo microelectrode recordings in hearts with inhibition of 
epicardial outgrowth showed a significantly reduced response of the heart rate 
to epinephrine compared to control hearts. This study suggests a role for the 
epicardium as autonomic modulator during early cardiac development.  
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1. INTRODUCTION
The cardiac autonomic nervous system (cANS) is essential in modulating cardiac 
function by altering heart rate (chronotropy), conduction velocity (dromotropy) 
and force of contraction (inotropy).1 Dysfunctioning of the cANS plays a role in 
the pathogenesis of arrhythmias1 and hypertension2 and is involved in disease 
progression in heart failure.3 Furthermore, normal functioning of the cANS is 
important for the prognosis of adult patients with congenital heart disease.4 
Understanding the processes that govern normal cANS development may help 
to unravel the pathophysiology of abovementioned disease processes and to 
develop targeted treatment options.
 The cANS can be divided into a sympathetic and parasympathetic component. 
In general, sympathetic stimulation results in an increase of heart rate, 
conduction velocity and force of contraction, while parasympathetic stimulation 
has an opposing effect. Sympathetic neurons have their cell bodies primarily in 
the paravertebral stellate ganglion, whereas parasympathetic cell bodies are 
located in the cardiac ganglia.5 The cells contributing to the cANS are derivatives 
of neural crest cells (NCCs) and cells of the nodose placode.6,7 Kroese et al. 
demonstrated that prior to cardiac sympathetic innervation of the developing 
chicken embryo, the heart already responds to the catecholamine epinephrine.8 
This neurotransmitter binds to beta (β) adrenergic receptors, thereby 
activating cAMP dependent signaling9, resulting in an increase in heart rate, 
conduction velocity and force of contraction.5 It is remarkable that expression 
of enzymes necessary for production of catecholamines was found throughout 
the myocardium during cardiac development in rat10,  even before production 
is observed in the adrenal glands.11,12 After addition of epinephrine in chick at 
Hamburger and Hamilton (HH13) stage 20-24, several hemodynamic parameters, 
including heart rate, increased significantly.8 This supports an important role for 
catecholamines in the heart during early embryonic development. Furthermore, 
stimulation of chick embryos with isoproterenol (β-agonist) at embryonic day 
7 (HH30-31) resulted in an increase in cAMP.14 In addition to responding to 
β-adrenergic stimulation, the early embryonic chicken heart was also shown to 
respond to β-adrenergic receptor blockade by reducing heart rate and cardiac 
output.15 Thus prior to establishment of the cANS, the heart already responds to 
autonomic stimulation and blockade. 
 Interestingly, Kroese et al. showed that after treatment with all-trans retinoic 
acid (RA) the reaction to epinephrine, including the increase in heart rate, was 
significantly reduced.8 Normal RA signaling has been shown to be important for 
proper development of the epicardium.16 This single layer of cells is derived from 
the proepicardial organ (PEO) and covers the initially bare primary myocardial 
heart tube. Cells derived from the epicardium are known to play an essential role 
176  Chapter 8 
8
during normal cardiac development and defects in epicardial development result 
in cardiac malformations (reviewed in17). 
 The aim of the current study was to identify which cell population in the 
developing heart plays a role in modulating the autonomic response during early 
development. Our studies reveal unanticipated expression of neuronal markers 
in the epicardium during early cardiac development. To investigate a potential 
role of the epicardium, electrophysiological experiments were performed with 
and without inhibition of epicardial outgrowth.
2. MATERIAL AND METHODS
2.1. ANIMALS
Immunohistochemical analysis was performed in wild type mouse embryos with 
a mixed genetic background of different embryonic stages (E9.5-E17.5, mice 
described in18). The morning of the vaginal plug was considered E0.5. Pregnant 
mice were euthanized using CO2 exposure and cervical dislocation. Animal care 
was in accordance with national and institutional guidelines and approved by 
the animal experiments committee of the Leiden University Medical Center. 
 To study protein expression in chick embryos, fertilized eggs of the White 
Leghorn chicken were incubated at 37°C and 80% humidity. Hearts were excised, 
and staged according to the Hamburger and Hamilton (HH) criteria.13 Tissue 
was fixed in 4% paraformaldehyde for 24 hours and subsequently embedded in 
paraffin and sectioned (5µm) for immunohistochemical analysis. 
2.2. HUMAN FETAL TISSUE
A 5-week-old human fetal heart was collected after elective abortion based 
on individual informed consent procedures conforming to the Declaration of 
Helsinki. Furthermore, the study was approved by the Medical Ethics committee 
of the Leiden University Medical Center. Tissue was treated as described above.
2.3. IMMUNOHISTOCHEMISTRY
The protocol used for immunohistochemical staining was described previously.19 
Briefly, slides were rehydrated, subjected to heat-induced epitope retrieval and 
incubated with the following list of antibodies: anti-cardiac Troponin I (CTNI) 
(myocardial marker, 1:1000, 4T21/2, HyTest Ltd), anti-Wilms’ tumor-1 (WT1) 
(expressed in the epicardium, 1:1000, ab89901, Abcam), anti-tubulin beta-3 
chain (TUBB3) (neuronal marker, 1:200, AB78078, Abcam), Neural Cell Adhesion 
Molecule (NCAM) (neuronal marker, 1:250, AB5032, Merck), anti-β1 adrenergic 
receptor (β1AR) (receptor for epinephrine, 1:200, PA528808, Thermo Scientific), 
and anti-β2 adrenergic receptor (β2AR) (receptor for epinephrine, 1:200, 
ab61778, Abcam). To amplify WT1 expression Tyramide Signal Amplification 
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(PerkinElmer) was used. Visualization was achieved by incubation with Alexa 
Fluor® 488 streptavidin (Invitrogen). The remainder of primary antibodies was 
visualized with Alexa-conjugated fluorescent secondary antibodies (Invitrogen) 
at a final concentration of 1:200. DAPI (D3571, 1/1000; Life Technologies) was 
used as a nuclear stain, after which slides were mounted with Prolong gold (Life 
Technologies).
2.4. MECHANICAL BLOCKING OF THE PROEPICARDIAL ORGAN 
Mechanical inhibition of epicardial outgrowth in the chicken embryo was 
performed as described previously.20 At HH15, a window was created in the 
eggshell, after which the embryonic membranes were opened. Subsequently, a 
small piece of eggshell membrane was placed between the PEO and developing 
heart tube, after which the egg was reincubated until the desired stage. In order 
to verify that outgrowth of the epicardial layer was hampered, hearts were 
sectioned and Haematoxylin and Eosin staining was performed. 
2.5. EX OVO EXTRACELLULAR MICROELECTRODE 
RECORDINGS AND EPINEPHRINE ADMINISTRATION
To investigate the effect of epinephrine on heart rate, electrophysiological 
measurements were performed in embryonic chicken hearts at different 
developmental stages. After reaching the desired stage of development, embryos 
were extracted from the egg. The heart and some surrounding tissue was excised 
and placed in a temperature-controlled (37 ± 0.1°C) tissue bath containing 
Tyrode. Recordings were performed using a previously described protocol.21 
Recording electrodes were placed on the atrium and the ventricular apex, and 
a reference electrode in the tissue bath. The hearts of five groups of embryos 
were studied: 1. HH15 embryos (n=5), when the heart is not yet covered by 
epicardium; 2. HH19 embryos (n=3), when epicardial covering of the sinus 
venosus, atria and AV canal has commenced; 3. HH21 embryos (n=3), when 
migration of epicardial cells around the heart is (nearly) complete22; 4. HH24-25 
control embryos (n=9, no surgical manipulation), when epicardial covering has 
been completed and subepicardial mesenchyme is present; 5. HH24-25 embryos 
(n=9) after inhibition of epicardial outgrowth. 
 The hearts were allowed to reach a stable baseline heart rate (which was 
comparable between all studied groups (Supplemental Fig. 1), after which 
100μl of pre-warmed epinephrine (1mg/ml, Centrafarm, The Netherlands) was 
directly pipetted onto the heart. Pre-warmed Tyrode was administered as a 
negative control to HH24-25 hearts (n=6). The relative response to epinephrine 
was calculated by correcting the change in heart rate for the baseline heart rate. 
The heart rate was calculated every 10 seconds and plotted. 
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2.6. STATISTICAL ANALYSIS
The Mann-Whitney U-test (two groups) or Kruskal-Wallis test (>two groups) 
were used, since the data was not normally distributed. P<0.05 was considered 
statistically significant. Data shown is mean ± S.E.M. Statistical analysis was 
performed using the Graphpad Prism 6 software package (Graphpad Software).
3. RESULTS
3.1. DURING EARLY CARDIAC DEVELOPMENT THE NEURONAL 
MARKER TUBB3 IS EXPRESSED BY THE EPICARDIUM
In order to investigate which cell population plays a potential role in modulation 
of the early cardiac autonomic response, protein expression of the neuronal 
marker TUBB3 was analyzed during cardiogenesis.
 At E9.5, the primary heart tube is not covered by epicardial cells and the PEO is 
recognizable (Fig. 1a-d). Co-expression of neuron-specific TUBB3 and WT1 was 
observed in a subset of cells in the PEO (Fig. 1a-d). WT1+/TUBB3- and WT1-/
TUBB3+ cells were also present (Fig. 1a-d), confirming the heterogeneity of the 
PEO.23 At E10.5, the epicardial layer started to envelope the heart and showed co-
expression of TUBB3 and WT1 in most epicardial cells (Fig. 1e-h). Co-expression 
of TUBB3 and WT1 was still clearly present at E11.5 in the majority of epicardial 
cells (Fig. 1i-l). Strong expression of TUBB3 was observed in the mesenchyme 
of the endocardial cushions in the outflow tract (OFT) and AV canal, shown at 
E11.5 (Fig. 1i-l). TUBB3 expression in the epicardium decreased with ongoing 
development. At E12.5, only faint expression was observed in the epicardium 
(Fig. 1m-p), disappearing at E13.5 (Fig. 1q-t). At this stage, TUBB3 expression 
was only observed in subepicardial nerve fibers (Fig. 1q-t) and no co-expression 
of TUBB3 and WT1 was observed in the epicardium or subepicardium.
 To confirm the neuronal phenotype of the epicardium, NCAM (neuronal 
marker) expression was analyzed. At E11.5, co-expression of NCAM and TUBB3 
was seen in the nervous system, including the neural tube and dorsal root 
ganglion (Supplemental Fig. S2a-d). Furthermore, NCAM expression was seen 
in the epicardium, co-localizing with TUBB3 (Supplemental Fig. S2e-h), thereby 
confirming the neuronal phenotype of the epicardium.
 In addition, TUBB3 expression was analyzed during early human fetal 
development. A subset of epicardial cells and cells in the endocardial cushions 
showed expression of TUBB3 (Supplemental Fig. S3b-c). Furthermore, cells in 
the subepicardial space showed TUBB3 expression (Supplemental Fig. S3d-e). 
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Figure 1. The neuronal specific marker TUBB3 is expressed in the epicardium and 
subepicardium during early development 
a-d. At E9.5, the PEO (dotted line) is recognizable and the heart tube is not covered by epicardium. 
WT1+/TUBB3+ cells (white arrowheads in b-d), WT1+/TUBB3- cells (black arrowheads in b-d) and 
WT1-/TUBB3+ cells (arrows in in b-d) are observed within the PEO. e-h. At E10.5 the heart is partially 
surrounded by epicardial cells and co-expression of TUBB3 with WT1 is seen in most epicardial cells 
(arrowheads in f-h).  i-l. Co-expression of TUBB3 and WT1 in the epicardium is still present at E11.5 
(arrowheads in j-l). TUBB3 expression is also seen in the endocardial cushions (arrows in j-l), shown 
here at E11.5. m-p. Co-expression of TUBB3/WT1 decreases from E12.5 (compare white arrowhead 
in k with white arrowhead in o). q-t. At E13.5 the expression of TUBB3 in the WT1+ epicardium 
(black arrowheads in r-t) is lost but is now present in subepicardial nerve fibers (arrows in r-t). AVC: 
atrioventricular cushion, HT: heart tube, LA: left atrium, LCV: left cardinal vein, LV: left ventricle, PEO: 
proepicardial organ, RA: right atrium, RV: right ventricle, SV: sinus venosus. 
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3.2. A SUBPOPULATION OF CELLS IN THE CENTRAL NERVOUS 
SYSTEM CO-EXPRESSES WT1 AND TUBB3
The neuronal marker TUBB3 showed protein expression in the epicardium, co-
expressing with WT1. In order to provide possible evidence that these proteins 
are involved in normal neuronal function, expression of TUBB3 and WT1 was 
studied in the nervous system. At E11.5, the developing nervous system showed 
expression of TUBB3 (Fig. 2a-d). No WT1 expression was found (Fig. 2a-d). 
Microscopic analysis at E13.5 revealed co-expression of TUBB3 and WT1 in the 
ventral region of the neural tube, as well as the roof of the 4th ventricle of the 
brain (Fig. 2e-g). WT1 expression was observed along the entire length of the 
neural tube (Fig. 2e). Co-expression of TUBB3 and WT1 in the spinal cord was 
still present at E17.5 (Fig. 2h-k). 
3.3. DURING EARLY CARDIAC DEVELOPMENT THE 
CATECHOLAMINE RECEPTOR β2AR IS EXPRESSED BY THE 
EPICARDIUM
To further confirm a potential neuronal phenotype of the epicardium, expression 
of the beta1 (β1) and beta2 (β2) adrenergic receptors (AR) was studied. To 
confirm neural co-expression of TUBB3 and β2AR, these markers were studied 
at E11.5 in the nervous system. Co-labeling of TUBB3 and β2AR was seen in the 
dorsal root ganglion and neural tube (Fig. 3a-d).
 In murine embryos at E11.5, most epicardial cells are TUBB3+, and a 
subpopulation of  epicardial cells showed co-expression with β2AR (Fig. 3e-
h). β2AR+ cells were found throughout the epicardial layer, predominantly 
seen in the AV sulcus (arrowheads in Fig. 3e) and interventricular sulcus (Fig. 
3e-h). Furthermore, expression of β2AR was seen in endocardial cells and a 
subpopulation of cells in the endocardial cushions (Fig. 3e). Expression of 
TUBB3 and β2AR was seen in the subepicardium at E12.5, with a subset of cells 
co-expressing both markers (Fig. 3i-l). β1AR expression was not observed in 
these stages (not shown).
 
3.4. INHIBITION OF EPICARDIAL OUTGROWTH RESULTS IN A 
DIMINISHED RESPONSE TO EPINEPHRINE
At HH21 of chick development, expression of β2AR was found in the epicardium, 
PEO and endocardium (Supplemental Fig. S4), which is in agreement with 
the β2AR expression found in mice. First, the role of the epicardial layer in the 
response of the heart to epinephrine was studied. For this purpose, chick hearts 
from embryos of subsequent stages of epicardial development were analyzed 
using ex ovo microelectrode recordings (Fig. 4 and Supplemental Fig. S5). The 
relative increase ((maximal heart rate – baseline)/(baseline)) * 100%) in heart 
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Figure 2. WT1 is expressed in the ventral horn of the spinal cord
a-d. At E11.5 TUBB3 is present in the neural tube. However, no co-expression with WT1 is found. e-g. 
At E13.5 co-expression of WT1 and TUBB3 is observed in the ventral horn of the neural tube and the 
roof of the 4th ventricle of the brain (arrowheads). h-k. Co-expression of TUBB3/WT1 is still present 
in the spinal cord at E17.5 (arrowheads in i). DRG: dorsal root ganglion, NT: neural tube, SC: spinal 
cord.
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Figure 3. β2 adrenergic receptor expression in epicardium and subepicardium during 
development
a-d. Co-expression of β2AR (green) and TUBB3 (red) is found in the dorsal root ganglia during 
murine embryonic development from E11.5 onwards. Separate grey values are shown for TUBB3 
(c) and β2AR (d). e-h. At E11.5, a subpopulation of TUBB3+ epicardial cells is positive for β2AR 
(arrowheads in f-h). i-l. At E12.5 co-expression of TUBB3 and β2AR in the epicardium is lost. There is, 
however, expression of β2AR in the subepicardium of which a subset shows co-labeling with TUBB3 
(arrowheads in j-l). AVC: atrioventricular cushion, DRG: dorsal root ganglion, LCV: left cardinal vein, 
LV: left ventricle, NT: neural tube, RA: right atrium, RV: right ventricle. 
Figure 4. The epicardium modulates the response to epinephrine during early development 
a. Administration of epinephrine to isolated hearts at HH15 results in a slight decrease in heart 
rate. b-d. Administration of epinephrine to isolated hearts at HH19, HH21 and HH24 results in a 
strong increase in heart rate. e. Relative response of hearts at HH19, HH21 and HH24 is significantly 
increased compared to the response of hearts at HH15. *p<0.05
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rate after administration of epinephrine was calculated. HH15 hearts, which 
lack epicardial covering, showed no increase in heart rate after administration 
of epinephrine (Fig. 4a and Supplemental Fig. S5a). A significant increase in 
heart rate was observed in hearts of HH19 (when epicardial covering of the sinus 
venosus, atria and AV canal has initiated), HH21 (epicardial covering is (nearly) 
finished) and HH24 (the occurrence of subepicardial mesenchyme) embryos 
compared to HH15 (Fig. 4b-e and Supplemental Fig. S5b). This indicates that 
the presence of epicardium is required for the response to epinephrine during 
early developmental stages. 
 To further substantiate the role of the epicardium in the response to 
epinephrine, an experimental model was used in which outgrowth of the 
epicardium was inhibited in chick embryos. To confirm epicardial inhibition, 
hearts were analyzed histologically, after the electrophysiological measurements. 
Analysis of the epicardial response to epinephrine was conducted at stage HH24, 
when the effects of the epicardial inhibition are clearly observed. At HH24, 
control hearts showed epicardial covering of the entire heart, with a cell-rich 
subepicardial space (Supplemental Fig. S6a). After epicardial inhibition, large 
portions of the heart were not covered by epicardium and the regions covered 
with epicardium showed less subepicardial cells (Supplemental Fig. S6b). 
Furthermore, compaction was hampered, as shown by a less dense compact 
myocardial layer compared to controls (Supplemental Fig. S6b). 
 Ex ovo microelectrode recordings were performed after administration of 
epinephrine in control and inhibited hearts. After administration of epinephrine 
to control hearts (n=9), a fast increase in heart rate was observed (Fig. 5a 
and Supplemental Fig. S5b). The relative increase in heart rate was 57,2 ± 
7,20%. After epicardial inhibition (n=9) however, this response was decreased 
(Fig. 5b,d  (p = 0,03) and Supplemental Fig. S5d), with a relative increase in 
frequency of 24,8 ± 4,33%. Pre-warmed Tyrode served as a negative control. 
Upon administration a short decrease in heart rate was observed, after which 
the heart rate returned to the baseline frequency (Fig. 4c and Supplemental 
Fig. S5c). 
 The earliest electrical activity is generated in the myocardium of the sinus 
venosus (SV).21 Since the response to epinephrine was altered after epicardial 
inhibition, the next step was to evaluate epicardial covering of the SV myocardium 
in these hearts. Hearts that were classified as successful inhibition of epicardial 
outgrowth in Fig. 4 were microscopically subdivided into two categories based 
on epicardial covering of the SV. Hearts were classified as “mild inhibition” (n=4) 
when the myocardium of the SV was covered by epicardium, but no subepicardial 
cells were present (Fig. 6a,b).  Hearts were classified as “severe inhibition” 
(n=5) when the myocardium of the SV was (largely) devoid of epicardium and 
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Figure 6. Severity inhibition epicardial covering sinus venosus correlates to response to 
epinephrine
Hearts microscopically subdivided based on covering of sinus venosus (SV). a-b. Mild inhibitions 
show epicardial covering of myocardium SV, subepicardial cells not present. * in a = SAN, higher 
magnification in b. d-e. Severe inhibition lack epicardial covering myocardium SV, subepicardial 
cells not present.* in d = SAN, higher magnification in e. Arrowhead in e shows boundary epicardial 
covering. c. Response to epinephrine after mild inhibition is hampered (compare with 4a) f. 
Administration of epinephrine to hearts with severe inhibition (HH24) does not result in increase in 
heart rate. g. Relative response in severe vs mild inhibition significantly reduced, *p=0,016. R/LCV: 
right/left cardinal vein, V: ventricle.
Figure 5. Repression of epicardial covering reduces cardiac response to epinephrine 
a. Fast increase in heart rate after administration of epinephrine to isolated control hearts at HH24. 
b. Response strongly reduced after epicardial inhibition c. Administration of Tyrode to isolated 
control hearts results in a slight decrease in heart rate. d. Relative response of hearts after epicardial 
inhibition is significantly reduced compared to the response of control hearts, *p<0,05. 
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subepicardial cells were not present (Fig. 6d,e). Microelectrode recordings 
revealed that the relative response to epinephrine was hampered in the mild 
inhibition group. The increase in heart rate was less pronounced and it took longer 
to return to the baseline heart rate after epinephrine administration compared to 
the control group (Fig. 6c). In the severely inhibited group, virtually no response 
to epinephrine was observed (Fig. 6f). The relative response to epinephrine was 
significantly decreased in the group classified as “severe inhibition” as compared 
to the “mild inhibition” group (p=0,016 Fig. 6g).
4. DISCUSSION
Autonomic modulation is essential for proper functioning of the heart and 
contributes to the prognosis of patients with heart failure and congenital heart 
disease. Early in development, the heart already responds to sympathetic 
stimulation, even prior to the presence of sympathetic nerve fibers.8 The exact 
mechanism behind this early response is poorly understood. The current study 
provides new evidence that can account for this response. Key findings of this 
study are: 1) the epicardium expresses TUBB3, NCAM and β2AR during early 
development, which are known neuronal markers; 2) inhibition of epicardial 
outgrowth results in a disturbed response to epinephrine; 3) the severity of 
inhibition of epicardial covering of the sinus venosus myocardium correlates 
to the severity of disturbance in the response to epinephrine. Together, these 
results suggest a role for the epicardium in autonomic modulation of the heart 
during early development.
 The current work describes expression of proteins known to be of importance 
in the nervous system in the epicardium. The tubulin isoform TUBB3 is primarily 
expressed in neurons and is important for axonal guidance and maintenance.24 
Expression however is not limited to neurons, since melanocytes (derived 
from the neural crest, as do neurons) also show TUBB3 expression.25,26 To 
ensure the neuronal phenotype, staining of another neural marker, neural cell 
adhesion molecule (NCAM) was performed. NCAM expression was also present 
in the epicardium, confirming the neuronal phenotype of the epicardial layer. 
More indirect evidence suggesting a possible role for the epicardium in neural 
function is the co-expression of WT1 and TUBB3 in the central nervous system. 
WT1, a transcription factor expressed in the embryonic PEO and epicardium, 
is necessary for normal epicardial and cardiac development.27 The current 
manuscript shows WT1/TUBB3 co-expression in the central nervous system, 
which is in agreement with previous reports demonstrating an important role 
for WT1 in neural functioning.28–32
 In addition to epicardial expression of NCAM and TUBB3, the receptor for 
epinephrine, β2AR, was expressed in the epicardium. Epinephrine binds to β2AR, 
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which activates adenyl cyclase, resulting in cAMP-dependant signaling9, which 
leads to sympathetic modulation of the heart rate, conduction velocity, and force 
of contraction.   
  To investigate the functional role of the epicardium in autonomic modulation, 
the response to epinephrine was analyzed in an experimental model in which 
normal outgrowth of the epicardium was inhibited. Results showed a significantly 
reduced response to epinephrine after epicardial inhibition. To further validate 
these results, epinephrine was administered in control chicken embryos at HH15, 
a stage in which no epicardial cells are present on the heart tube. Interestingly, 
these embryos did not show a response to epinephrine, confirming the data 
seen after epicardial inhibition. These results show that epicardial covering of 
the heart is (at least partially) responsible for a normal response to epinephrine 
during early cardiogenesis. 
 Absence of epicardial covering of the sinus venosus myocardium, as was 
described in the “severe inhibition group”, results in absence of the epicardial 
β2AR. If epinephrine cannot bind to this receptor, cAMP mediated signaling 
is likely to be hampered, resulting in an absent response to epinephrine. 
Furthermore, it was recently shown that the β2AR forms protein complexes 
with the "funny current" ion channel HCN4, responsible for spontaneous 
depolarization of pacemaker cells. Disturbing the formation of the β2AR/HCN4 
protein complexes results in a hampered response to sympathetic stimulation33, 
a result also observed after epicardial inhibition (this study). 
 Kroese et al. showed that disturbance of retinoic acid signaling results in a 
hampered response to epinephrine. Disturbing RA signaling in the epicardium 
by epicardial deletion of the retinoid X receptor-α (RXRα), results in defective 
epithelial-to-mesenchymal transition (EMT), thinning of the myocardium, 
disturbed coronary arteriogenesis and ventricular pre-excitation.34,35 This 
phenotype is also seen after disturbance of epicardial outgrowth in avian 
embryos36 and in Wt1-null mice.27,37 Wt1 regulates RA signaling by activating 
RALDH2, the enzyme involved in RA synthesis38, and Wt1-null mice show 
downregulation of RALDH2.27 Vice versa, induction of RA signaling results in 
upregulation of Wt1 expression in chick epicardium-derived cells.39 Therefore, 
disturbing the normal outgrowth of the epicardium could result in hampering of 
RA signaling. Previous data showed that RA treatment in vitro results in neuronal 
differentiation, with an increase in β2AR expression.40 This indicates that RA 
signaling is important for normal β2AR expression. Disturbing this by epicardial 
inhibition (or administration of teratogenic concentrations of all-trans RA8) 
could therefore result in aberrant β2AR expression and an impaired response to 
its ligand, epinephrine. 
 Finally, recent work showed that normal development of the cardiac veins 
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is required for normal development of the sympathetic nervous system of the 
heart.41 This process is driven by nerve growth factor (NGF), secreted by vascular 
smooth muscle cells in subepicardial blood vessels.41 Interestingly, the smooth 
muscle cells in the coronary vasculature derive from the epicardium after 
EMT.42,43 Disturbing epicardial outgrowth results in abnormal development of 
the coronary vasculature.36 The hampered response to epinephrine described in 
the current study could possibly be explained by disruption of the earliest stages 
of blood vessel formation and NGF production, which is required for normal 
development of the autonomic nervous system.41 
 The current study has several limitations. It cannot be excluded that inhibition 
of the outgrowth of the epicardium has secondary effects on the heart which can 
affect cardiac functioning, since epicardial cells are important for differentiation 
and maturation of cardiomyocytes.44 However, our results show that epicardial 
covering is important for the response to epinephrine, since normal hearts 
without epicardium (HH15) do not respond to epinephrine. As soon as cardiac 
outgrowth of epicardial cells has commenced (HH19), the heart shows a rapid 
response to epinephrine. The early response seen at HH19, makes it unlikely that 
myocardial differentiation is responsible for the change in heart rate seen after 
administration of epinephrine. Furthermore, the response seen in normal hearts 
at HH15 was comparable to the response seen in epicardially inhibited hearts. 
This again shows that it is not myocardial differentiation, but the presence of 
epicardium which is responsible for the response to epinephrine. Although the 
chicken model demonstrates highly reproducible results, the results described in 
the current work could possibly be strengthened by electrophysiological testing 
in a mammalian model, which shows defects in epicardial covering. However, 
up to date there is no mouse model specifically affecting outgrowth of the 
epicardium, since the genes commonly used for epicardium-specific expression 
of Cre are known to be expressed more broadly throughout the fetus during 
development.19,45
 In conclusion, the current study provides evidence indicating a role for the 
epicardium in autonomic modulation during early development. Autonomic 
modulation is essential for proper cardiac functioning and dysfunctioning of 
the autonomic nervous system is implicated in several diseases, such as cardiac 
arrhythmias, heart failure, congenital heart disease and hypertension.1–3 Further 
research is required to investigate the role of the epicardium in autonomic 
dysfunction seen in common cardiac disorders, and to explore the mechanisms 
responsible for the early heart rate response mediated by the epicardium.
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Supplemental Figure 1. Baseline heart rate of the experimental groups does not differ between 
the groups
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Supplemental Figure 2. Epicardial co-expression of the neuronal markers NCAM and TUBB3 
confirms the neuronal phenotype of the epicardium
a-d. NCAM and TUBB3 are co-expressed in the nervous system, shown here in the neural tube (NT) 
and dorsal root ganglia (DRG). e-h. A subpopulation of epicardial cells co-express TUBB3 and NCAM 
(white arrowheads in f-h). AVC: atrioventricular cushion, LCV: left cardinal vein, LV: left ventricle, RA: 
right atrium, RV: right ventricle.
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Supplemental Figure 3. The neuronal marker TUBB3 is expressed in the epicardium and 
subepicardium during early human development
a-c. Expression of TUBB3 is found in the epicardial layer (arrows in b,c), the subepicardium (white 
arrowheads in b,c) and the endocardial cushions (black arrowheads in b,c) of the human embryonic 
heart at week 7. a, d-e. Expression of TUBB3 is found in the subepicardial layer of the human 
embryonic heart (white arrowheads in d,e). AVC: atrioventricular cushion, LV: left ventricle, RV: right 
ventricle.
Supplemental Figure 4. β2AR expression in the epicardium in chick
a-c. At HH21 in chicken, expression of β2AR is present in the proepicardial organ (PEO), epicardium 
(arrowheads in b-c) and endocardium. A: atrium, LCV: left cardinal vein, OFT: outflow tract, SV: sinus 
venosus.
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control - HH15 - post epinephrine (105 bpm)
control - HH15 - pre epinephrine (112 bpm)
a
200ms
control - HH24 - post epinephrine (165 bpm)
control - HH24 - pre epinephrine (118 bpm)
control - HH24 - post Tyrode (110 bpm)
inhibition - HH24 - post epinephrine (124 bpm)
inhibition - HH24 - pre epinephrine (110 bpm)
200ms






Supplemental Figure 5. Representative electrode recordings 
a. The heart rate at HH15 did not increase after administration of epinephrine. b. The heart rate 
at HH24 did not increase after administration of Tyrode. c. The heart rate at HH24 increased after 
administration of epinephrine. d. The heart rate at HH24 after epicardial inhibition showed a 
decreased response to epinephrine.
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Supplemental Figure 6. Inhibition of epicardial outgrowth in chicken embryos
a. Control heart at stage HH24 showing epicardial covering and a thick, cell-rich subepicardial space. 
b. Inhibition of epicardial outgrowth results in incomplete epicardial covering of the heart and a 
thin subepicardial space at stage HH24. Black arrowheads demarcate the border of the epicardial 
lining. Note the abnormal shape of the ventricle with a thin compact myocardium in the region where 
epicardial covering is absent (between arrowheads). AVC: atrioventricular cushion, LA: left atrium, 
LV: left ventricle, OFT: outflow tract, RA: right atrium, RV: right ventricle. * Eggshell membrane.
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ABSTRACT
The current work provides an overview of the different fate mapping and cell 
tracing techniques aimed at elucidating the developmental origin of the cardiac 
conduction system. Special focus will be on the specific limitations and advantages 
of these techniques. The data obtained from the different fate mapping and cell 
tracing techniques will be evaluated critically and a possible working model for 
the development of the cardiac conduction system is generated.
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1. GENERAL INTRODUCTION
The cardiac conduction system (CCS) consists of specialized cardiomyocytes 
that initiate, propagate and modulate electrical activation of the heart. 
Disturbances in this system lead to cardiac arrhythmias, an important cause of 
morbidity and mortality worldwide. Understanding the embryological origin 
and molecular mechanisms underlying normal CCS development contributes to 
elucidating the etiology and pathophysiologic mechanisms that ultimately lead 
to cardiac arrhythmias. Historically, the developing CCS has been studied using 
classical light microscopy, histological stainings and electron microscopy.1–4 A 
comprehensive basis providing insight in sequential stages of CCS development 
was founded using these techniques. Unfortunately, analyzing the developmental 
origin of the CCS is not possible using these methods. To answer these questions, 
several techniques such as genetic tracing and vital dye labeling have been 
developed. After an introduction of the basic processes of CCS development, this 
review will provide an overview of current available data on fate mapping and 
cell tracing of the CCS, highlighting advantages but also pitfalls in interpretation 
of these techniques. The results are used to generate a working model on CCS 
development.  
1.1. BASIC CARDIAC DEVELOPMENT AND ANATOMY OF THE 
CCS
The heart is derived from the mesodermal layer of the embryonic plate. During 
gastrulation, mesodermal cells arise from the primitive streak and subsequently 
migrate cranially and laterally to form the cardiogenic plates. The first sign of 
cardiomyocyte differentiation is seen in this region at Hamburger and Hamilton 
(HH) stage 8-9 in chick and between E6.5-7.5 in mice, when cardiac troponin-I 
(cTnI) and sarcomeric myosin (MF20) are first detected. Fusion of the bilateral 
plates of splanchnic mesoderm establishes the primary heart tube (PHT).5,6 
During further development, cells from the splanchnic mesoderm differentiate 
and are added to the PHT at the venous and arterial pole. A controversial, but 
popular view in cardiac developmental biology is the distinction between a first 
and second heart field. In this view, the cardiomyocytes of the cardiac crescent 
and PHT are derivatives of the first heart field (FHF). The FHF will contribute 
to the atria, atrioventricular (AV) canal and ventricles.5 The cells that are added 
to the PHT at the venous and arterial pole are considered to derive from a 
distinct cardiogenic field, the second heart field (SHF).5 The SHF will contribute 
to the outflow tract and all cardiac structures except a part of the left ventricle 
(LV).5,7 Whether the distinction between FHF and SHF is valid is not the focus 
of the current review. In addition to cardiac growth at the arterial and venous 
poles, several processes, including cardiac looping, septation, outgrowth 
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and remodelling of the different chambers, will establish the mature electro-
mechanically functional 4-chambered heart with separated pulmonary and 
systemic circulations (reviewed in8,9).
 The CCS is of myocardial origin10 and consists of cardiomyocytes with a distinct 
differentiation program compared to the working myocardium cardiomyocytes 
(reviewed in11). During early development, the entire myocardium of the 
PHT displays a pacemaker-like phenotype (e.g. relatively high automaticity, 
slow conduction, poor electrical coupling).12 However, even at early stages of 
development, the first electrical activation of the heart is already preferentially 
at the inflow of the heart, also called the sinus venosus myocardium.13 The 
heartbeat is initiated by the sinoatrial node (SAN), which is derived from the 
sinus venosus myocardium. During embryonic stages, a transient left-sided SAN 
can be distinguished.13,14 In the adult, the definitive right-sided SAN is a comma-
shaped structure  located with its “head” at the entrance of the superior caval 
vein in the right atrium, and the “tail” is situated along the terminal crest (i.e. the 
adult counterpart of the embryonic right venous valve) (Fig. 1).15 
 The second key structure of the CCS is the atrioventricular node (AVN), which 
is situated on the right side of the base of the atrial septum in the triangle of Koch 
(formed by i. the tendon of Todaro, ii. the septal leaflet of the tricuspid valve, 
and iii. the ostium of the coronary sinus) (Fig. 1).16 The adult AVN is a complex, 
heterogeneous structure, consisting of a compact node, covered with transitional 
cells (which show a transition in gene and protein expression between the atrial 
and nodal myocardium) at the atrial side of the node.17 Furthermore, nodal 
extensions run from the AVN towards the vestibules of the tricuspid and mitral 
valve.17–21 The AVN delays the depolarization wave after fast electrical activation 
of the atria, thus ensuring adequate filling of the ventricles. The atria and 
ventricles are electrically insulated by the annulus fibrosus (Fig. 1). 
 After delay in the AVN the electrical impulse accelerates and traverses the 
annulus fibrosus through the common AV bundle, also known as bundle of His. 
From the AV bundle, the depolarization wave reaches the left and right bundle 
branches, after which it is passed to the ventricular cardiomyocytes through 
the Purkinje fiber network. The Purkinje fiber network consists of specialized 
cardiac muscle fibres that guarantee fast electrical activation of the ventricular 
cardiomyocytes (Fig. 1). The AV bundle, bundle branches and Purkinje fiber 
network together are called the ventricular conduction system (VCS).22 
 To be able to study cardiac development, several techniques have been used 
to trace the origin and fate of CCS cells. These experiments have resulted in 
advances in our knowledge on development of the CCS. An overview of these 
techniques and what can be concluded from these experiments with respect to 
development of the CCS will be described in the subsequent paragraphs.
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Figure 1. The adult cardiac conduction system 
Different components of the adult CCS. AF: annulus fibrosus, AVN: atrioventricular node, CB: common 
bundle, CS: coronary sinus, ICV: inferior caval vein, LA: left atrium, LBB: left bundle branch, LV: left 
ventricle, MB: moderator band, PF: Purkinje fiber network, PV: pulmonary vein, RA: right atrium, 
RBB: right bundle branch, RV: right ventricle, SAN: sinoatrial node, SCV: superior caval vein, TK: 
triangle of Koch, VS: ventricular septum.
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2. CELL TRACING TECHNIQUES APPLIED TO CCS DEVELOPMENT
A recent review provided an overview of the available techniques to trace the 
fate of cells.23 A number of these techniques have also been used to identify 
progenitors of the CCS. In the next section the different methods used to study 
CCS development will be introduced and discussed. 
2.1. GENETIC TRACING
A widely used tool in developmental biology is based on site-specific 
recombination of the genome. Most mouse models developed utilize the P1 
Bacteriophage derived enzyme Cre-recombinase, which recognizes a 34-bp 
sequence called the loxP site, and induces recombination between pairs of these 
sites.24 The Cre-loxP system, combined with the ability to knock-in sequences at 
specific sites in the genome has been used to study the origin of the developing 
CCS. See Table 1 for an overview of Cre lines used for these experiments. 
Table 1. Overview Cre lines used to study development of CCS
Genotype Reporter Used to study Ref
Tbx18Cre R26RlacZ; R26RmT/mG SAN, AVN, VCS 1,2,3
HCN4CreErt2 R26RlacZ; R26RmT/mG SAN, AVN, VCS 2
Isl1Cre R26RmT/mG; Gata4flap SAN, AVN, VCS 2,4
Isl1MerCreMer R26RlacZ SAN, AVN 5
Nkx2-5Cre R26RmT/mG SAN, AVN, VCS 2
Shox2Cre R26RlacZ SAN, AVN 6,7
Tbx2Cre R26RlacZ; Z/EG AVN, VCS 3,8
cGATA6Cre R26RlacZ AVN 9
Mef2c-AHF-Cre Z/EG AVN, VCS 3
Cx40CreERT2 R26RlacZ VCS 10
Wnt1Cre CAG-CATeGFP;R26RlacZ VCS 11,12,13
References: 1. Wiese, C. et al. Circ. Res. 104, 88–97 (2009), 2. Liang, X. et al. Circ. Res. 113, 399–407 (2013), 3. 
Aanhaanen, W.T.J. et al. Circ. Res. 107, 728-36 (2010), 4. Ma, Q. et al. Dev. Biol., 323, 98-104 (2008),  5. Sun, Y. et al. 
Dev. Biol. 304, 286–96 (2007), 6. Sun, C. et al. Genesis. 51, 515–522 (2013), 7. Sun, C. et al. J. Biol. Chem., 290, 2007-
23 (2015), 8. Aanhaanen, W.T.J. et al. Circ. Res., 104, 1267-74 (2009), 9. Davis, D.L. et al. Mech. Dev., 108, 105-19 
(2001), 10. Miquerol et al. Circ. Res. 107, 153-161 (2010), 11. Nakamura, T. et al. Circ. Res. 98, 1547-1554 (2006), 
12. Poelmann, R. et al. Anat. Embryol., 208, 389-393 (2004), 13. Miquerol, L. et al. Dev. Dyn. 242, 665-677 (2013)
2.1.1. BASICS OF GENETIC TRACING
To use the Cre-loxP system for genetic tracing, several steps are necessary (Fig. 
2). The basis of the Cre-loxP system is crossing a Cre transgenic mouse strain 
with a mouse in which a reporter gene is flanked by LoxP sequences (“floxed”). 
First, the sequence coding for Cre-recombinase is knocked into the locus of the 
gene of interest, for example Isl1. The next step is crossing the Isl1Cre mouse line 
with a reporter line (Fig. 2A). The genetic tracing experiments in this review 
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were mostly performed in reporter lines that utilize the Rosa26 locus (R26R), 
but different loci (e.g. Gata425) are used. Important characteristics of a potential 
reporter locus are ubiquitous expression of the gene and viability and fertility 
of the mouse strain after homozygous inactivation of the reporter locus by 
insertion of a reporter gene, such as lacZ or a single or multiple fluorescent 
proteins. To control expression of the reporter gene, a floxed sequence preventing 
transcriptional read-through (also referred to as a “stop-cassette”) is placed 
before the reporter gene sequence (Fig. 2A). 
 Crossing the reporter line with the Cre line results in offspring carrying both 
constructs (Fig. 2B). Cells expressing the gene of interest will produce Cre-
recombinase, which will result in permanent deletion of the stop-cassette and 
expression of the reporter gene (Fig. 2C). Since expression is under control of 
the Rosa26 promoter, these cells and their progeny will retain reporter gene 
expression, thereby enabling tracing of these cells. The above-described method 
is referred to as “constitutive” genetic tracing in this review (Fig. 2D). 
 With another form of genetic tracing, referred to as “inducible” genetic tracing, 
it is possible to gain temporal control of recombination (Fig. 2D). This system is 
based on fusion of a mutated ligand-binding domain (LBD) of the human estrogen 
receptor (ER) and Cre-recombinase. The resulting protein is only sensitive to the 
anti-estrogen tamoxifen, not to the endogenously present estradiol.26 The fusion 
gene is inserted in the locus of the gene of interest, which results in production 
of the fusion protein upon expression of the gene of interest. The Cre fusion 
protein is located in the cytoplasm and is unable to enter the nucleus, due to the 
presence of the mutated LBD. Administration of tamoxifen results in binding to 
the LBD, which enables translocation of Cre-recombinase to the nucleus, where it 
induces gene specific recombination.27 Thus, recombination can only occur after 
administration of tamoxifen, resulting in temporal control of lineage labeling 
(Fig. 2D).
2.1.2. ADVANTAGES OF GENETIC TRACING
The most important advantage is the ability to investigate which genes are 
expressed by the structure of interest’s progenitor pool. Combining these 
results with known expression patterns of the gene of interest (e.g. based on 
immunohistochemical staining patterns) and with other cell tracing techniques 
has provided important information on the developmental origin of the CCS. 
 Furthermore, genetic lineage tracing is non-invasive, in contrast to e.g. 
performing prospective tracing with microinjection of vital dyes or viral 
constructs. In chick, the egg has to be opened and the dye or viral construct 
has to be administered directly to live cells, frequently accompanied by extra 
microsurgical manipulation. After these steps, the egg can be reincubated.28 
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Figure 2. The Cre-lox system
A. Genetic tracing with Cre line in which one allele of gene of interest (here “locus a”, e.g. Isl1) is 
replaced by coding sequence Cre-recombinase (fused with estrogen receptor (ER) if aim is inducible 
genetic tracing). Crossed with reporter mouse with floxed (between black triangles) stop codon and 
reporter gene (e.g. lacZ) inserted in reporter locus (here “locus b”, e.g. R26R). B. Crossing results in 
offspring with coding sequence Cre-recombinase on locus gene of interest (“locus a”, e.g. Isl1) and 
floxed stop codon and reporter gene in reporter locus (“locus b”, e.g. R26R). C. Expression gene of 
interest results in synthesis Cre-recombinase enzyme, which removes floxed stop codon. D. Difference 
between constitutive (left) and inducible (right) tracing. Constitutive tracing: expression of gene of 
interest results in Cre-recombinase (indicated in Fig. as Cre) expression, which enters nucleus and 
induces reporter gene expression. Inducible tracing: in absence of tamoxifen, the estrogen receptor 
prohibits Cre-recombinase to enter the nucleus. In presence tamoxifen, Cre-recombinase enters 
nucleus and induces reporter gene expression.
x
Cre line Reporter line
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In murine embryos it is necessary to extract the embryo from the uterus, followed 
by culturing the embryo in for example a rolling culture system.29 The time of 
follow-up is therefore hampered in murine embryos and extracting the embryo 
is an extra invasive procedure. Genetic tracing on the other hand is non-invasive, 
as long as insertion of the sequence for Cre does not impair normal development 
of the embryo.
 Inducible genetic tracing has an important advantage over constitutive 
genetic tracing, namely temporal control of Cre expression. With constitutive 
genetic tracing there is no control of timing of Cre expression. Expression of the 
gene of interest at any given (and frequently unknown) time point will result in 
reporter gene expression (if the level of Cre expression is sufficient to induce 
reporter gene expression, see below). With inducible tracing, reporter gene 
expression will only occur in the presence of tamoxifen.26 
2.1.3. DISADVANTAGES OF GENETIC TRACING
Common pitfalls in interpretation of results from genetic lineage tracing are given 
in Fig. 3. Finding reporter gene expression in the tissue or structure of interest 
can result from several scenarios. In the ideal situation, depicted in Fig. 3A, it can 
show that at time point 0, a certain structure with known expression of the gene 
of interest is a progenitor for the structure with reporter gene expression at a 
later time point (Fig. 3A). However, it can also reflect expression of the gene of 
interest at the later time point, since active expression of the gene will also result 
in reporter gene expression (Fig. 3B). Finally, expression of the gene of interest 
in an entirely different progenitor pool (e.g. different tissue or at a different time 
point) can contribute to the structure of interest (Fig. 3C). The latter two scenarios 
could lead to a wrong conclusion on the lineage of the structure of interest. The 
difficulty in interpretation of genetic tracing experiments was demonstrated by 
constitutive genetic tracing of Tbx18. Tbx18 is commonly used as a marker for the 
sinus venosus and epicardium. Constitutive genetic tracing was performed with 
a Tbx18Cre in the R26RlacZ background and reporter gene expression was found in 
myocardial cells, which led to the conclusion that these cardiomyocytes derived 
from epicardial cells.30 However, later experiments showed active expression 
of Tbx18 in cardiomyocytes, which was put forward as an explanation for the 
observed reporter gene expression.31 Using constitutive genetic tracing, reporter 
gene expression in cells shows that either these cells have expressed the gene of 
interest at an unknown time during development, or still express this gene. 
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Figure 3. Pitfalls of the Cre-lox system (legend on page 207)
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 Even though timing is far more accurately determined using inducible genetic 
tracing, exact timing of recombination and reporter gene expression remains 
difficult. It was shown that after intraperitoneal injection of tamoxifen at E8.5 
in pregnant dams, the first signs of lacZ activity in the embryos were seen 6 hrs 
after injection, with an increase in expression at 12, 24, and 48 hrs.32 Analysis of 
reporter gene expression after tamoxifen injection therefore is dependent on the 
duration of tamoxifen exposure, which complicates exact timing. Furthermore, 
the dosage of tamoxifen has also been shown to influence reporter gene 
expression, with higher doses resulting in reporter gene expression in more 
cells.32 This shows that analysis of reporter gene expression and interpretation 
of these results can be problematic. 
 In genetic tracing experiments, interpreting positive results can be 
problematic, but a far more complex problem arises in case of lack of reporter 
gene expression (Fig. 3D). A large number of genetic tracing experiments utilize 
the R26R locus, which is also the most commonly used reporter locus described in 
the current review. Genetic tracing experiments comparing the R26R locus with 
a Gata4 based reporter system showed differences in reporter gene expression 
Figure 3. Pitfalls of the Cre-lox system (figure on page 206)
Ideal situation shown in A0-2. At time point 0 (A0), structure of interest A expresses gene of interest, 
but not yet reporter gene. Other tissue (e.g. structure B) does not express gene of interest (or reporter 
gene). At later time point 1 (A1), structure A expresses gene of interest and reporter gene. Structure 
B shows no expression of gene of interest or reporter gene. At final time point 2 (A2), structure of 
interest C shows reporter gene expression, no expression of gene of interest and is derived from 
structure A and B, with reporter gene expression only being derived from structure A. B0-2. At time 
point 0 (B0), structure of interest D expresses gene of interest (not yet reporter gene), while other 
tissue (e.g. structure E) does not express gene of interest or reporter gene. At time point 1 (B1), 
reporter gene expression is seen in structure D, not structure E. However, structure D and E both 
do not contribute to final structure of interest F (B2). At time point 2 (B2), structure of interest F 
actively expresses gene of interest, resulting in reporter gene expression. This could result in falsely 
concluding that structure F receives a cellular contribution from structure D. C0-2. At time point 0 
(C0) structure of interest G and unknown structure H (i.e. expression of gene of interest was not 
studied in this structure) both express gene of interest (no reporter gene expression yet). At time 
point 1, reporter gene expression is present in both structures G and H. At time point 2 (C2), final 
structure of interest I shows reporter gene expression (C2). However, cells expressing reporter gene 
derive from unknown structure H, not initial structure of interest G. This results in falsely concluding 
that final structure of interest I receives contribution from structure G. D0-D2. At time point 0 (D0) 
structure of interest J expresses gene of interest (no reporter gene yet). At later time point 1 (D1) 
structure J loses expression gene of interest. However, expression gene of interest is too low to induce 
recombination at level high enough to detect reporter gene expression, resulting in lack of reporter 
gene expression. At time point 2 (D2), final structure of interest L (partially derived from structure 
J), shows no reporter gene expression due to sub-threshold level of expression to induce expression 
of reporter gene (i.e. false-negative cells). This could result in the incorrect conclusion that structure 
J does not contribute to structure L.
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between the two lines.25 Constitutive genetic tracing of Isl1 and Nkx2-5 (both 
genes are discussed in more detail below) showed more extensive reporter gene 
expression in the Gata4 reporter line, indicating that the Gata4 locus was more 
sensitive to recombination than the R26R locus.25 The difference in reporter 
gene expression shows that different reporter strains have different thresholds 
for reporter gene expression, resulting in different conclusions based on the 
reporter used. An example of the importance of this is shown by reassessment 
of the fate of Isl1+ progenitors.25 This gene is commonly used as marker for the 
SHF.7,33 However, the expanded pattern of reporter gene expression in the Gata4 
reporter line showed that nearly all cells (including the LV, which is commonly 
described as being derived from the FHF) of the heart derive from an Isl1+ 
progenitor. This shows that Isl1 is not suitable as a SHF marker.25 mRNA34 and 
protein35 expression of Isl1 in the cardiac crescent, classically considered to be a 
FHF structure, further substantiates this. 
 The absence of reporter gene expression is also an important difficulty in 
interpreting results from inducible genetic tracing experiments, since reporter 
gene expression is dependent on dosage of tamoxifen.32 This shows that it is very 
difficult to draw conclusions from tissue lacking reporter gene expression, since 
absence of reporter gene expression can be caused by absence of expression of 
the gene of interest, or absence of recombination due to sub-threshold levels of 
Cre expression, not sufficient to induce reporter gene expression.
 Therefore, when performing constitutive or inducible genetic tracing 
experiments, one should be cautious with interpretation of the results. In 
constitutive genetic tracing, reporter gene expression demonstrates that labeled 
cells have expressed or still actively express the gene of interest. It does not provide 
information on the initial source/location of the progenitor cells. With inducible 
genetic tracing, temporal control of Cre expression is possible.  Expression of the 
reporter gene shows that Cre is present in the labeled cell between the time of 
tamoxifen administration and the moment of analysis. Finally, interpretation of 
negative results in genetic tracing is challenging and results need to be verified 
by additional tracing techniques and gene/protein expression experiments at 
sequential stages of development. 
2.2. VITAL DYE AND VIRAL LABELING EXPERIMENTS
With vital dye and viral labeling it is possible to directly label clusters of cells. 
This method is widely used in developmental biology in several species, and has 
provided essential information on the developmental origin of the CCS. 
2.2.1. BASICS OF VITAL DYE AND VIRAL LABELING EXPERIMENTS
To perform microinjection of minute quantities of either vital dye or viral 
Lessons learned from tracing experiments 209
9
constructs, the embryo needs to be exposed. The technique to expose the chick 
embryo was described recently in detail elsewhere.28 An important advantage 
of chick embryos is the easy accessibility of the embryo in the egg, which allows 
long-term reincubation after labeling. In mice, it is first necessary to extract 
the embryo from the uterus, followed by reincubation in culture medium, for 
example in rolling bottles.29 Labeling of cells is performed with a glass capillary 
mounted to micromanipulators, and a pneumatic microinjector to inject small 
amounts of dye or virus in the region of interest. 
 Vital dye labeling is performed with lipophilic dyes which can label distinct 
cell compartments (Fig. 4A).35 Commercial dyes are available in different colors, 
which enables simultaneous labeling of different clusters of cells and studying 
the direction of migration and potential intermingling of different cell clusters. 
 Viral labeling experiments are aimed at induction of reporter gene 
expression in specific regions of the embryo. This technique utilizes the ability 
of retroviruses to infect the cell and to incorporate its genome in the genome of 
the infected cell.36–38 Retroviral vectors driving the expression of a reporter gene 
(such as LacZ) enable cell tracing of infected cells (Fig. 4B). More targeted viral 
tracing can be performed by placing expression of the reporter gene under the 
transcriptional control of a specific promoter, which enables tracing of cells that 
express the gene of interest (Fig. 4C).39
2.2.2. ADVANTAGES OF VITAL DYE LABELING EXPERIMENTS
With physical labeling of a progenitor pool, it is possible to select the progenitor 
pool based on location and to time the moment of labeling. An important 
advantage of this technique is the opportunity to select a physical cluster of cells, 
rather than a genetic expression domain (as is the case with genetic tracing). 
An important drawback of genetic tracing therefore does not apply to physical 
labeling of cells. The pitfall described in Fig. 3C, in which a distinct progenitor 
population is missed, will not occur in physical labeling, since location of labeling 
is known. Combining physical labeling with a viral vector in which reporter gene 
expression is driven by a specific promoter results in selection of an even smaller 
domain of cells. Selecting this population is then based on location and gene 
expression of a gene of interest, while minimizing the risk of missing a distinct 
progenitor pool (Fig. 3C). 
 Performing physical labeling experiments is relatively cost efficient and 
easy, especially in chick embryos. Working with mice in general, and complex 
transgenic mouse strains in particular, requires advanced biotechnical and 
animal care facilities, which are not needed when working with chick embryos. 
Furthermore, labeling can be combined with other microsurgical procedures. 
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Figure 4. Vital dye and viral labeling
A1. Vital dye labeling of structure expressing 4 genes. A2. Label (red cells) directly visible on all cell 
types. A3. Disadvantage is dilution (pink cells) of label during further development. B1. Viral labeling 
of same structure. B2. Disadvantage is that label is not visible directly after infection (dark grey cells), 
all cell types infected. B3. No dilution of labeling (red cells) during long-term follow-up, labeling seen 
in all cell types. C1. Gene-specific (for gene D) viral labeling of same structure. B2. Infection (dark 
grey) of all cell types, labeling not visible directly. C3. Labeling only seen in cells expressing gene D 
(red cells), no dilution, no labeling in other cell types (dark grey). See legend for color coding.
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2.2.3. LIMITATIONS OF VITAL DYE AND VIRAL LABELING
As with genetic tracing, physical labeling experiments start with selection of 
the progenitor population, which results in only tracing this cluster of cells. 
Knowledge about the possible progenitor pool is necessary to perform the 
experiment and unexpected contributions are easily missed with this technique. 
 Furthermore, physically labeling cells is relatively invasive and manipulation 
of the embryo can result in developmental defects. It is therefore necessary 
to carefully select embryos that show no macroscopic abnormalities and use 
appropriate control embryos when indicated. Toxicity of the dyes itself appears 
to be negligible.40,41 With viral labeling, there is random integration of the 
viral genome in the host cells DNA, which could result in damage or abnormal 
functioning of the infected cell.23
 When performing physical labeling experiments in murine embryos, culturing 
the embryo ex utero results in limited follow-up, since simple diffusion of oxygen 
and nutrients is only sufficient during early development.  When using the chick 
as a model, approaching the desired structure can be a challenge depending on 
the anatomical location, since the embryo is positioned on the left side. Ex ovo 
culturing offers alternatives but, as with the murine model, the culture is time-
limited.
 Leakage of dye or infection of cells in the vicinity of the designated progenitor 
pool could result in incorrect conclusions about the fate of the progenitor cells. 
It is therefore essential to analyze in detail the location of dye directly after 
administration.35,42 Histological evaluation of embryos directly after labeling is 
crucial, but follow-up is impossible after histological evaluation. Live-imaging 
of vital dyes41,43,44 could help to minimize this limitation. Furthermore, delay 
in reporter gene expression with viral labeling omits direct evaluation of the 
location of labeling. In addition, efficiency of the reporter gene expression in 
the desired cells has to be previously tested to ascertain activation of expression 
in the specific cell type within the animal model (i.e. species differences in 
expression levels in specific cell types).
 Rapid cell division in early embryos results in dilution of the vital dyes, which 
complicates long-term follow-up of the labeled cells.45 The extent of dilution 
is dependent on the rate of proliferation and the amount of dye administered, 
which therefore necessitates titration of the dye with every new experiment. 
With retroviral labeling, integration of the reporter gene in the host cells DNA 
results in stable and high expression of the reporter gene in the daughter cells46, 
which overcomes the problem of dilution. 
 In conclusion, the disadvantage of vital dye labeling is dilution, while the 
possibility of direct evaluation after labeling is an important advantage. The 
opposite is true for viral labeling, where direct evaluation is not possible, but 
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dilution of dye does not occur after stable integration of the viral vector. Therefore, 
a possible solution to overcome these limitations is to combine vital dye labeling 
with viral labeling.
 Finally, to perform viral labeling experiments, advanced biosafety laboratories 
are crucial to safely perform experiments with potentially hazardous viral 
constructs. 
2.3. RETROSPECTIVE CLONAL ANALYSIS
The above-mentioned techniques can be described as prospective fate mapping 
techniques. Knowledge on gene and protein expression profile, timing of 
expression and/or location of progenitors is necessary to perform subsequent 
prospective labeling of this progenitor pool.23 The following section focuses on 
retrospective clonal analysis. 
2.3.1. BASICS OF RETROSPECTIVE CLONAL ANALYSIS
Retrospective clonal analysis is based on infrequent and spontaneous 
recombination of the nLaacZ reporter.47 This reporter gene encodes the LacZ 
gene, with an inactivating duplication inserted in the reading frame, thereby 
inhibiting transcription of functional β-galactosidase. A spontaneous and rare 
recombination event can result in removal of the duplication and subsequent 
production of β-galactosidase (Fig. 5A).47 Reporter gene expression can be 
followed in progeny of cells in which spontaneous recombination of the nLaacZ 
construct occurred.47 Targeting of this construct to an allele highly expressed 
in cardiac muscle (e.g. α-cardiac-actin), enables retrospective clonal analysis of 
cardiac cells, irrespective of gene expression.48–50 
 Clonal analysis is based on statistical evaluation of the chance that reporter 
gene expression in different cells is based on separate spontaneous recombination 
events, or that these different cells are progeny of one recombination event (and 
thus share a common progenitor during development). A statistical method 
commonly used is the fluctuation test of Luria and Delbrück.51 This famous 
experiment showed that mutations in bacteria occur spontaneously (not induced 
by selection) and at a constant rate, which was used to formulate a probability 
distribution.51 This distribution is used to calculate the probability of one or 
more recombination events, and will therefore determine whether cells showing 
reporter gene expression are most likely clonally related or are derived from 
different recombination events (Fig. 5B).47–49,52 Early recombination (i.e. during 
early stages of development) will give large clusters of cells with reporter gene 
expression (Fig. 5C), while late spontaneous recombination will give smaller 
clusters of lacZ positive cells (Fig. 5D). 
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Mouse model

















Figure 5. Retrospective clonal analysis
A. Shows mouse model used. Rare, spontaneous recombination results in deletion of an intragenic 
duplication in the nlaacZ gene, resulting in reporter gene expression of the nlacZ gene. B. Reporter 
gene expression in this example is seen in VCS and working cardiomyocytes (dark blue with 
light blue stroke), which, based on statistical analysis is most likely based on one spontaneous 
recombination event in a common progenitor for both cell types (and not two unrelated spontaneous 
recombination events).49 C-D. Early spontaneous recombination will result in a large clone (C), while 
late recombination will result in a small clone (D).
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2.3.2. ADVANTAGES OF RETROSPECTIVE CLONAL ANALYSIS
To perform prospective lineage tracing, some basic knowledge on the progenitor 
population that will be traced is required. This information is not necessary when 
performing retrospective clonal analysis. Studying whether certain structures 
or clusters of cells are clonally related is done independent of gene expression 
or any other preconceived idea of a possible progenitor pool. Retrospective 
clonal analysis can therefore establish clonal relationships that are less apparent 
at first sight, such as the clonal relationship between head musculature and 
cardiomyocytes from the outflow tract and right ventricle.53
 Furthermore, as described previously, prospective genetic tracing is 
hampered by the difficulty to draw conclusions from the absence of reporter 
gene expression. With the retrospective clonal approach, analysis is based on 
lacZ positive cells. LacZ expression in different structures or tissues is mapped 
and statistical analysis is performed to calculate whether these different tissues 
or structures are clonally related.  
 Finally, as with genetic tracing, retrospective clonal analysis is non-invasive. 
2.3.3. LIMITATIONS OF RETROSPECTIVE CLONAL ANALYSIS
The retrospective approach has several drawbacks. Since data is analyzed 
retrospectively, it is not possible to locate the common progenitor, either in time 
or space. Therefore it is not possible to perform further experiments with these 
progenitors (e.g. characterization or ablation). Retrospective clonal analysis has 
to be performed in conjunction with other fate mapping techniques to build the 
complete lineage tree of a structure or organ. In this sense, the most important 
advantage of this technique is also its most important drawback. Starting 
with a certain progenitor pool based on timing, location and/or gene/protein 
expression profile excludes contributions from other (sometimes unexpected) 
progenitors, but does directly pinpoint a possibly important progenitor pool for 
the structure/tissue of interest. 
  Spontaneous recombination of the nlaacZ gene is rare and it is therefore 
necessary to obtain a large library of embryos with lacZ positive clones. 
Thousands of embryos or adult mice will have to be sacrificed and analyzed. 
Although this is laborious and causes distress to the animals, it is important to 
realize that after establishing this large library of clones, answers to numerous 
scientific questions in all fields of developmental biology can potentially be 
found.
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3. THE SINOATRIAL NODE
Several techniques have been used to investigate the progenitors that will 
ultimately form the adult SAN. The next section gives an overview of these 
techniques, which are summarized in Table 2. 
3.1. GENETIC TRACING AND SAN DEVELOPMENT
Several Cre-based genetic tracing studies have been performed to identify SAN 
progenitors. An important gene studied in sinus venosus and SAN development 
is T-box transciption factor gene 18 (Tbx18). Tbx18 is linked to the embryonic 
venous pole and is involved in development of the epicardium and sinus 
venosus myocardium, including the SAN.54 Tbx18Cre:R26RlacZ tracing experiments 
showed lacZ staining of the SAN head and tail at E17.5, which indicated that the 
progenitors of the SAN express Tbx18 at some time point during development. 
Since atrial myocardium lacked lacZ staining, the authors concluded that atrial 
myocardium is not derived from Tbx18+ progenitors.15 In a recent study, genetic 
tracing experiments were performed, utilizing several constitutive and inducible 
Cre lines.55 In this study, the derivation of the SAN head and tail from a Tbx18+ 
progenitor pool was confirmed using a different Tbx18Cre, crossed with the 
R26RmT/mG reporter line.55 This reporter construct utilizes the R26R locus and 
expresses the membrane-bound fluorescent protein Tomato in all cells.56 Cre-
mediated excision of mTomato results in expression of membrane-bound GFP.56
 Another important gene studied extensively in CCS function and development 
is the hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4). This 
channel delineates the (developing) CCS14 and is the main driving force behind the 
"funny current", which enables pacemaker cells to depolarize spontaneously.57 
Genetic tracing experiments were performed with an inducible HCN4CreERT2 line, 
which was crossed with the R26RlacZ reporter mouse.55 Induction with tamoxifen 
at E6.5 and analysis at E16.5 revealed lacZ expression in the coronary sinus, but 
not the SAN. Induction at E7.5 showed lacZ expression in a larger region, with 
staining present in the SAN tail at E16.5. With inductions from E8.5 onwards, the 
entire SAN showed lacZ activity, indicating that from ~E7.5-8.5 onwards, SAN 
precursors express HCN4.55 
 Constitutive and inducible tracing of Islet1 (Isl1), a LIM homeodomain 
transcription factor important for cell proliferation, differentiation and survival58 
and known to be essential for normal development and function of the SAN59,60, 
was also performed. Constitutive tracing with Isl1Cre:R26RmT/mG showed that the 
SAN is derived from Isl1+ progenitors.44 Inducible genetic tracing was performed 
with the Isl1MerCreMer mouse line. Induction of Cre-recombinase at E9 and analysis 
of lacZ staining at E11 revealed lacZ expression in the SAN, which shows that 
around E9, SAN progenitors express Isl1.7 
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 Nkx2-5, which is commonly used as an early precardiac marker61, was studied 
using constitutive tracing with Nkx2-5Cre:R26RmT/mG mice.55 The SAN head showed 
no reporter gene expression. A subpopulation of cells in the SAN tail did show 
GFP expression, and the authors therefore concluded that these cells are derived 
from an Nkx2-5+ precursor.55 As mentioned, active expression of Nkx2-5 could 
also result in reporter gene expression (Fig. 3).
 Finally, the Shox2Cre mouse line was used to investigate whether Shox2 
expressing progenitors contributed to the SAN.62 Shox2 is important for 
recruitment of sinus venosus myocardium during early development61 and 
is necessary for pacemaker differentiation and normal SAN function.63–66 The 
R26RLacZ mouse was used as reporter and analysis of β-galactosidase staining 
was performed between E9.5-11.5.62 Reporter expression was seen in the SAN. 
However, at these stages, the SAN actively expresses Shox2.61,62 Reporter gene 
expression is therefore likely the result of active expression of Shox2 by the cells 
from the SAN and does not give lineage information. 
3.2. VITAL DYE LABELING AND SAN PRECURSORS
Elegant vital dye labeling experiments were performed by Bressan et al., aimed 
at identifying the precursor cells of the SAN.42 Labeling was performed during the 
first stages of embryonic development in chick (HH5-10). Results showed that 
during early embryonic stages, pacemaker precursor cells are positioned in the 
NKX2-5/ISL1 negative portion of the right lateral plate mesoderm.42 This region 
was posterior to the ISL1/NKX2-5 expressing heart field.42 Furthermore, labeling 
cells within the left portion of the inflow and subsequent follow-up showed that 
these cells did not contribute to the right-sided SAN.42 
 Tracing the fate of cells deriving from the NKX2-5-/ISL1- right lateral plate 
mesoderm showed that cells arising from this mesoderm also contribute to 
the atria, AV junction and proepicardial organ. Since this region showed no 
expression of NKX2-5 and ISL1 (markers commonly used to define the FHF 
and SHF), the authors termed this region the tertiary heart field. However, as 
described above, Isl1 has been shown to be unsuitable as marker for the SHF. 
It remains therefore the question whether the different (i.e. first, second and 
tertiary) heart fields represent true distinct cell populations, or that they form a 
continuum and reflect different stages of differentiation of progenitor cells with 
a cardiac fate.25,35,67
 Another series of vital dye labeling experiments was aimed at tracing the fate 
of  sinus venosus myocardium.35 In ovo labeling of ISL1+/TNNI2+ sinus venosus 
myocardium at HH15 resulted in SAN labeling after 24-48h of follow-up. This 
confirms that the SAN is derived from the sinus venosus myocardium (Table 2).
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3.3. CONCLUSION TRACING EXPERIMENTS AIMED AT THE 
DEVELOPMENTAL ORIGIN OF THE SAN
The tracing experiments support the now widely accepted idea that SAN 
precursors reside in the myocardium of the sinus venosus. Furthermore, 
pacemaker cell fate is established during the first stages of embryonic 
development, even prior to formation of the heart tube.42
4. THE ATRIOVENTRICULAR NODE
The AVN is a complex heterogeneous structure and the developmental origin is 
still subject of debate. The following section focuses on the genetic tracing and 
fate mapping experiments that were performed to identify progenitors of the 
AVN. Results are summarized in Table 3.
4.1. GENETIC TRACING AND THE AVN
An essential gene in AVN development is the gene encoding the T-box transcription 
factor (Tbx) 2. Tbx2 is a repressor of transcription and during development is 
expressed in the  myocardium of the outflow tract and AV canal.68 Constitutive 
genetic tracing with the Tbx2Cre was performed using either the R26RlacZ or Z/EG 
reporter mouse.69 The Z/EG mouse expresses lacZ in a varying degree in different 
tissues. Cre mediated excision of the lacZ gene results in irreversible expression 
of eGFP in cells expressing Cre, making this model suitable for genetic tracing.70 
No clear distinction was made between the results obtained from the different 
reporter constructs. At E8-8.5, reporter gene expression (and Tbx2 mRNA 
expression) was seen in the inflow tract.69 Unfortunately, the exact description 
of the inflow tract (either anatomical or based on marker expression) was not 
provided. Analysis at E9.25 revealed reporter gene expression (and Tbx2 mRNA 
expression) in the AV canal.69 The authors concluded that the AV canal is derived 
from the Tbx2+ inflow tract.69 Analysis of Tbx2+ lineage data at E17.5 showed 
expression of eGFP (reporter gene) in the complete AVN and AV ring bundle.69 
It was concluded that the AVN and AV ring bundle derive from the AV canal.69 
Reporter gene expression (in the Z/EG line) at P14 was found in all Hcn4+/Tbx3+ 
atrial cells at the AV junction. The authors concluded that this could indicate 
that the AV canal contributes to the atrial components of the AV conduction axis, 
including the transitional cells and nodal extensions.71 It is important to mention 
that active expression of Tbx2 mRNA (which was found in cells of the AV canal 
up till E17.5, later stages not described69) could also result in reporter gene 
expression, which complicates the analysis of the described experiments.  
 Another series of genetic tracing experiments were performed with a GATA6-
gene heart-region-specific enhancer.72 The GATA6 gene is an evolutionary 
conserved gene encoding a transcription factor important for early specification 
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of cardiac progenitors.73,74 Genetic tracing was performed with the gene encoding 
Cre inserted at the locus of this enhancer, combined with the R26RlacZ reporter 
mouse. Analysis of reporter gene expression was performed at E8.5, E9.5, E12.5 
and in the neonatal stage.72 The embryonic stages showed expression in the AV 
canal. In neonatal hearts, reporter gene expression was found in the AVN and 
AV bundle and a subset of cells in the LV and atria also showed lacZ-staining.72 
However, expression of this enhancer (as shown by inserting the gene encoding 
lacZ in the locus for the cardiac enhancer) was found in the AV canal at E14. 
No data is presented on neonatal expression of the enhancer itself.  This could 
mean that reporter gene expression merely reflected active expression of the 
GATA6 enhancer, which does not give lineage information. It is therefore difficult 
to interpret the results from the genetic tracing experiments performed in this 
study.
 The genes used for genetic tracing experiments aimed at the precursors of the 
SAN were also used to study the developmental origin of the AVN.  Constitutive 
genetic tracing with two different Tbx18Cre mouse models55,71, crossed with 
either R26RlacZ, 71 or R26RmT/mG, 55 showed no reporter expression in the compact 
portion of the AVN at E16.5-17.5. It was concluded that the atrial portion of the 
AV conduction axis71 or the AVN in general55 is not derived from Tbx18 positive 
progenitors. Again, it is important to mention that negative results are difficult to 
interpret in genetic lineage tracing experiments (see Section 2.1.3.).
 Inducible genetic tracing with HCN4 to study the developmental origin of 
the AVN has also been performed.55 The HCN4CreERT2 mouse was bred with either 
R26RlacZ or R26RmT/mG reporter mice. Tamoxifen was administered at E6.5-9.5 and 
E11.5-12.5 in the R26RlacZ reporter and at E7.5, 9.5, 12.5 and 16.5 in the R26RmT/mG 
reporter. Analysis was performed at E16.5 and P1. After induction at E6.5, only a 
small number of positive cells was found in the coronary sinus and AV region, but 
not the AVN.  Induction from E7.5 onwards resulted in reporter gene expression 
in the AVN, and later inductions resulted in more positive labeling of the AVN.55 
This shows that the precursors of the AVN start expressing HCN4 from ~E7.5-
8.5.55
 Contribution of Isl1+ precursors to the AVN was investigated with constitutive 
and inducible genetic tracing. Inducible tracing with the Isl1MerCreMer mouse and 
R26RlacZ reporter line showed that induction with tamoxifen at E9 resulted in 
reporter gene expression in a subset of AVN cells.7 The results from earlier 
inductions did not mention the AVN explicitly in this study.7 Constitutive genetic 
tracing with the Isl1Cre combined with the R26RmT/mG reporter mouse confirmed 
the R26R-based inducible genetic tracing, showing that approximately 9.4% of 
AVN cells are derived from an Isl1+ progenitor.55 These results indicate that at 
least a part of the AVN is derived from Isl1+ progenitors. However, as described 
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above, Gata4-based constitutive tracing revealed that (nearly) all cardiomyocytes 
are derived from Isl1+ progenitors, including the cardiomyocytes of the AV 
canal.25 This again demonstrates the importance of the reporter line used and 
underlines the difficulty of interpreting genetic tracing experiments. 
 Constitutive genetic tracing experiments were also performed for Nkx2-5. 
Crossing the Nkx2-5Cre with the R26RmT/mG showed that most cells of the AVN 
(+/- 98%) at E16.5 show reporter gene expression. The authors concluded that 
the AVN is derived from the FHF.55 However, according to the used definition 
of the FHF and SHF, Nkx2-5 is expressed in both FHF and SHF progenitors 
and derivatives.5 Therefore, Nkx2-5 is not suitable as lineage marker for the 
FHF. Furthermore, Nkx2-5 is actively expressed in the AV conduction system.75 
Therefore, reporter gene expression is likely to reflect active expression of Nkx2-
5, rather than informing on the fate of Nkx2-5+ precursors.
 Since Shox2 is expressed in the AV conduction system62, constitutive genetic 
tracing was performed by Sun et al. with a Shox2Cre mouse line, combined with 
the R26RlacZ reporter line.76 Reporter gene expression was analyzed at E12.5, 
E18.5 and P7. The authors conclude that the AVN does not receive cellular 
contributions from Shox2+ progenitors.76 Instead, it was concluded that the cells 
derived from a Shox2+ lineage contribute to the dorsal mesenchymal protrusion 
(DMP).76 The DMP is a mesenchymal protrusion from the dorsal mesocardium 
which plays an important role during AV septation by contributing to the base 
of the atrial septum, together with the mesenchymal cap and AV cushions.77 
The Shox2+ cells in the AV junction showed expression of Hcn4 and Tbx3, and 
had a pacemaker-like genetic profile with nodal-like electrophysiological 
characteristics.76 However, we proposed that the anatomical designation of the 
DMP and developing AVN may be questioned as the Hcn4+/Tbx3+ cells in the AV 
junction with nodal-like electrophysiological characteristics and a pacemaker-
like genetic profile may well correspond to the putative AVN, and not the DMP.78
 The final Cre-line that has been used to perform genetic tracing of the AVN 
is the Mef2c-AHF-Cre.71 Mef2c is an important cardiac transcription factor and 
R26R-based fate map previously showed reporter gene expression in the outflow 
tract, right ventricle (RV), ventricular septum and DMP.79,80 The constitutive 
genetic tracing experiments aimed at the AVN were performed in the Z/EG line.71 
No eGFP expression was found in the atrial part of the AV conduction axis. The 
authors concluded that the outflow tract, RV, ventricular septum and DMP do not 
contribute to the AVN (Table 3).71   
 
4.2. VITAL DYE LABELING STUDIES AND AVN PROGENITORS 
Analysis of the fate of cells from the posterior SHF in mouse embryos resulted in 
findings which could be of importance to AV canal and AVN development.29 The 
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posterior SHF was defined in this study as the region that was positive for Islet1 
and negative for Fgf10. Vital dye labeling of the left and right side of this region 
was performed in mouse embryos of 2, 4 and 6 somites and analyzed at the 20-25 
somite stage.29 The results show that cells from the Islet1+/Fgf10- region, which 
is distant from the cardiac crescent and PHT, contribute to the sinus venosus, 
atria and AV canal in a craniocaudal fashion. This means that the cranial portion 
of the Islet1+/Fgf10- region will contribute to the AV canal and the more caudal 
region will contribute to the sinus venosus, with atrial progenitors in between.29 
It was not investigated whether the cells from the posterior SHF will contribute to 
the AVN. The results however show that Islet1+ cells outside the cardiac crescent 
and PHT will contribute to the AV canal.
 In chick it was shown that at HH8, the progenitors of the AV junction reside 
in the ISL1/NKX2-5 negative lateral plate mesoderm.42 Even though the AVN 
itself was not investigated, it does show that during early development AV canal/
junction progenitors are found outside the cardiac crescent or PHT.29,42 
 Vital dye labeling at older stages in chick were aimed at investigating a possible 
contribution from sinus venosus myocardium to the developing AVN.35 Labeling 
of the ISL1+/TNNI2+ myocardium of the sinus venosus was performed at HH15-
17 and the location of cells was traced after 24 and 48 hours.35 Labeled cells 
could be traced to a myocardial continuity between the myocardium of the sinus 
venosus and posterior region of the AV canal. qPCR analysis of this continuity 
showed mRNA expression of ISL1 and HCN4. Furthermore, single-cell patch clamp 
experiments showed pacemaker-like electrophysiological characteristics.35 
Together, these results show that the sinus venosus myocardium contributes 
to the posterior AV canal and the cells from this region show a pacemaker-like 
phenotype.35 Based on the location of the myocardial continuity between the 
sinus venosus and AV canal, it was postulated that the continuity contributes to 
the nodal extensions or transitional cells of the AVN (Table 3).35 
4.3. CONCLUSION FATE MAPPING AND CELL TRACING AIMED 
AT THE AVN
Based on the results from the above-described lineage tracing experiments 
(summarized in Table 3), we propose the following working model for AVN 
development. During early development, the progenitors of the AV canal are 
positioned outside the cardiac crescent and PHT, in the lateral plate mesoderm.42 
During early development, no ISL1, NKX2-542 and Hcn455 expression is seen. 
Perhaps Tbx2 expression can already be found at this stage, but this was 
not investigated. During further development, the cells from this region are 
sequentially incorporated in the inflow tract/sinus venosus and start to express 
Isl1, Hcn4, and Tbx2.35,55,69 The cells from the inflow tract69 and sinus venosus35 
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are incorporated in the AV canal. Interestingly, in the mef2c-/- mouse line, this 
sequential incorporation of inflow tract was shown to be disturbed.81 After 
targeted deletion of mef2c, precursors of the AV canal (as labeled by cGATA6 
expression) remained in the sinoatrial region.81 The Tbx2+/cGATA6+ AV canal 
will form (at least) the compact AVN.69 The craniocaudal patterning of the 
Isl1+/Fgf10- splanchnic mesoderm29 and late incorporation of sinus venosus 
myocardium35 could help to explain the different cell types present in the adult 
AVN. We hypothesize that the most cranial part of the inflow tract will generate 
the compact AVN, whereas more caudal cells from the sinus venosus contribute 
to the nodal extensions and/or transitional cells. However, further research is 
needed. We propose combining early dye/viral labeling of AV canal/junction 
progenitors with live imaging, long-term follow-up and characterization of these 
cells. This could prove the gradual incorporation of cells from outside the cardiac 
crescent and PHT in the AV canal and AVN. Characterization of labeled cells could 
help to understand the origin of the different components of the AVN. 
5. THE VENTRICULAR CONDUCTION SYSTEM
The ventricular conduction system (VCS) ensures rapid and synchronous 
electrical activation of the ventricles and consists of the AV bundle, the left and 
right bundle branches (LBB/RBB) and Purkinje fiber (PF) network (Fig. 1).22 The 
following section provides an overview of experiments aimed at investigating 
the cellular origin of the VCS, which are summarized in Table 4.
5.1. GENETIC TRACING AND VCS ORIGIN
Intercellular communication between cardiomyocytes is necessary for electrical 
coupling and is achieved by gap junctions. An important marker for the VCS 
is Connexin40 (Cx40), which is one of the major gap junction proteins, and is 
expressed in the atrial working myocardium, the AVN, and the fast conducting 
cells of the VCS.82,83 To perform prospective tracing experiments, a transgenic 
mouse line was generated in which the tamoxifen inducible CreERT2 was placed 
in the Cx40 locus.49 The mice were crossed with the R26RlacZ line and tamoxifen 
was administered between E10.5-18.5 followed by analysis of reporter gene 
expression at P7. Interestingly, inducing translocation of Cre to the nucleus with 
tamoxifen at E10.5-E14.5 resulted in lacZ expression in both conductive as well 
as working cardiomyocytes at P7.49 However, after induction with tamoxifen 
from E16.5 onwards, reporter gene expression was almost entirely restricted 
to conduction system cardiomyocytes.49 This study indicates that around E16.5, 
Cx40+ progenitors start to generate progeny with a more restricted conductive 
fate, as compared to Cx40+ progenitors during earlier developmental stages.49 
 In addition, several of the Cre lines described for the SAN and AVN have also 
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been used to study the origin of the VCS. Constitutive tracing with the Tbx18Cre, 
either in the R26RlacZ or R26RmT/mG strain was performed. Analysis of reporter 
gene expression was performed at E10.571, E16.555 and E17.5.71 No reporter gene 
expression was found in the components of the VCS in either of the studies.55,71
 Inducible genetic tracing experiments were performed with the HCN4CreERT2 
mouse line combined with either the R26RLacZ or R26RmT/mG.55 Tamoxifen 
inductions were performed at different developmental stages and analyzed at 
either E16.5 or P1. Inductions at E6.5 showed no reporter gene expression in 
the components of the VCS at E16.5. Inductions at E7.5 resulted in labeling of the 
LBB, PF network of the LV and sporadic labeling in the PF network of the RV. 55 
Tamoxifen administration at E8.5 resulted in additional labeling in the His bundle. 
Interestingly, absent or reduced expression in the PF network, His bundle and 
LBB was seen when inductions were performed at E9.5-E12.5. Labeling at E16.5 
resulted in labeling of all the components of the CCS, including the RBB and PF 
network.55 The authors concluded that all components of the VCS derive from the 
FHF, except the RBB and a subset of PFs of the RV, which are derived from the SHF. 
Furthermore, components of the CCS show de novo or re-expression of HCN4 (as 
shown by inductions performed at E16.5) according to the authors.55 However, 
absent reporter gene expression could also be explained by Cre expression below 
the threshold to induce reporter gene expression.25 As described above, previous 
work showed that R26R-based genetic tracing is susceptible to this problem, 
with a higher recombination threshold for the RV.25 Furthermore, reporter gene 
expression in the performed experiments could also reflect active expression 
of HCN4 in the components of the CCS, which complicates tracing the HCN4+ 
lineage, again stressing the need for careful interpretation of results obtained by 
genetic lineage tracing.
 Constitutive genetic tracing of Isl1+ progenitors was performed in different 
reporter strains. R26R-based constitutive tracing with the R26RmT/mG line showed 
reporter gene expression in the RBB and PFs of the RV at E16.5.55 Interestingly, 
only a small number of cells in the His bundle, PFs of the LV and cells from the 
LBB showed expression of eGFP.55 Based on these results and HCN4 genetic 
tracing, it was concluded that the VCS is derived from the FHF, except the RBB. 
The latter is suggested to be derived from the SHF.55 However, since Isl1 is not 
suitable as SHF marker and lack of reporter gene expression can result from sub-
threshold levels of Cre-expression to induce recombination, these results need 
further confirmation. 
 To perform constitutive genetic tracing of Nkx2-5+ progenitors, the Nkx2-
5Cre was combined with the R26RmT/mG line.55 Analysis at E16.5 revealed reporter 
gene expression in the majority of cells from the His bundle, LBB, and PF network 
(both from the LV/RV). Far less reporter gene expression was found in the RBB. 
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The authors conclude that this is in line with derivation of the majority of the 
VCS from the FHF.55 However, Nkx2-5 is not solely a marker for the FHF and 
eGFP expression can also be explained by active expression of Nkx2-5 in the cells 
from the VCS. Again, sub-threshold levels of Cre expression in the RBB could also 
explain the difference in reporter gene expression.25
 The Mef2c-AHF-Cre was combined with the Z/EG reporter line to perform 
constitutive genetic tracing.71 Analysis of reporter expression at E14.5 showed 
labeling of the AV bundle. However, Cre expression was also found in the AV 
bundle. Therefore, reporter gene expression likely reflects active expression 
of the Mef2c-AHF gene. At P14 reporter gene expression was found in the AV 
bundle as well as the lower nodal cells.71 Unfortunately, Cre expression was not 
assessed, which is necessary to discriminate between active expression of Cre 
or follow-up of cells after irreversible excision of the lacZ gene (and subsequent 
continuous expression of eGFP). 
 Constitutive genetic tracing for Tbx2 was performed in the Z/EG background 
at E17.5 and P14.69,71 Both studies report absence of reporter gene expression in 
the components of the VCS69,71, indicating that either the progenitors of the VCS 
do not express Tbx2 or express Tbx2 at levels too low to reach the threshold to 
induce recombination of the reporter construct. The former possibility would 
indicate that the AVN and the proximal components of the VCS derive from a 
different genetic expression domain. 
 Constitutive tracing of neural crest cells (NCCs) was performed using the 
Wnt1Cre. The Wnt1 gene is expressed in the neural plate, dorsal neural tube and 
in early migratory cells from the neural crest.84 The migratory NCCs migrate 
to the heart where they, together with cells from the nodose placode, form the 
cardiac autonomic nervous system.85,86 Furthermore, NCCs play an important 
role during development of the pharyngeal arch arteries, outflow tract septation 
and evidence has been found that NCCs play an important role during lamellar 
organization and compaction of the His bundle.87,88 Genetic tracing experiments 
were performed with the Wnt1Cre combined with the CAG-CATeGFP or R26RlacZ 
reporter lines to trace the fate of NCCs.89 Cells in the CAG-CAT-eGFP line start 
expressing eGFP after Cre-mediated excision of the CAT gene.89 Results are 
described to be identical between the two reporter lines.89 Analysis of reporter 
gene expression was performed at E17.5 and showed positive labeling in 
the region of the proximal VCS (posterior nodal tract, His bundle, and bundle 
branches).89 Based on these results the authors concluded that NCCs contribute 
to the proximal VCS. However, previous constitutive genetic tracing experiments 
performed with a Wnt1Cre and the R26RlacZ reporter indicated that NCCs were 
contiguous with the VCS, but did not contribute to the VCS.87 In addition, more 
recent tracing experiments with a Wnt1Cre combined with the R26RlacZ reporter 
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argue against a contribution from NCCs to the proximal VCS.50 Tracing was 
performed using the Cx40-GFP line as background, which expresses GFP in the 
Cx40+ cells of the VCS.50 No co-expression of lacZ (the reporter gene) and GFP 
(delineating the VCS) was seen. Reporter gene expression was seen in close 
proximity to the AV bundle50, which is in agreement with previous constitutive 
genetic tracing experiments.87 These results indicate that cells from the VCS do 
not originate from a Wnt1+ progenitor pool (Table 4). 
5.2. VCS PROGENITORS AND VIRAL LABELING
Targeted labeling of cells using genetically modified retroviruses has been 
performed in order to understand the cellular origin of the VCS. Over two 
decades ago, in ovo microinjection experiments were performed in chick 
embryos, utilizing 2 different viral vectors, which either induced expression of 
β-galactosidase in nuclei (SNTZ virus) or the cytoplasm (CXL virus) of infected 
cells.90 Either the neural tube was labeled at E2 to trace the fate of cardiac 
NCCs, or the ventricular wall was labeled at E3. Analysis of β–gal expression at 
E14 or E18 showed that labeling of the neural tube did not result in labeling 
of the VCS, indicating that (conform more recent genetic tracing studies, see 
above50,87) NCCs do not contribute to the VCS.90 Positive labeling was found in 
ALD58+ cells surrounding the coronary vessels, which were designated to be 
PFs.90 No contribution to the AV ring tissue, AV bundle, or bundle branches was 
found.90 Furthermore, labeling of myocytes at E3 resulted in β-gal expression 
in working and conductive cardiomyocytes. Finally, between E14 and E18, an 
increase in total β–gal+ cells was found, while the number of cells contributing 
to the PFs remained constant.90 These results indicate that the PFs derive from 
cardiomyocytes of the ventricular wall at E3. Furthermore, working myocardium 
and PFs derive from a common precursor at E3, with PFs committing earlier to a 
non-proliferative phenotype.90
 The results of this study are largely in agreement with later performed 
adenoviral and retroviral labeling experiments.10 Again, in a larger dataset, 
no contribution from NCCs to the CCS was found.10 Injection of these viral 
vectors at E2.5-3 in the pericardial cavity resulted in reporter gene expression 
in cardiomyocytes of the atria, ventricles and outflow tract at E4.5. At E10-19, 
expression was found in EAP-300+ cells, which were designated to be PFs.10 
Interestingly, in a small number of embryos (~5% of total embryos) in this larger 
dataset with additional adenoviral tracing constructs, expression was found in AV 
ring tissue, the His bundle and bundle branches.10 Expression was also present 
in working myocardium. Together, these results indicate that the proximal and 
distal components of the VCS derive from the myocardium of the early tubular 
heart.10 Unfortunately, the SAN and AVN are not mentioned specifically in the 
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results. Important to note is that administering viral vectors in the pericardial 
cavity resulted in reporter gene expression in cardiomyocytes of the atria, 
ventricles and outflow tract (the sinus venosus myocardium is not mentioned 
specifically). Therefore, the viral labeling experiments cannot be used to answer 
the question which of these initially labeled structures ultimately gave rise to the 
proximal components of the VCS (Table 4). 
5.3. RETROSPECTIVE CLONAL ANALYSIS AND VCS 
PRECURSORS
Retrospective clonal analysis was performed with the nlaacZ gene under 
transcriptional control of the α-cardiac actin locus, which restricts expression 
of nlacZ (after spontaneous recombination) to cardiomyocytes.49 This reporter 
line was bred into the Cx40GFP line, which delineates the Cx40+ cells of the central 
(His bundle, bundle branches) and proximal (PF network of the RV and LV) VCS.49 
Analysis of reporter gene expression was performed at a postnatal age of 3 weeks. 
Mixed (GFP+ and GFP- β-galactosidase+ cells) and unmixed (either GFP+ or GFP- 
β-galactosidase+ cells) clusters were found. The mixed clusters indicate that 
working (Cx40-) and conductive (Cx40+) cardiomyocytes derive from a common 
progenitor.49 Furthermore, the occurrence of unmixed clusters of conductive 
cells shows that after lineage restriction, cells still proliferate.49 The results are 
in agreement with the inducible genetic tracing results (from the same study) in 
the Cx40CreERT2 mouse line, which showed progressive lineage restriction to either 
working or conductive cardiomyocytes during development.49 Interestingly, while 
the number of conductive cardiomyocytes in mixed clusters between the RV and 
LV were comparable, the number of working cardiomyocytes was significantly 
higher in mixed clusters of the LV.49 This indicates that the progenitor population 
for conductive and working cardiomyocytes of the LV is different to that of the RV. 
The mechanisms leading to this difference remain to be elucidated.
 A more recent study by the same group also reports on retrospective clonal 
analysis in α-cardiac actinnlaacZ:Cx40GFP mice, aimed at elucidating the mechanism 
of development of the VCS.50 In a small number (18/912 hearts) of 3-week-old 
mice, large clusters of β-galactosidase+ cells (>1000 cells) were found. Large 
clusters of β-galactosidase+ cells indicate that the spontaneous recombination 
occurred during early development (see Fig. 4C). β-gal expression in conductive 
cardiomyocytes was found in 16/18 of the hearts analyzed, combined with 
expression in working cardiomyocytes.50 This again indicates that working 
cardiomyocytes and conductive cardiomyocytes of the VCS share a common 
progenitor. Reporter gene expression was found in all components of the 
VCS. Within one heart, expression was mostly found in two or more separate 
components of the VCS. Interestingly, no hearts were found with simultaneous 
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expression of nlacZ in the AV bundle, LBB and RBB.50 Two separate groups could 
be identified, based on either β-galactosidase+ cells in the PF network of the RV, 
or β-galactosidase+ cells in the LBB, corresponding to contribution from either 
a right or left lineage.50 These results indicate that the left and right VCS derive 
from a different progenitor population. Reporter gene expression in the AV 
bundle and RBB was found together with β-gal expression in either the LBB/PF 
network of the LV or the PF network of the RV, which indicates that both lineages 
contribute to the AV bundle and RBB (Table 4).50
5.4. CONCLUSION FATE MAPPING AND CELL TRACING AIMED 
AT THE ORIGIN OF THE VCS
The above-described results are summarized in Table 4. The cells contributing 
to the VCS are of myocardial origin and share a common progenitor with working 
cardiomyocytes. The cells contributing to the VCS derive from Cx40+ progenitors, 
which initially produce working and conductive cardiomyocytes. From E16.5 
onwards, predominantly conductive cardiomyocytes are produced by Cx40+ 
progenitors. The cardiomyocytes of the left and right portion of the VCS derive 
from a different progenitor pool. An important question that still needs to be 
answered is whether continuity between (the primordia of) the AVN and the VCS 
is present from the onset of development or that these structures are initially 
separate and connect during further development. During early development 
in mouse embryos (E8-10), no clear AVN or AV bundle could be discriminated.2 
However, the region of the putative AVN and primitive interventricular septum 
(the location of the future proximal VCS) showed continuity at these early 
developmental stages.2 Furthermore, from E11 onwards, the AVN and AV 
bundle are distinguishable and are continuous as well.3,69 Finally, discontinuity 
between the AVN and VCS in human is rare, even in complex structural heart 
disease affecting cardiac septation, such as (atrio)ventricular septal defects and 
congenitally corrected transposition of the great arteries.11 In left isomerism of 
the atrial appendages discontinuation between the AVN and the VCS is found.91 
However, damage to the normal continuity of the AVN and VCS rather than 
failure of the AVN and VCS to fuse is suggested as causative mechanism for the 
discontinuation.91 The available data therefore appears to point towards the 
hypothesis that (the progenitors of) the AVN and VCS are already continuous 
from the onset of development. However, since the exact location of AV bundle 
progenitors has not been mapped to date92, further research is needed to provide 
a final answer to this question.
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6. SUMMARY AND CONCLUSIONS
This review provides an overview of cell tracing and fate mapping techniques 
used to study the developmental origin of the CCS (Fig. 6) and advantages 
and limitations of these techniques were discussed. One of the conclusions 
that must be drawn is that caution is necessary when performing cell tracing 
or fate mapping. Analysis of results must be performed keeping the specific 
advantages and limitations of the used technique in mind. Omitting this can lead 
to false conclusions about clonal relationships or lineage information. Combining 
different techniques and the use of live imaging will help to minimize this risk.
 Even though every technique has its limitations, immense progress has been 
made in understanding the developmental origin of the CCS. Based on the results 
described here, the following working model (Fig. 6) on general CCS development 
is proposed: 
 The inflow tract and sinus venosus myocardium will give rise to the SAN 
(that is initially dual in Anlage with a transient left SAN) and myocardium of 
the AV canal. The AV canal will generate the compact portion of the AVN and 
possibly a portion of the transitional cells and/or nodal extensions. The sinus 
venosus contributes cells to the nodal extensions and transitional cells. The 
primordia of the AVN (posterior AV canal) and AV bundle and bundle branches 
(primitive interventricular septum crest and septum) are continuous from the 
onset of development, and therefore no fusion of these structures is needed. 
Further differentiation of ventricular cardiomyocytes (which are connected to 
the surrounding myocardium and bundle branches) towards PFs establishes the 
final connection between the proximal and distal components of the VCS, thereby 
completing the electrical wiring of the adult heart.  
Figure 6. Summary of cell tracing and fate mapping experiments aimed at elucidating the 
developmental origin of the CCS (figure on page 231)
The results from the different techniques used to investigate the embryological origin of the different 
components of the CCS are summarized. Based on these results, the (possible) developmental origin 
of the different structures is provided.
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SUMMARY & FUTURE PERSPECTIVES
SUMMARY
In the current thesis the embryological origin of the developing atrioventricular 
(AV) canal and atrioventricular node (AVN) was investigated, using different 
techniques, including immunohistochemical staining, lineage tracing and genetic 
characterization. In addition, the role of the RHOA-ROCK signaling pathway on 
development of key components of the cardiac conduction system (CCS) was 
studied. Finally, the potential role of the epicardium in autonomic modulation of 
the heartbeat was investigated. 
In chapter 2, a general introduction on cardiac and CCS development was 
provided. Development of the CCS was linked to clinical arrhythmias found in 
the pediatric and adult population. Furthermore, arrhythmias occurring in the 
setting of congenital heart disease were discussed. Finally, a working model for 
the developmental background of cardiac arrhythmias was generated. In this 
working model, embryological structures were linked to their adult counterparts 
and the arrhythmias arising from these structures.
Chapter 3 described the specific advantages and limitations of the avian embryo as 
model system in developmental biology, also based on experience obtained from 
the experiments described in the current thesis. Furthermore, the techniques 
that were performed in avian embryos to understand the development of the 
CCS were discussed. The results from these experiments showed that the avian 
embryo was and still is an essential tool to study developmental biology.
In chapter 4, lineage tracing of the AVN area was performed. An important finding 
was protein expression of ISL1 (commonly used as second heart field marker) in 
the chick cardiac crescent. In literature, this structure is described to be part of 
the first heart field. This indicates that ISL1 is unsuitable as a marker for the 
second heart field. Immunohistochemical analysis of the embryonic heart at later 
stages of development revealed a myocardial continuity between the myocardium 
of the sinus venosus and posterior portion of the AV canal. This region showed 
protein and mRNA expression of TNNI2, HCN4 and ISL1 and single-cell patch 
clamp revealed pacemaker-like electrophysiological characteristics. Lineage 
tracing using vital dye labeling showed that the myocardium of the sinus venosus 
was incorporated in the region of the myocardial continuity between the sinus 
venosus and posterior AV canal. Based on the superioposterior location of this 
myocardial continuity in relation to the AV canal, it was postulated that cells from 
the sinus venosus contribute to the transitional cells and/or nodal extensions of 
the AVN. 
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Recently, it was suggested by a report in literature that the dorsal mesenchymal 
protrusion (DMP), a mesenchymal structure contributing to the base of the atrial 
septum, acts as a temporary pacemaker during development. In chapter 5, we 
have questioned this, as we believe that the anatomical description of the DMP is 
not correct. The region designated as DMP in early mouse embryos in the specific 
report is in our opinion more likely to be the putative AVN, based on expression 
profile and electrophysiological characteristics.
In chapter 6, the role of the RHOA-ROCK signaling pathway on sinus venosus and 
sinoatrial node (SAN) development was studied. This pathway has important 
functions in a.o. cell migration and gene transcription. RHOA-ROCK signaling 
was chemically inhibited during early chick development. This resulted in 
prolongation of the immature state of the sinus venosus, shown by an increase in 
ISL1 expression, persisting pacemaker potential in the entire sinus venosus and 
a significantly reduced heart rate. Furthermore ROCK inhibition caused aberrant 
expression of typical SAN genes like ROCK1, ROCK2, SHOX2, TBX3, TBX5, ISL1, 
HCN4, CAV3.1, CX40 and NKX2.5 and the left-right asymmetry genes PITX2C and 
NODAL. The immature phenotype of the right-sided SAN and residual pacemaker 
potential of the left side of the sinus venosus was confirmed with patch clamp 
electrophysiology. Together these results showed that RHOA-ROCK signaling is 
involved in establishing the right-sided SAN as the definitive pacemaker of the 
heart and restricts typical pacemaker gene expression to the right side of the 
sinus venosus myocardium. 
The experiments performed in chapter 6 showed that normal RHOA-ROCK 
signaling is essential in SAN development. However, previous research showed 
that disturbing RHOA-ROCK signaling also resulted in AV conduction disturbances 
in adult mice. In chapter 7, we have examined the effect of ROCK inhibition on AVN 
development and have shown that inhibition during early chicken development 
results in different degrees of AV block, ranging from first degree AV block to 
advanced grades of block, including AV dissociation. This novel model system can 
be used to investigate the developmental background of AV block. Furthermore, 
the development of the myocardial continuity in the region of the putative AVN 
(described in detail in chapter 4) was shown to be disturbed, which may, at least 
in part, explain the AV block observed in this model. Finally, evidence was found 
that expression of SHOX2 and ISL1 was disturbed in the region of the putative 
AVN. The consequence of disturbed gene expression in this region warrants 
further investigation.
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For proper physiological responses, the SAN and AVN depend on innervation 
by the autonomic nerve system. In the adult heart, both the SAN and AVN are 
richly supplied by autonomic nerve fibers. Development of cardiac autonomic 
innervation is established by major contributions of the cardiac neural crest 
cells. However, during early cardiac development, when autonomic innervation 
has not yet been established, the heart already responds to catecholamines such 
as epinephrine. In chapter 8 we showed expression of neuronal markers, as 
well as the β2 adrenergic receptor (one of the receptors for epinephrine) in the 
epicardium. Specifically inhibiting the outgrowth of the epicardial layer during 
development resulted in a reduced heart rate response to epinephrine. The more 
severely the epicardial covering of the sinus venosus was disturbed, the more 
severely the heart rate response to epinephrine was hampered. Our results show 
that the epicardium is (at least partially) responsible for autonomic modulation 
of the early embryonic heart. 
FUTURE PERSPECTIVES
The cell tracing and fate mapping experiments aimed at elucidating the origin of 
the components of the CCS (described in more detail in chapters 3, 4, 7 and 9), 
share that they provide a static representation of a dynamic process. Combining 
live-imaging, high-resolution confocal microscopy and either physical or genetic 
labeling of cells would enable “four-dimensional” analysis of the fate of these cells. 
If for example a fluorescent label is applied to the sinus venosus myocardium, 
the active incorporation of this structure in the region of the putative AVN could 
be verified, thereby dynamically confirming the static observation described in 
chapter 4.
 We have shown that the RHOA-ROCK signaling pathway plays an essential role 
in normal development of the CCS. Future research could focus on identifying 
the exact molecular pathway by which RHOA-ROCK signaling influences SAN and 
AVN development. It would be interesting to perform microarray analysis on 
(control and ROCK inhibited) tissue isolated from specific key CCS regions (such 
as the right and left-sided SAN and the putative AVN), using the laser capture 
microdissection technique described in this thesis. This genetic characterization 
will shed light on the mechanisms leading to pacemaker dysfunction and AV 
block after inhibition of the RHOA-ROCK pathway.
 Finally, the current thesis describes a novel and important role for the 
epicardium in modulation of the autonomic response prior to establishment of 
the cardiac autonomic nervous system (chapter 8). Epicardial cells have already 
been shown capable of secreting different factors and to become reactivated in 
response to damage. The exact mechanism by which the epicardium regulates 
autonomic responses remains to be elucidated. Future experiments could be 
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aimed at the in vitro neurogenic potential of epicardial and epicardium-derived 
cells. Furthermore, (single-cell) microarray analysis could help to identify genes 
that are involved in epicardial modulation of the autonomic response. Finally, it 
would be interesting to confirm the results in mammals as well as in adult stages, 
for example after damage. Epicardium-specific knockdown of the β2 adrenergic 
receptor, followed by microelectrode recordings would be interesting to confirm 
the importance of the epicardium in general and the epicardial β2 adrenergic 
receptor in particular in autonomic modulation of the heart.  









In dit proefschrift werd de embryonale ontwikkeling van het atrioventriculaire 
kanaal en de atrioventriculaire knoop onderzocht. Hiervoor werden verschillende 
technieken gebruikt, waaronder cell tracing en genetische karakterisatie. 
Hiernaast werd gekeken naar de rol van de RHOA-ROCK signalerings-cascade 
tijdens ontwikkeling van het cardiale geleidingssysteem. Tot slot werd er 
onderzoek verricht naar de relatie tussen de ontwikkeling van het epicard en het 
cardiale autonome zenuwstelsel.  
In hoofdstuk 2 werd een algemene inleiding gegeven over de ontwikkeling 
van het hart en het cardiale geleidingssysteem. Er werd getracht specifieke 
ritmestoornissen te verklaren vanuit de ontwikkeling van het cardiale 
geleidingssyteem. Verder werd in dit hoofdstuk aandacht besteed aan 
ritmestoornissen die optreden bij aangeboren hartafwijkingen. Deze informatie 
werd gebruikt om een model te creëren waarbij embryonale structuren 
en de “volwassen” structuren die hieruit ontstaan, werden gekoppeld aan 
ritmestoornissen.
Hoofdstuk 3 beschreef de voor- en nadelen van het aviaire embryo als 
modelsysteem binnen de ontwikkelingsbiologie. Verder werd een overzicht 
gegeven van de verschillende technieken die werden verricht met behulp van 
dit modelsysteem om inzicht te krijgen in de ontwikkeling van het cardiale 
geleidingssysteem. De resultaten van deze experimenten laten zien dat het 
aviaire embryo een essentieel modelsysteem is binnen de ontwikkelingsbiologie.
In hoofdstuk 4 werd de embryonale oorsprong van de atrioventriculaire knoop 
onderzocht. Een belangrijke vondst was eiwit-expressie van ISL1 (frequent 
beschreven als marker voor het second heart field) in de cardiac crescent. 
Echter, in de literatuur wordt de cardiac crescent gerekend tot het first heart 
field. Deze bevinding laat zien dat ISL1 ongeschikt is als marker voor het second 
heart field. Immunohistochemische analyse van het embryonale hart tijdens 
latere embryonale stadia liet een myocardiale verbinding zien tussen de sinus 
venosus en de achterzijde van het atrioventriculaire kanaal. Deze verbinding 
liet mRNA expressie van TNNI2, HCN4 en ISL1 zien, met pacemaker-achtige 
elektrofysiologische eigenschappen. Met behulp van vital dye lineage tracing 
experimenten werd aangetoond dat het myocard van de sinus venosus wordt 
geïncorporeerd in de myocardiale verbinding tussen de sinus venosus en het 
atrioventriculaire kanaal. Op basis van de lokatie van de myocardiale verbinding 
werd gepostuleerd dat het sinus venosus myocard bijdraagt aan de transitionele 
cellen en/of de nodale extensies van de atrioventriculaire knoop.  
248  Chapter 11 
11
In een recent artikel werd gesuggereerd dat de dorsal mesenchymal protrusion 
(DMP), een mesenchymale structuur die bijdraagt aan de basis van het atrium 
septum, als een tijdelijke pacemaker fungeert tijdens de hartontwikkeling. In 
hoofdstuk 5 werd dit door ons in twijfel getrokken, aangezien wij geloven dat de 
anatomische beschrijving van de DMP in dit artikel niet correct is. De structuur die 
wordt beschreven als DMP is naar onze mening waarschijnlijk de (toekomstige) 
atrioventriculaire knoop, gezien het (eiwit en mRNA) expressie-profiel en de 
elektrofysiologische eigenschappen van de desbetreffende structuur. 
In hoofdstuk 6 werd de rol van de RHOA-ROCK signalerings-cascade tijdens 
ontwikkeling van de sinus venosus en sinus knoop onderzocht. Deze cascade 
speelt een belangrijke rol tijdens onder andere cel migratie en gentranscriptie. 
RHOA-ROCK signalering werd chemisch geremd tijdens de vroege embryonale 
ontwikkeling in de kip. Dit resulteerde in langer immatuur blijven van de sinus 
venosus, hetgeen bleek uit een toename van ISL1 expressie, persisteren van 
een pacemaker-achtig fenotype van de gehele sinus venosus en een significante 
reductie van het hartritme. Remming van de RHOA-ROCK signaleringscascade 
resulteerde verder in afwijkende expressie van zowel genen die typisch zijn voor 
de sinus knoop, zoals ROCK1, ROCK2, SHOX2, TBX3, TBX5, ISL1, HCN4, CAV3.1, 
CX40 en NKX2.5, als PITX2C en NODAL, genen die een belangrijke rol spelen bij 
het ontstaan van asymmetrie van de organen. Het immature fenotype van de 
rechtszijdige sinus knoop en het aanhoudende pacemaker-achtige fenotype 
van de linkerzijde van de sinus venosus werd verder bevestigd met patch clamp 
experimenten. Tezamen lieten de resultaten zien dat RHOA-ROCK signalering 
noodzakelijk is voor de normale ontwikkeling van de (rechtsgelegen) sinus 
knoop. 
Hoofdstuk 6 liet zien dat RHOA-ROCK signalering van belang is tijdens de normale 
ontwikkeling van de sinus knoop. Echter, eerder uitgevoerde experimenten in 
volwassen muizen lieten zien dat het verstoren van RHOA-ROCK signalering 
ook in AV geleidingsstoornissen resulteerde. Daarom werd in hoofdstuk 7 het 
effect van inhibitie van de RHOA-ROCK signalerings-cascade op de ontwikkeling 
van de atrioventriculaire knoop onderzocht. Chemische remming van RHOA-
ROCK signalering in kippenembryo’s resulteerde in verschillende gradaties van 
AV-blok, variërend van eerstegraads AV-blok tot hooggradig AV-blok (inclusief 
AV dissociatie). De morfologie van de myocardiale verbinding tussen de sinus 
venosus en het atrioventriculaire kanaal (uitgebreid beschreven in hoofdstuk 
4) was verstoord, hetgeen de gevonden AV geleidingsstoornis in ieder geval 
deels verklaart. Genexpressie van SHOX2 en ISL1 leek ook verstoord te zijn in 
de (toekomstige) atrioventriculaire knoop. De consequentie van deze verstoorde 
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genexpressie moet verder onderzocht worden. Een interessante bijkomstigheid 
is dat het in hoofdstuk 6 en 7 beschreven nieuwe modelsysteem kan worden 
gebruikt om de pathofysiologie en behandeling van AV-blok te onderzoeken.    
Voor een normale fysiologische respons van het hart op externe stimuli moeten 
de sinus en atrioventriculaire knoop geïnnerveerd worden door het autonome 
zenuwstelsel. Het cardiale autonome zenuwstelsel is afkomstig van cardiale 
neurale lijst cellen. Tijdens de embryonale ontwikkeling reageert het hart al op 
catecholamines (zoals epinefrine) met o.a. een stijging van de hartfrequentie 
vóórdat innervatie door het cardiale autonome zenuwstelsel is bewerkstelligd. 
In hoofdstuk 8 werd aangetoond dat het epicard zowel neuronale markers als 
de β2 adrenerge receptor (één van de receptoren voor epinefrine) tot expressie 
brengt. Remming van de uitgroei van het epicard tijdens de vroege embryonale 
ontwikkeling resulteerde in een verminderde respons van de hartfrequentie op 
epinefrine. Hoe minder epicardiale cellen gezien werden in het gebied van de 
sinus venosus, hoe minder het hart reageerde op epinefrine. Deze resultaten 
laten zien dat het epicard van groot belang is voor autonome regulatie van het 
vroeg embryonale hart. 
TOEKOMST PERSPECTIEF
De verschillende cell tracing en fate mapping technieken die in dit proefschrift 
werden beschreven (zie hoofdstuk 3, 4, 7 en 9) hebben met elkaar gemeen dat 
zij een statische weergave geven van een dynamisch proces. Het combineren van 
live-imaging, hoge resolutie confocale laserfluorescentiemicroscopie en fysieke 
(met bijvoorbeeld een vital dye) of genetische markering geeft de mogelijkheid 
om “vierdimensionale” analyse uit te voeren van het lot van voorlopercellen. 
Wanneer bijvoorbeeld myocard van de sinus venosus van een fluorescente 
markering wordt voorzien, dan kan met de bovenbeschreven combinatie van 
technieken definitief worden bevestigd dat er een actieve incorporatie is van 
myocard van de sinus venosus in de regio van de toekomstige atrioventriculaire 
knoop (zoals beschreven in hoofdstuk 4). 
 We hebben aangetoond dat de RHOA-ROCK signalerings cascade een 
essentiële rol speelt tijdens de ontwikkeling van het cardiale geleidingssysteem. 
Toekomstig onderzoek moet aantonen via welke moleculaire mechanismes 
RHOA-ROCK signalering invloed uitoefent op de ontwikkeling van de sinoatriale 
en atrioventriculaire knoop. Microarray analysis van specifieke gebieden van het 
geleidingssysteem (geïsoleerd met behulp van de in dit proefschrift beschreven 
laser capture microdissection methode) van zowel controle als ROCK-geremd 
materiaal zou een eerste stap kunnen zijn. Het in kaart brengen van afwijkingen 
in genexpressie na remming van RHOA-ROCK signalering zal helpen bij het 
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vaststellen welke processen leiden tot sinus knoop dysfunctie en AV-blok. 
 Tot slot werd in dit proefschrift een nieuwe functie van het epicard beschreven. 
Het epicard blijkt een belangrijke rol te spelen tijdens autonome regulatie van 
het hart, nog voordat het cardiale autonome zenuwstelsel is aangelegd. Eerder 
onderzoek heeft reeds aangetoond dat het epicard in staat is om verschillende 
factoren uit te scheiden en om gereactiveerd te worden na schade aan het hart. 
Hoe precies het epicard als autonome regulator fungeert moet nog worden 
uitgezocht. Toekomstige experimenten kunnen gericht zijn op het onderzoeken 
van het mogelijke in vitro neurogene potentieel van epicardcellen en epicard-
afkomstige cellen. Tevens kan single-cell microarray analysis worden toegepast 
om genen te identificeren die betrokken zijn bij de door het epicard gereguleerde 
autonome respons. Tot slot is het interessant om de gevonden resultaten te 
verifiëren in zowel een zoogdiermodel als in volwassen stadia, bijvoorbeeld na 
schade aan het hart. Microelectrode analysis na epicard-specifieke knockdown 
van de β2 adrenerge receptor in muizenembryo’s kan de belangrijke rol van het 
epicard en de epicardiale β2 adrenerge receptor tijdens autonome regulatie van 
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CURRICULUM VITAE
Tim Peter Kelder was born on the 7th of December 1986 in Leiden, where he 
graduated from secondary school in 2005 (Da Vinci College, Leiden). In the 
same year he started medical training at the Leiden University Medical Center 
(LUMC), during which he worked as student-researcher at the Departments of 
Cardiology, Pathology and Obstetrics of the LUMC. Furthermore, he worked as 
student-assistant during microscopy and anatomical training courses for (bio)
medical students, and as a technical assistant at the MRI imaging facility of the 
LUMC. In the course of his medical training he became interested in pediatric 
cardiology and cardiac development and therefore did his master thesis on the 
role of the epicardium in electrical activation of the embryonic chicken heart at 
the Department of Anatomy & Embryology of the LUMC (supervised by Prof. Dr. 
A.C. Gittenberger-de Groot and Dr. M.R.M. Jongbloed). 
 After finishing the theoretical (2010, cum laude) and clinical (2012, cum 
laude) part of his medical training, he started as PhD-student at the Department 
of Anatomy & Embryology of the LUMC (promotores: Prof. Dr. M.C. DeRuiter and 
Prof. Dr. M.-J. Goumans;  co-promotor: Dr. M.R.M. Jongbloed). He stayed active 
in the training of (bio)medical students during courses in cardiac development, 
anatomy and microscopy. The work described in this thesis is largely published 
in international, peer-reviewed journals and the work was presented at different 
national and international conferences. In 2015, he completed the experiments 
described in the current thesis and started working as a pediatric resident 
(ANIOS) at the Sint Franciscus Gasthuis in Rotterdam. In February 2017, he 
started working as pediatric resident (ANIOS) at the Juliana Children’s Hospital 
in The Hague. He aspires to become a pediatrician and remain active in medical 
research. 

